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Abstract 
 
Atopic dermatitis (AD) is a common, chronic inflammatory skin disorder caused by 
both genetic and environmental factors. The primary cause of AD is epidermal barrier 
dysfunction, which leads to impaired protective function of skin and promotes Th2 
immune response. The barrier defect in AD can be induced by dysregulations of 
numerous molecules, including imbalance between serine proteases kallikreins (KLKs) 
and their inhibitor LEKTI. The importance of serine protease-protease inhibitor balance 
has also been revealed in Netherton Syndrome (NS), which is caused by loss-of-
function mutations in the LEKTI encoding gene SPINK5. Hyperactivity of KLKs in NS 
can result in severe skin barrier defect. AD and NS both exhibit up-regulated activity of 
KLKs, and they share some clinical features including atopy and skin inflammation. 
Therefore, it was speculated that up-regulated KLKs might play an important role in 
AD pathogenesis.  
In this project, up-regulation of a key epidermal protease kallikrein 5 (KLK5) and 
disturbed expression of barrier-related proteins were confirmed in AD skin. In order to 
eliminate the influences of other causes of AD and investigate the role of up-regulated 
KLK5 in barrier defect, keratinocytes overexpressing KLK5 (KLK5-cells) were 
generated. Over-degradation of desmoglein 1 (DSG1) and impaired function of protease 
activated receptor 2 (PAR2) were found in KLK5-cells. In vitro organotypic cultures 
and in vivo skin grafts generated from KLK5-cells exhibited AD-like histological 
features and barrier abnormalities including disrupted keratinocyte growth. In order to 
further study the influences of up-regulated KLK5 on keratinocyte growth and cytokine 
production, related phospho-kinase and cytokine arrays were performed. There were 
increased levels of p53, heat shock protein 60 (HSP60) and elevated secretion of IL-8, 
thymic stromal lymphopoietin (TSLP) and IL-10 in KLK5-cells. As p53 and HSP60 are 
involved in the regulation of cell growth and cytokine production respectively, up-
regulation of KLK5 could result in disorganized keratinocyte 
proliferation/differentiation and aberrant cytokine levels by up-regulating p53 and 
HSP60, consequently exacerbating the skin barrier dysfunction in AD. Finally, 
sunflower trypsin inhibitor analogue (SFTI-G) was used to inhibit the unopposed 
activity of KLK5. The results showed restored level of DSG1, reduced expression of 
p53/HSP60 and decreased production of inflammatory cytokines in KLK5-cells treated 
with SFTI-G. Therefore, improvement of epidermal barrier function by inhibiting up-
regulated KLK5 is a promising therapeutic intervention for AD. 
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1.1 The epidermal barrier   
Skin is composed of dermis and epidermis. It is the largest organ in human body and 
serves as a physical and chemical barrier against the external environment. Skin can 
protect the internal tissues from mechanical stress, UV radiation and harmful agents. 
Other main functions of skin include sensation, thermoregulation and prevention of 
body fluid loss. The role as ‘first line of defence’ of skin is attributed to the epidermal 
barrier, which resides within the epidermis, the outermost layer of skin.  
 
1.1.1 The epidermis 
The epidermis is a highly stratified epithelium, which mainly consists of stratum basale 
(SB, basal layer), stratum spinosum (SS, spinous layer), stratum granulosum (SG, 
granular layer) and stratum corneum (SC, cornified layer) (Figure 1.1). 
 
Figure 1.1. Structure and composition of the epidermis. 
The epidermis is mainly composed of stratum basale, stratum spinosum, stratum granulosum and stratum 
corneum. 
 
The keratinocyte is the predominant cell type in the epidermis. Each keratinocyte 
migrates superficially from the SB to the SC. They undergo cell proliferation, 
differentiation and desquamation along the way with complete cell turnover occurring 
every four weeks. Therefore, the epidermis is a dynamic tissue, which is continuously 
renewed through proliferation of keratinocyte stem cells in the SB.  
	 19	
Proliferated keratinocytes move upward to the suprabasal layers and commit to 
differentiation. In the upper SS and SG, lamellar granules appear in the cells. These 
granules can release numerous types of lipids and proteins, which are secreted into the 
extracellular space during the formation of SC. For instance, lamellar granules deliver 
not only lipid constituents/lipid precursors but also the enzymes required to form the 
lipid matrix in the SC, which encases the corneocytes like mortar and prevents internal 
water loss. The proteases and protease inhibitors released by lamellar bodies orchestrate 
the orderly degradation of adhesion molecules corneodesmosomes, further allowing 
corneocytes to dissociate and shed from the skin surface (Caubet et al. 2004; Brattsand 
et al. 2005). In addition, antimicrobial peptides (AMPs) secreted by the lamellar 
granules play important roles in innate immunity. They are able to protect the skin 
against infectious agents (Oren et al. 2003; Braff et al. 2005). As cells continuously 
migrate upwards, the appearance of keratinocytes changes dramatically. The nuclei and 
cytoplasma start to disappear and the keratin intermediate filaments aggregate to form 
microfibrils, and the cells start to transform into the corneocytes that form the SC. 
During the final stage of terminal differentiation, keratinocytes change from 
metabolically active cells to corneocytes. Corneocytes are flattened cells, which lost 
their nuclei and sub-cellular organelles and become densely packed with keratin fibres. 
In order to maintain certain thickness of the epidermis, corneocytes are separated from 
each other through the proteolysis of intercellular adhesion molecules and shed from the 
skin surface. This process is known as desquamation. The corneocytes that flake off 
from the epidermis are continually replaced by the underneath keratinocytes undergoing 
terminal differentiation (Rook and Burns 2004).  
Thus, various layers work in concert to provide strength and flexibility of the epidermis. 
The growth of keratinocyte is modulated by multiple pathways, which involve the 
functions of various molecules. For instance, transforming growth factor-mediated 
signalling could control keratinocyte proliferation and differentiation (Dahler et al. 
2001). Mitogen-activated protein kinases also play a regulatory role in keratinocyte 
differentiation (Eckert et al. 2002). Transcription factor p53 may participate in the 
modulation of keratinocyte proliferation and differentiation (Dazard et al. 2000). In 
addition, the process of epidermal desquamation is strictly regulated by proteases and 
protease inhibitors. Therefore, the rates of keratinocytes proliferation, differentiation 
and desquamation are delicately balanced to allow a continual renewal of the epidermis 
and leave the skin sufficiently intact to exert its defensive function.  
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1.1.2 The epidermal barrier 
The protective function of skin relies on epidermal barrier, which is established during 
the formation of SC. When granular keratinocytes transform into corneocytes, the 
plasma membrane is replaced with an insoluble protein layer called ‘cornified envelope’ 
(CE). Meanwhile, the lamellar granules secret numerous types of lipids into the 
extracellular space at the interface between SG and SC. These lipids are orderly 
organized to form the lamellar membranes. One layer of lipids binds to cornified 
envelope covalently, and multiple layers of these membrane structures fill the spaces 
between the corneocytes. Furthermore, the structural integrity of the SC is also 
maintained by specialized desmosomes called corneodesmosomes, which bind the 
corneocytes together by incorporating into the cornified envelope.  
Therefore, several layers of protein-rich corneocytes are surrounded by lipid-rich 
lamellae membranes and held together with corneodesmosomes in the SC. This highly 
organized structure is known as epidermal barrier. In a simplified model, the highly 
organized structure of epidermal barrier is often described as similar to a brick wall, 
with the corneocytes and lipid lamellae analogous to the bricks and mortar respectively 
(Figure 1.2). Both the bricks and mortar are produced by granular keratinocytes, which 
release the lipids mortar into the space between the cells as they are being transformed 
into the corneocytes bricks. To extend this model, corneodesmosomes link the 
corneocytes together and act as “iron rods”, which pass down through holes in the 
bricks to give the wall its tensile strength (Getsios et al. 2004; Cork et al. 2006; Naoe et 
al. 2010). This barrier serves to limit passive water loss from the body, reduce the 
absorption of chemicals from the environment and prevent the infection of microbial 
pathogens.  
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Figure 1.2. The “bricks, mortar and iron rods” model of the epidermal barrier.  
The corneocytes represent the bricks and the lamellar lipid represents the mortar. Corneodesmosomes 
hold the corneocytes together as iron rods. Corneocytes are protected externally by the cornified 
envelope (CE). One layer of lipids bound to CE covalently, and multiple layers of lipid lamellae 
membranes fill the spaces between the corneocytes. 
 
 
The cornified envelope is mainly composed of epidermal structural proteins, such as 
filaggrin (FLG), loricrin, involucrin, and small proline-rich proteins, which are cross-
linked together by the action of transglutaminases. This envelope provides strength to 
the corneocytes. In addition, FLG and its breakdown products natural moisturizing 
factors (NMFs) are essential for the retention of water within corneocytes and 
maintenance of SC hydration (Fuchs and Raghavan 2002; Candi et al. 2005; Segre 
2006). The intercellular lipid matrix consists of ceramides (about 50% by mass), 
cholesterol (about 25% by mass), fatty acids (about 10-20% by mass) (Madison et al. 
1987). Thus, non-continuous corneocytes are surrounded by the continuous matrix of 
specialized lipids, which prevents the development of gaps between the corneocytes and 
give flexibility to the SC, further enhancing the integrity of the skin barrier. These lipids 
also help to prevent the escape of internal moisture/water-soluble materials and make 
the skin resistant to the penetration of allergens and pathogens (Elias 1983; Rawlings 
2003; Harding 2004; Proksch et al. 2008). Corneodesmosomes are composed of cell 
adhesion proteins and linking proteins. The adhesion proteins include transmembrane 
glycoproteins of the cadherin family, such as desmoglein (DSG) and desmocollin 
(DSC). Desmoglein 1 (DSG1) and desmocollin 1 (DSC1) constitute extracellular parts 
of corneodesmosomes. Inside of the corneocytes, DSG1 and DSC1 are connected with 
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intracellular keratin filaments via corneodesmosomal plaque proteins. The cytoplasmic 
plaques are attached into and become parts of cornified envelopes (Green and Simpson 
2007; Garrod and Chidgey 2008; Ishida-Yamamoto et al 2011). These 
corneodesmosomal proteins are degraded during epidermal desquamation to allow the 
corneocytes to dissociate and shed from the surface of skin. The processes involved in 
epidermal desquamation has been described as the network of degradatory proteases, 
which break down the extracellular domains of corneodesmosomal adhesion proteins, 
consequently resulting in the dissociation of corneocytes and triggering desquamation 
(Caubet et al. 2004; Descargues et al. 2006).  
 
1.1.3 The function of epidermal barrier 
Epidermal barrier prevents internal water loss and protects our body against the 
exogenous irritants from the surrounding environment. These defensive functions 
depend on the integrity of the barrier. Thus, the protective roles of epidermal barrier 
rely on several components, which determine the formation and maintenance of the SC. 
For instance, cornified envelope and corneodesmosomes provide the scaffold for 
structural integrity and mechanical resistance of the epidermal barrier. Moreover, 
intercellular lipid lamellae are essential for the prevention of transepidermal water loss 
(TEWL). Furthermore, FLG and NMFs are key molecules maintaining the hydration of 
the epidermis. FLG is extensively degraded into small peptides and then into free amino 
acids. The free amino acids are then catabolized into the constituents of NMFs, such as 
lactic acid, sodium pyrrolidone carboxylic acid, urocanic acid and urea. The NMFs are 
essential for the retention of water within corneocytes, and results in their optimal 
hydration and swelling. Sodium pyrrolidone carboxylic acid and lactic acid, in 
particular, are intensely hydroscopic. They both can absorb water and act as very 
efficient humectants, which prevents the development of gaps between the corneocytes, 
enhancing the integrity of the epidermal barrier and making it resistant to the 
penetration of irritants and allergens (Harding et al. 2000).  
In addition, proteases and protease inhibitors can interact with each other to control the 
rate of skin desquamation. Both exogenous and endogenous proteases are implicated in 
cleavage of the corneodesmosomal junctions. Among the endogenous proteases, a 
cocktail of serine and aspartic proteases are secreted into the extracellular space at the 
SG/SC interface by lamellar granules and participate in the degradation of 
corneodesmosomes (Ekholm and Egelrud 1998; Ekholm et al. 2000; Bernard et al. 
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2005). The human kallikreins (KLKs) are main epidermal proteases involved in skin 
desquamation (Ekholm and Egelrud 1998; Ekholm et al. 2000; Hansson et al. 2002). 
Other enzyme capable of degrading corneodesmosomal adhesion proteins include 
aspartate protease, cathepsin D (Horikoshi et al. 1999; Igarashi et al. 2004; Bernard et 
al. 2005). Research by other groups also revealed the regulatory role of matrix 
metalloproteases (MMPs) in desquamation (Ohler et al. 2010). The activity of these 
proteases and the speed of desquamation-related proteolysis are strictly controlled by a 
complementary cocktail of protease inhibitors. For instance, the lympho-epithelial 
Kazal-type-related inhibitor (LEKTI) is a particularly important regulator of epidermal 
desquamation and possesses potent inhibition towards KLKs (Deraison et al. 2007). In 
addition, human epidermis also expresses the cystatin protease inhibitors, A and M/E, 
which are specific for cysteine proteases (Zeeuwen et al. 2001).  
These factors work together to maintain the integrity of epidermal barrier. Therefore, 
the barrier formation and function are delicately regulated in healthy skin. However, 
dysregulation in any of these fundamental components can result in skin barrier 
dysfunction, consequently leading to a wide range of skin disorders including AD.   
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1.2 Atopic dermatitis 
AD is a common, chronic inflammatory skin disease. The clinical features of AD 
include xerosis (dry skin), pruritus (itchy skin) and relapsing erythematous lesions 
(redness of the skin) (Bieber 2008). For a long period, immune dysregulation was 
considered to be the primary cause of AD, and epidermal barrier impairment was the 
consequence of inflammatory response. However, immunological dysfunction is not 
found in all AD patients, suggesting there are some non-immune causative factors that 
can trigger this disease (Flohr et al. 2004; Bieber, 2008). Some researchers proposed 
that skin barrier defect could be the initial event but not the secondary phenomenon in 
AD, which was also supported by further studies (Elias et al. 1999; Taïeb 1999; Elias 
and Feingold 2001; Flohr et al. 2004; Cork et al. 2006; Callard and Harper 2007; Bieber 
2008). For example, variants within genes encoding epidermal barrier structural protein 
FLG and epidermal protease inhibitor LEKTI can directly result in skin barrier 
dysfunction in AD, consequently promoting the development of this skin disorder 
(Chavanas et al. 2000; Kato et al 2003; Nishio et al. 2003; Irvine and McLean 2006; 
Barker et al. 2007; Brown et al. 2008). In addition, environmental factors such as 
overuse of soap or detergents can lead to the epidermal barrier defect and trigger the 
flare-ups in AD (Ananthapadmanabhan et al. 2004; Flohr et al. 2004; Cork et al. 2009). 
Therefore, AD is increasingly ascribed to primary barrier dysfunction.  
 
1.2.1 Epidemiology 
AD affects around 10–20% of children and 1–3% of adults worldwide (Leung et al. 
2004). It occurs in any race throughout the world. Genetic variants in diverse 
populations were found to be associated with the prevalence of AD (Kato et al. 2003; 
Nishio et al. 2003; Vasilopoulos et al. 2004; Irvine and McLean 2006; Hubiche et al. 
2007; Ekelund et al. 2008; Weidinger et al. 2008). Wide variations of AD prevalence 
have been observed in populations with similar genetic backgrounds within close 
geographic areas, suggesting the environmental factors may also play a critical role in 
AD (Leung et al. 2004). The people living in urban area seem to be more susceptible to 
AD. The prevalence of AD has been rising progressively in industrialized countries 
since the 1940s and has increased two- to three-fold during the past three decades. In 
contrast, the prevalence remains much lower in countries with predominantly rural or 
agricultural areas (Taylor et al., 1984; Williams, 1992; Leung and Bieber 2003; Leung 
et al. 2004). In addition, another study revealed that the disease burden in cities is much 
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higher compared with the countryside (Schram et al. 2010). These findings suggest that 
apart from the genetic causes, environmental factor also play an important role in the 
expression of this disease.  
The manifestations of AD usually start and occur during childhood but can still persist 
or start in adulthood (Spergel 2010). It begins in the first year of life in 60% of cases, 
and by the age of five years in nearly 85% of cases. AD will clear in almost 40% of 
patients by adulthood (Williams and Strachan 1998; Williams 2005; Burr et al. 2013). 
The prevalence data of AD also show a slight female to male preponderance (Williams 
et al. 1999; Daniels and Harper, 2002; Kang et al. 2003). Therefore, the various 
observations of the prevalence of AD reveal the complex etiology of this skin disorder, 
which is possibly triggered by the interaction of multiple causative factors. 
 
1.2.2 Etiology  
AD is a multifactorial disease caused by numerous genetic and environmental factors. 
These factors interact with each other and contribute to the epidermal barrier 
dysfunction and immune dysregulation in AD. Therefore, various causes work together 
to determine the severity of AD or the likelihood of developing this skin disorder.  
1.2.2.1 Genetic factors associated with AD  
AD exhibited genetic linkage to chromosome 1q21. This region consists of the 
epidermal differentiation complex (EDC), which contains genes regulating epidermal 
barrier integrity and function. Many research groups have revealed that changes in 
genes encoding epidermal barrier structural proteins in this region are related to AD 
(Walley et al. 2001; Vasilopoulos et al. 2004; Palmer et al. 2006; Morar et al. 2007). 
Among these genes, loss-of-function mutation in the FLG gene was considered to be the 
most significant genetic factor related with AD (Irvine and McLean 2006; Marenholz et 
al. 2006; Palmer et al. 2006; Weidinger et al. 2006; Barker et al. 2007; Morar et al. 
2007; Brown et al. 2008; Ekelund et al. 2008). The most common variants are R501X 
and 2282del4, which are carried by about 10% of AD patients of European origin 
(Barker et al. 2007; Sandilands et al. 2007). Apart from variants in FLG gene, 
importance of several genes encoding adhesion proteins has been implicated in the 
maintenance of a functional epidermal barrier. Deficiencies of these proteins may also 
be associated with the development of AD. Mice lacking DSC1 exhibit a fragile 
epidermis (Chidgey et al. 2001). There are less desmosomes in desmoplakin knockout 
mice, which could lead to a significant deficiency of the barrier integrity (Gallicano et 
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al. 1998; Vasioukhin et al. 2001). Furthermore, down-regulated expression of tight-
junction proteins Claudin-1, Claudin-23 and a corneodesmosomal component DSG-1 in 
AD has also been recently reported (De Benedetto et al. 2008). 
Variations of genes encoding epidermal proteases have also been found in AD. The 
gene that has been intensely investigated is human tissue kallikrein 7 (KLK7). It has 
been reported that gene polymorphism of KLK7 could contribute to the development of 
AD. In a case–control study on 103 AD patients and 261 matched healthy controls, the 
results imply a possible association between an AACC insertion in the 3'UTR on the 
KLK7 gene and AD. Thus, the 4-bp insertion could potentially increase the half-life of 
KLK7 mRNA, leading to an increased level of this enzyme in the skin of individuals 
with AD (Vasilopoulos et al. 2004). In addition, transgenic mice overexpressing human 
KLK7 exhibit enhanced chymotrypsin-like proteolytic activity and develop pathologic 
changes in the skin similar to those observed in chronic AD, such as increased 
epidermal thickness, dermal inflammation and severe pruritus (Hansson et al. 2002). 
Since the initial publication of the AACC insertion of KLK7 gene in AD patients, 
another two studies have been conducted in European populations. However, the results 
from these studies indicate that the 4-bp insertion mutation of KLK7 may not be 
associated with AD (Hubiche et al. 2007; Weidinger et al. 2008).  
Variants in genes encoding protease inhibitors are associated with AD as well. 
Recently, strong association between serine protease inhibitor Kazal-type 5 (SPINK5) 
gene polymorphisms and AD patients has been revealed by several studies (Chavanas et 
al. 2000; Kato et al 2003; Nishio et al. 2003). SPINK5 gene encodes LEKTI. LEKTI is 
a multi-domain serine protease inhibitor, which can target multiple serine proteases in 
the epidermis. LEKTI is able to inhibit the activity of many epidermal proteases such as 
trypsin, elastase and shows exceptional inhibitory activity against KLKs (Mitsudo et al. 
2003; Paliouras and Diamandis 2006; Fortugno et al. 2011). Loss-of function mutations 
of SPINK5 and deficiency of LEKTI are found in patients with Netherton Syndrome 
(NS), a rare but severe autosomal recessive skin disorder. AD shares several clinical 
features with NS such as atopic manifestations and eczematous lesions. In order to 
investigate the link between AD and NS, several studies have been carried out to 
investigate the SPINK5 gene variants and LEKTI expression in both AD and NS 
patients. One of the most common polymorphisms is G1258A in SPINK5 gene, which 
can lead to Glu420Lys substitution in LEKTI. Impaired expression of LEKTI protein 
was found in keratinocytes from AD patients carrying this polymorphism (Walley et al. 
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2001; Kato et al. 2003; Nishio et al. 2003; Roedl et al. 2009). In addition, another study 
revealed a frequent and non-conservative LEKTI variant, E420K, impacts on LEKTI 
function by increasing the likelihood of LEKTI precursor cleavage within the linker 
region D6-D7. This prevents the formation of the LEKTI fragment D6-D9, which is 
known to display the strongest inhibitory activity against kallikrein 5 (KLK5) (Fortugno 
et al. 2012). Therefore, these findings shed light on the importance of LEKTI deficiency 
and insufficient inhibition of epidermal proteases in the pathogenesis of AD. AD and 
NS both exhibit epidermal barrier defect, and they share some clinical features 
including atopy and skin inflammation. Polymorphisms of SPINK5 associated with AD 
could result in up-regulated activity of epidermal proteases and further result in skin 
barrier dysfunction, subsequently producing a similar but milder phenotype compared to 
NS.  
Apart from gene variants in SPINK5 gene, a mutation in the cystatin A (CSTA) gene 
has been identified to correlate with AD. CSTA gene encodes the cysteine protease 
inhibitor cystatin A, which is able to inhibit the endogenous cathepsins B, -H and –L 
and the exogenous proteases from house dust mites, such as dermatophagoides 
pteronyssinus (Der p) 1 and dermatophagoides farinae (Der f) 1. The CSTA gene is 
located in chromosome 3q21, which has been confirmed as one of the major 
susceptibility loci for AD (Lee et al. 2000). Decreased expression of cystatin A has been 
found in the skin of patients with AD (Seguchi et al. 1996). The variant results in 
decreased mRNA stability and, therefore, decreased levels of the cystatin A within the 
skin (Vasilopoulos et al. 2007). As a consequence, inhibition of both endogenous and 
exogenous cysteine proteases is reduced, resulting in the over-degradation of the 
corneodesmosomes and defect of the epidermal barrier, which subsequently favours the 
penetration of exogenous pathogens and allergens (Vasilopoulos et al. 2007). 
Furthermore, transgenic mice carrying a null mutation in the gene encoding cystatin 
M/E also exhibited severe barrier defect characterized as disturbed cornification and 
desquamation, and die shortly after birth (Zeeuwen et al. 2001). 
In addition, variations of genes encoding cytokines are also correlated with AD. The 
most investigated immune genes are IL-4, IL-4 receptor alpha (IL4Ra) and IL-13 
(Kawashima et al. 1998; He et al. 2003; Kiyohara et al. 2008). IL-4 promotes the 
development of Th2 cells in allergic inflammation and decreases gene expression in the 
EDC that contribute to barrier function (Kim et al. 2008; Sehra et al. 2010). IL-13 
promotes tissue inflammation and is up-regulated in eczematous skin lesions (Sehra et 
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al. 2010). Multiple SNPs in IL-13 have been significantly associated with eczema in 
Canadian, Japanese, Dutch, and German populations. IL-4 and IL-13 also share a 
common receptor subunit, IL4Ra, and SNPs in IL4Ra have also been identified in 
subjects with AD (Oiso et al. 2000; Callard et al. 2002). The association of TSLP gene 
polymorphisms with AD has also been reported. TSLP is a pro-Th2 cytokine, which can 
initiate the differentiation of Th2 cells and promote Th2 cytokine secretion (Liu et al. 
2007; Gao et al. 2010; Roan et al. 2012; Bell et al. 2013; Jang et al. 2013; Duchatelet 
and Hovnanian 2014).  
 
1.2.2.2 Environmental factors relevant to AD  
Several environmental effectors on AD have also been reported. For instance, soap and 
detergents are considered as the most common irritants in contact dermatitis of the 
hands, and they can also trigger flares of AD (Meding and Swanbeck 1987). In AD 
patients, skin pH is extremely higher than that of normal donors (Eberlein-Konig et al. 
2000). Overuse of soap and detergents is considered to be one of the main causes of 
increased pH in AD skin (Ananthapadmanabhan et al. 2004). Recent studies indicate 
that increased skin pH causes hyperactivity of some epidermal proteases which have 
optimum activity at slightly alkaline pH, resulting in over-degradation of 
corneodesmosomes and consequently leading to epidermal barrier defect (Flohr et al. 
2004; Cork et al. 2009). Furthermore, the acute irritant effects of soap and detergents 
could be partially explained by their ability to promote the release of pro-inflammatory 
cytokines from corneocytes (Wood et al. 1996, 1997). In addition to inducing the 
cytokines release, the use of detergents is also able to cause impaired expression of 
keratinocyte differentiation markers and epidermal proteases (Torma et al. 2008), 
consequently exacerbating the skin barrier defect. In addition, the prevalence of AD is 
much higher in areas where hard water is used to wash the skin compared with areas 
where the water is soft, which may be attributed to the irritant chemicals in hard water 
(McNally et al. 1998). The irritation caused by soap, detergents and hard water could 
contribute to the epidermal barrier dysfunction in AD, subsequently promoting the 
development of this skin disorder. 
As AD is an allergic inflammation, various contact allergens and aeroallergens are 
considered as potential risk factors in the initiation and aggravation of AD. Proteolytic 
activity from allergens has been demonstrated to play an important role in the 
pathogenesis of AD. Exogenous proteases, such as those produced by house dust mites 
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and Staphylococcus aureus (S. aureus), are the common causes of AD (Kato et al. 
2005). House dust mites are the source of over 30 different proteins that can trigger 
immune responses, such as serine and cysteine proteases (Yasueda et al. 1993; Stewart 
and Thompson 1996). Reports have shown that two proteins called Der p1 and Der p2 
derived from house dust mite exhibit proteolytic activity, and these proteins are able to 
induce immune reactions and further cause skin irritation through their proteolytic 
activity directly (Deleuran et al. 1998). It has also been revealed that allergens in house 
dust mite are able to result in the barrier dysfunction and lead to increased penetration 
of other allergens (Jeong et al. 2008). Furthermore, research by another group revealed 
that AD patients showed a higher prevalence of mites on their skin compared to healthy 
individuals, which could be involved in allergic sensitization and disease exacerbation 
(Teplitsky et al. 2008). S. aureus has been identified as an environmental factor 
associated with AD since the nineteenth century (Storck et al. 1948). It can produce 
numerous proteases and may also play a role in the chronicity and severity of AD 
through the release of superantigenic exotoxins. Apart from their immunological 
effects, these toxins could also damage the epidermal barrier directly (Leung et al. 
1993). In addition, proteases produced by S. aureus are able to degrade AMPs, such as 
the human cathelicidin LL-37 (Sieprawska-Lupa et al. 2004). Keratinocytes express a 
number of AMPs when stimulated by microbes or tissue injury. AMPs are responsible 
for the control of S. aureus and viral replication (Kuo et al. 2013). Deficiencies of 
AMPs may predispose to microbial colonization and skin inflammation in AD.  
AD is an allergic inflammation characterized by Th2 immune response. The level of 
IgE, which indicates the extent of allergic sensitization, is associated with AD.  A high 
total serum IgE level is a strong risk factor for AD and correlates with the disease 
severity. IgE-mediated food allergies can trigger the flare-up in AD either through skin 
contact during food preparation or through food consumption (Laske & Niggemann 
2004). Food allergy has been well documented in approximately one-third of children 
with moderate-to-severe AD. Cow's milk, hen's egg, peanut, wheat, soy, nuts, and fish 
are responsible for over 90% of food allergy in children with AD. The incidence and 
type of food allergy can vary with age. In infants, cow's milk, hen's eggs, peanuts, and 
soy and, in older children, wheat, fish, and tree nuts are the most common food 
allergens. Adolescents and adults also react to foods, but reactions to 'classical' food 
allergens such as cow's milk and hen's eggs are not as common as in childhood (Werfel 
& Breuer 2004). Some children and adults with AD also react to pollen-associated 
foods (Werfel & Breuer 2004). Birch-associated foods have also been described as 
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potential triggers of AD in children as well as in adults (Vieths et al. 2002). Based on 
clinical data from the past few decades, it is clear that food allergy can directly provoke 
flares of AD particularly in sensitized infants, whereas inhaled allergens and pollen-
related foods are of greater importance in older children, adolescents and adults (Werfel 
& Breuer 2004; Bergmann et al. 2013). The diagnosis of food allergy in AD is currently 
based on the clinical history, skin prick tests, or blood test screening, followed by an 
elimination diet and/or standardized oral food challenge.  
 
1.2.3 Pathogenesis  
Although the pathogenesis of AD is not completely understood, both defective 
epidermal barrier and abnormal skin immune responsiveness play important roles in the 
development of this skin disorder. For a long period, AD is thought to be driven by 
primary immunological dysfunction, and epidermal barrier defect is the secondary 
consequence of the inflammatory response to irritants and allergens (‘inside-to-outside’ 
view of AD pathogenesis) (Leung 2000; Williams 2000; Baker 2006) (Figure 1.3A). At 
that time, most researchers focused on the immune dysregulation of AD. The infectious 
agent most often involved in AD is S. aureus, which colonizes in approximately 90% of 
AD patients (Watson and Kapur 2011). Increased colonization with S. aureus can 
consequently aggravate barrier function and facilitate microbial invasion in AD through 
down-regulation of epidermal free fatty acids, which is a key component of the lipid 
lamellae in epidermal barrier and also exhibits potent antimicrobial activity (Otto 2004; 
Clarke et al. 2007). In addition, proteases produced by S. aureus are capable of 
degrading AMPs. The presence of AMPs in the skin provides the first-line of defence 
against a wide variety of infectious agents. However, the deficiency of these AMPs 
could facilitate the invasion of exogenous allergens and pathogens, consequently 
exacerbating microbial colonization and triggering skin inflammation. Apart from the 
degradation of AMPs (Sieprawska-Lupa et al. 2004), proteases from S. aureus can also 
promote the premature cleavage of DSG1, subsequently resulting in impaired barrier 
integrity and contributing to epidermal barrier dysfunction (Hirasawa et al. 2010).  
In addition, AD is characterized by predominant Th2 immune response. Previous 
studies have revealed that exposure to protein antigens results in Th2 immune response 
and elevated IgE level in AD, which is indicative of immune hyper-reactivity (Williams 
2000; Callard and Harper 2007; Bieber, 2008; Newell et al. 2013). Researchers also 
suggested that the Th2-type inflammation evoked in AD skin could down-regulate the 
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level of lipid production in the epidermis and result in the epidermal barrier dysfunction 
(Sawada et al. 2012). Furthermore, exogenous application of the Th2 cytokines can lead 
to decreased amount of corneodesmosomal proteins and abrogate the cohesion of 
epidermis, subsequently aggravating the epidermal barrier defect (Kobayashi  et al. 
2004; Hatano et al. 2013). It has also been revealed that Th2-type cytokines are able to 
inhibit the expression of keratinocyte differentiation-related proteins, most notably 
FLG, possibly resulting in disorganized keratinocyte growth and disturbed skin barrier 
formation (Howell et al. 2007). Furthermore, members of two key families of AMPs, 
LL-37 and beta-defensins are down-regulated in a Th2-dependent manner in AD, which 
could consequently exacerbates the barrier defect in this skin disorder (Ong et al. 2002; 
Nomura et al. 2003).  
Nevertheless, immune dysregulation is not present in all AD patients, and around 20% 
of patients are non-atopic and never develop a raised IgE level (Flohr et al. 2004; 
Bieber, 2008). These findings suggested there are some non-immune causative events in 
the development of AD, thus other explanations for the pathogenesis of AD were raised. 
Some researchers thought the epidermal barrier defect was the initial event in AD 
(‘outside-to-inside’ view of AD pathogenesis) (Elias et al. 1999; Taïeb 1999; Elias and 
Feingold 2001; Flohr et al. 2004; Cork et al. 2006; Callard and Harper 2007; Bieber 
2008) (Figure 1.3B). Since 1990s, Elias proposed that the epidermal barrier abnormality 
is not a secondary phenomenon, but rather may be the ‘driver’ of disease activity in AD 
(Elias et al. 1999), whereas some scientist were concentrated on immunological 
dysfunction in AD. A defective epidermal barrier allows the penetration of allergens 
through the skin, facilitating the interaction of these allergens with the immune cells. In 
some cases, this may result in the transition from the non-atopic state to the atopic state 
of the disease with increased IgE level (Novak et al. 2003; Bieber 2008). 
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Figure 1.3. Two pathogenetic mechanisms of AD.  
AD is considered to be driven by primary immunological dysfunction, and epidermal barrier defect is the 
secondary consequence of the inflammatory response to infectious agents (‘inside-to-outside’ view) (A). 
Recently, some researchers think the epidermal barrier defect is the initial event in AD, which results in 
the immune dysregulation and skin inflammation  (‘outside-to-inside’ view) (B). 
 
 
Findings by other research groups also provide evidence to support the ‘outside-to-
inside’ hypothesis. 1) Severity of disease phenotype in AD parallels the extent of the 
barrier abnormality (Seidenari and Giusti 1995; Angelova-Fischer et al. 2005; Proksch 
et al. 2006). 2) Clinically nonlesional sites of AD still display barrier abnormalities 
(Seidenari and Giusti 1995; Bieber 2008). 3) Barrier disruption caused by surfactants 
(such as sodium lauryl sulfate) or skin stripping leads to the release of cytokines, 
indicating that barrier damage alone can result in the production of cytokines, skin 
inflammation and flare of dermatitis (Wood et al. 1996, 1997; Elias et al., 1999). 4) The 
epidermal barrier disruption contributes to impaired protection against exogenous 
irritants and allergens, which subsequently results in the development of a Th2 immune 
response and allergic manifestations (Leung 2013). 5) Restoration of epidermal barrier 
such as utilization of emollient and specific lipid replacement therapies not only 
corrects the barrier abnormality, but also reduces the skin inflammation in AD (Chamlin 
et al. 2002; Grimalt et al. 2006).  
Therefore, epidermal barrier dysfunction is likely to be the initial event in AD and may 
drive the disease activity. Barrier defect can lead to impaired protective function of the 
skin and allows increased penetration of environmental allergens or pathogens, which 
may stimulate Th2 immune response and trigger the release of Th2 cytokines, 
consequently resulting in immune dysregulation and promoting the development of AD. 
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1.2.4 Epidermal barrier dysfunction in AD 
As the pathogenesis of AD is complicated, numerous genetic and environmental causes 
can contribute to the skin barrier defect in AD. For instance, genetic variations in FLG 
can result in deficiency or complete absence of FLG expression in AD (Irvine and 
McLean 2006; Marenholz et al. 2006; Palmer et al. 2006; Weidinger et al. 2006; Barker 
et al. 2007; Morar et al. 2007; Sandilands et al. 2007; Brown et al. 2008; Ekelund et al. 
2008). FLG is a key component of the epidermal barrier. It cross-links with other 
structural proteins such as loricrin, involucrin and transglutaminases to form the 
cornified envelope, which contributes to the structural integrity of the epidermal barrier. 
Furthermore, FLG can be digested by proteolytic enzymes to produce the amino acid 
components of NMFs. These moisturizers are essential for the retention of water within 
corneocytes, further maintaining the hydration of SC. Decreased hydration of the 
epidermis is the first and most obvious cause of barrier dysfunction in AD (Kezic et al. 
2008). Mutations in FLG gene can result in the deficiency of FLG protein and its 
breakdown products NMFs, which consequently contribute to increased TEWL and 
dehydration of the skin in AD. In addition, as NMFs levels fall, the pH within the 
epidermis will rise, leading to elevated activity of epidermal proteases especially KLKs, 
most of which exhibit alkaline pH optima (Brattsand et al. 2005). Although FLG 
deficiency was considered as a major predisposing factor and closely related to the 
defective barrier in AD, FLG null mutations may not be sufficient to cause the classic 
cutaneous abnormalities of AD. Around 50% of individuals with moderate-to-severe 
AD do not have FLG deficiency (Palmer et al. 2006; Sundberg et al. 2009). 
Furthermore, Th2-dominant immune responses in AD are not dependant on FLG status 
(Newell et al. 2013). These findings indicated that apart from FLG, there are other key 
causative factors that can trigger the skin barrier defect in AD. 
Variations within SPINK5 gene could result in deficiency of LEKTI in AD, 
consequently leading to up-regulated activity of epidermal proteases. For example, 
G1258A polymorphism has been identified to result in aberrant expressions of barrier-
related proteins such as KLK5 and DSG1 (Di et al. 2009). E420K variant in SPINK5 
gene results in hyperactivity of epidermal serine proteases. Epidermis with this variant 
also exhibits increased expression of the proallergic cytokines, reduced level of DSG1 
and correlates with accelerated FLG proteolysis, consequently contributing to defective 
skin barrier permeability (Fortugno et al. 2012). Moreover, SPINK5 knockdown in both 
organotypic human skin culture and transgenic mice models revealed that LEKTI 
deficiency results in hyperactivity of epidermal proteases KLK5 and KLK7, which 
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induced premature degradation of corneodesmosomal proteins DSG1, DSC1 and 
corneodesmosin, further resulting in impaired skin barrier integrity (Yang et al. 2004; 
Descargues et al. 2005; Wang et al. 2014).  
Furthermore, overuse of soap/detergents may lead to increased skin pH and 
hyperactivity of epidermal proteases, consequently resulting in over-degradation of 
corneodesmosomes and epidermal barrier defect in AD (Ananthapadmanabhan et al. 
2004; Flohr et al. 2004; Cork et al. 2009). Exogenous proteases in the allergens can 
disrupt the structure and function of epidermal barrier, thereby facilitating further 
penetration of allergens through the impaired skin barrier and consequently inducing 
Th2 response (Roelandt et al. 2008). Increased colonization with S. aureus in AD can 
disrupt the production of epidermal free fatty acids, which is a key component of the 
lipid lamellae in epidermal barrier and also exhibits antimicrobial activity. As a result, 
this can lead to epidermal barrier dysfunction and facilitate microbial invasion in AD 
(Otto 2004; Clarke et al. 2007). Recently, S. aureus has also been reported to produce 
extracellular V8 protease, which exhibits a similar specificity of glutamate-specific 
cleavage and a similar sequence to exfoliative toxins and cause epidermal permeability 
barrier dysfunction in the skin of nude mice by directly degrading DSG1 (Hirasawa et 
al. 2010).  
Many causative factors can contribute to the impairments of skin barrier in AD, such as 
deficiency of FLG and NMFs, disturbed production of lipid lamellae and up-regulated 
activities of proteases (Di Nardo et al. 1998; Hara et al. 2000; Kezic et al. 2008; Voegeli 
et al. 2009). These defects can result in increased risks of skin dehydration and 
uncontrolled proteolysis of corneodesmosomes, consequently leading to disturbed 
barrier integrity and higher susceptibility to skin infection. Notably, one of the 
phenomenons observed in these barrier impairments is up-regulation of epidermal 
proteases (Roelandt et al. 2008; Di et al. 2009; Cork et al. 2009; Fortugno et al. 2012). 
Furthermore, enhanced proteolytic activity in the epidermis shows potential to up-
regulated proinflammatory cytokines, trigger over-degradation of corneodesmosomal 
proteins and disturb the processing of FLG and lipid lamellae, consequently 
contributing to impaired epidermal barrier (Yang et al. 2004; Descargues et al. 2005; 
Stefansson et al. 2008; Bonnart et al. 2010; Hirasawa et al. 2010; Fortugno et al. 2012; 
Wang et al. 2014).  Therefore, we speculated that up-regulation of epidermal proteases 
is possibly involved in the development of AD though propagating the vicious cycle of 
protease-mediated skin barrier defect.  
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1.3 Epidermal proteases 
The balance between epidermal proteases and protease inhibitors is delicately balanced 
during skin desquamation. However, various genetic and environmental factors 
involved in AD pathogenesis can result in up-regulated proteolytic activity in this skin 
disorder. The question of whether unopposed proteolytic activity is a potential 
accelerator of the skin barrier defect in AD has been raised. Recently, accumulating 
evidences revealed that up-regulation of epidermal proteases could aggravate skin 
barrier dysfunction and subsequently trigger the development of AD (Cork et al. 2009).  
 
1.3.1 Proteases and protease inhibitors in the skin 
Proteases are proteolytic enzymes that hydrolyse peptide bonds, resulting in irreversible 
activation or inactivation of the target protein. Until now, members of the four families 
of proteases have been identified in the epidermis: serine proteases, such as KLKs, 
matriptase, subtilisins; cysteine proteases, including cathepsin C, L, V and calpains; 
aspartate proteases, such as cathepsin D and cysteine-aspartic acid proteases; and 
metalloproteases, including MMP-1, MMP-9, ADAM10, ADAM17 and meprin (Ohler 
et al. 2010). 
Epidermal proteases are involved in the skin desquamation by disassembling 
corneodesmosomal adhesion molecules. The functional role of epidermal proteases in 
skin desquamation was first investigated by Bissett et al. They reported that topical 
application of trypsin or the protease inhibitor could significantly accelerate or reduce 
the rate of desquamation respectively (Bissett et al. 1987). Subsequently, other 
researchers also confirmed the contribution of epidermal chymotrypsin-like proteases to 
skin desquamation (Egelrud and Lundström, 1991; Lundström and Egelrud, 1988, 
1990), which was followed by the involvement of trypsin-like proteases in epidermal 
desquamation (Suzuki et al. 1993, 1996). These endogenous proteases are important 
regulators of skin homeostasis. In particular, KLKs are abundantly detected in the 
epidermis, and they account for most of the proteolytic functions in skin desquamation. 
For instance, kallikrein 5 (KLK5, or stratum corneum tryptic enzyme, SCTE) and 
kallikrein 7 (KLK7, or stratum corneum chymotryptic enzyme, SCCE) are highly 
expressed in granular keratinocytes and secreted into extracellular space at SG/SC 
interface (Caubet et al. 2004). Other studies also indicated that kallikrein 14 (KLK14) 
was intensively detected in the SG and SC of the epidermis (Brattsand et al. 2005; 
Borgono et al. 2007).  
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The activity of the mentioned proteases, and thereby the rate of desquamation, is strictly 
regulated by a cocktail of protease inhibitors, such as metal ions, lipids, peptides and 
large protein complexes. They inhibit the activity of the proteases by forming the 
complexes with them and show inhibitory activity against various epidermal proteases 
especially KLKs (Goettig et al. 2010). For instance, KLK7 activity is inhibited by the 
serine leukoprotease inhibitor (Franzke et al. 1996). KLK7 is also inhibited by elafin, 
otherwise known as skin-derived antileukoprotease, which has been shown to 
covalently bind to corneocytes (Molhuizen et al. 1993). In addition, α1-antitrypsin and 
α2-macroglobulin have been reported to be the inhibitors against KLK5 (Yousef et al. 
2003a). Human epidermis also expresses the cystatin protease inhibitors, A and M/E, 
which are specific for cysteine proteases (Zeeuwen et al. 2001). Cystatin A is also 
secreted in sweat and forms a layer over the surface of the skin that protects the skin 
from exogenous proteases, such as those produced by house dust mites and S. aureus 
(Kato et al. 2005). Among these inhibitors, LEKTI is a secreted serine protease inhibitor 
(serpin) with putative inhibitory activity towards epidermal proteases especially KLKs 
(Mitsudo et al. 2003; Fortugno et al. 2011). Furthermore, recent studies also showed 
that LEKTI-2 encoded by SPINK9 and LEKTI-3 encoded by SPINK6 contributed to the 
control of epidermal KLKs and the regulation of the desquamation process. They are 
homologues to LEKTI, but contain one Kazal-type domain only (Brattsand et al. 2009; 
Meyer-Hoffert et al. 2009, 2010). 
As each inhibitor acts as a competitive substrate and binds to multiple protease targets, 
the binding between epidermal proteases and their inhibitors is delicately balanced 
(Longstaff et al. 1991; Khan et al. 2011). Thus, the activities of epidermal proteases are 
strictly regulated. Fine-tuned balance between these two groups of enzymes contributes 
to the maintenance of normal epidermal barrier integrity and function. However, the 
imbalance between epidermal proteases and their inhibitors can contribute to skin 
barrier dysfunction. 
 
1.3.2 Up-regulated activity of epidermal proteases in AD  
Previous findings suggest that numerous causative factors of AD can lead to barrier 
defect and consequently result in imbalance between epidermal proteases and protease 
inhibitors. This subsequently aggravates the barrier dysfunction and increasing the risk 
of developing AD. Recently, elevated expression and uncontrolled activities of 
epidermal serine proteases have been found in AD lesions (Voegeli et al. 2009, 2011), 
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suggesting unregulated proteolytic activity may play an important role in the 
pathogenesis of AD. 
As mentioned in Section 1.2.2, both genetic and environmental factors can induce 
epidermal barrier dysfunction and up-regulated proteolytic activity in AD. For instance, 
variations in protease genes such as KLK7 and protease inhibitor genes such as SPINK5 
may directly result in epidermal barrier defect and up-regulated proteolytic activity in 
AD (Figure 1.4). In addition, variants within FLG gene can cause decreased levels of 
NMFs in AD patients, consequently leading to increased pH and elevated activity of 
epidermal proteases especially KLKs (Brattsand et al. 2005). Moreover, environmental 
causes of AD such as overuse of soap or detergents and exogenous proteases from 
house dust mites and S. aureus can also result in skin barrier defect and contribute to 
increased activity of epidermal proteases. As a result, enhanced epidermal proteolytic 
activity could lead to over-degradation of corneodesmosomal adhesion molecules such 
as DSG1, consequently resulting in defective intercellular cohesion in the SC and 
deficient epidermal barrier integrity in AD skin (Descargues et al. 2005; Di et al. 2009). 
In addition, increased activity of epidermal proteases is able to induce decreased lipid 
lamellae synthesis, further exacerbating the barrier dysfunction in AD (Hachem et al. 
2006a). These skin barrier defects can lead to increased TEWL and favour the 
penetration of exogenous pathogens/allergens into the skin.  
 
 
Figure 1.4. The importance of up-regulated protease activity in epidermal barrier defect of AD.  
Changes in various genetic and environmental factors contribute to the enhanced epidermal protease 
activity and exacerbate skin barrier dysfunction in AD (Adapted from Cork et al. 2009). 
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Therefore, various causes of AD can contribute to enhanced proteolytic activity, 
consequently exacerbating the barrier defect and promoting the development of AD. 
The link between enhanced activity of epidermal proteases and the severity of skin 
barrier defect has also been revealed in NS, a much more severe condition owing to 
LEKTI deficiency and uncontrolled proteolytic activity of serine proteases. In 
“moderate” and “severe” NS, where the activity of serine protease is dramatically 
increased and extended into the deeper epidermis, corneodesmosomal proteins such as 
DSG1 are progressively degraded. In contrast, in “mild” NS, lower activity of serine 
proteases is found within the epidermis, and immunolabeling of DSG1 persists 
(Hachem et al. 2006b). Interestingly, the G1258A variant within SPINK5 gene, one of 
the most common polymorphisms in AD and NS, is proved to impact on the function of 
LEKTI through cleavage on D6-D7 domain. This prevents the formation of the LEKTI 
D6-D9 fragment that displays strong inhibition against KLK5-mediated degradation of 
DSG1, subsequently resulting in reduced level of DSG1 (Fortugno et al. 2012). In 
addition, unregulated activity of serine proteases has been revealed to trigger the 
overexpression of proinflammatory cytokines through protease activated receptor 2 
(PAR2), consequently resulting in the inflammatory response in NS (Briot et al. 2009; 
Hovnanian 2013). Furthermore, the G1258A variant of SPINK5 gene in AD and NS 
also leads to the uncontrolled activity of serine protease KLK5 and consequently 
induces the up-regulation of proinflammatory cytokines (Fortugno et al. 2012). These 
findings implicate that up-regulated activity of epidermal proteases especially serine 
proteases potentially aggravates epidermal barrier defect and triggers skin inflammation 
in AD, subsequently promoting the development of this skin disorder.  
 
1.3.3 Serine proteases kallikreins  
Among these above-mentioned epidermal proteases, kallikrein-related peptidases are 
major and the most intensely investigated proteases in the skin. They are the largest 
family of trypsin-or chymotrypsin-like secreted serine proteases expressed in the 
epidermis. KLKs family is composed of 15 members (KLK1–15), and all of them map 
to the same chromosomal region (19q13.4) in the human genome (Emami and 
Diamandis 2007). Moreover, KLKs genes share a lot of similar structural features, such 
as exons and introns organization, conserved intronic intervals, and the lengths of exons 
(Borgono & Diamandis 2004). KLK5 and the majority of KLKs function as trypsin-like 
serine proteases, which cleave after arginine or lysine residues. In contrast, KLK7 is a 
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chymotrypsin-like serine protease that cleaves after phenylalanine or tyrosine residues. 
KLK14 exhibits both activities (Eissa and Diamandis 2008). 
KLKs are always co-expressed in certain tissues and coordinate to exert the regulatory 
roles through proteolytic cascades. The term “KLK activome” was introduced to 
describe this serial activation of the KLKs zymogens by other mature KLKs. Apart 
from the cleavage of adhesion molecules such as corneodesmosomal proteins in the 
epidermis, these activation cascades have also been reported to participate in numerous 
biological functions such as semen liquefaction, neurodegeneration, and tumor-
promoting or -inhibiting effects (Borgono & Diamandis 2004; Yoon et al. 2009).  
Until now, eight KLKs have already been identified in the skin, including KLK5, 6, 7, 
8, 10, 11, 13 and 14 (Lundwall and Brattsand 2008). KLK5, 7, 8 and 14 seem to be 
most important,as they are the only KLKs present in active forms in the skin (Ekholm et 
al. 2000; Brattsand et al 2005; Stefansson et al. 2006; Voegeli et al. 2009). In granular 
keratinocytes, each of these KLKs is synthesized as inactive pre-pro-enzyme in the 
endoplasmic reticulum with lengths varying between 244 and 293 amino acids. The 
synthesized pre-pro-enzyme are transported to Golgi apparatus, where the pre-peptide 
of 16-33 amino acids is removed. Then they are delivered through trans-Golgi network 
to lamellar bodies (LB) and secreted to the extracellular space at the interface of 
granular layer and cornified layer as inactive pro-enzymes. Subsequently, pro-KLKs are 
activated to mature peptidases by specific proteolytic removal of a pro-peptide (i.e. 37 
amino acids in pro-KLK5 and 4-9 amino acids in the other pro-KLKs) from the N-
terminus. The removal of N-terminal pro-peptide is mediated via autocatalytic 
activation (KLK5) or by other KLKs or other endopeptidases in a cascade manner. 
Present understanding of the activation profiles of KLKs is based on in vitro proteolytic 
cleavage of KLK propeptides and activation of recombinant pro-KLKs. The activation 
cascades involve a complex network of KLKs (Yousef et al. 2003a; Clements et al. 
2004; Emami and Diamandis 2007; Debela et al. 2008; Eissa and Diamandis 2008). 
KLKs are key regulators involved in skin desquamation. The proteolytic cascade of 
KLKs has been proposed in the process of epidermal desquamation, in which activated 
KLKs are considered as activators of precursors of other KLKs, further resulting in 
rapid amplification of the overall proteolytic activities (Borgono et al. 2007; Lundwall 
and Brattsand 2008). Activated KLKs control the rate of desquamation through 
cleavage of corneodesmosomal proteins (Brattsand et al. 2005; Borgono et al. 2007). As 
recent studies revealed that KLK5 is able to activate itself as well as pro-KLK2, 3, 6, 7, 
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11, 12, and 14, KLK5 is believed to be the initiator of the KLKs activation cascade 
(Brattsand et al 2005; Borgono et al 2007; Lundwall et al. 2008; Yoon et al. 2008; 
Sotiropoulou et al. 2009). KLK5, 7 and 14 are the most abundant KLKs in the 
epidermis. They are all produced as inactive precursors, and removal of the pro-peptides 
leads to the formation of the proteolytically active enzymes (Egelrud and Lundström 
1991; Hansson et al. 2002). KLK5 is capable of activating KLK7 (Caubet et al. 2004) 
and KLK14 (Emami and Diamandis, 2008), in addition to self-activation (Egelrud and 
Lundström, 1991; Egelrud 1993; Ekholm and Egelrud 1998). After being activated, 
mature enzymes of KLKs are amenable to inactivation by their endogenous inhibitors 
such as LEKTI.  
LEKTI exhibits putative inhibition against KLKs (Mitsudo et al. 2003; Fortugno et al. 
2011). LEKTI is composed 1064 amino acids and 15 serine proteinase inhibitory 
domains (D1-D15). LEKTI is synthesized in granular keratinocytes as two pro-LEKTI 
precursors that are 145kDa and 125kDa respectively. These precursors are rapidly 
cleaved intracellularly by furin in the post-endoplasmic reticulum compartment (Bitoun 
et al. 2003; Tartaglia-Polcini et al. 2006; Deraison et al. 2007; Fortugno et al. 2011). As 
LEKTI is a multi-domain protease inhibitor, it has been speculated that LEKTI may 
target multiple serine proteases in the epidermis. In order to determine the molecular 
mechanism by which LEKTI functions in the skin, many studies have been carried out. 
The full-length protein of LEKTI shows no inhibitory activity against KLKs, but is 
capable of inhibiting trypsin (Paliouras and Diamandis 2006). Another research group 
has also demonstrated the inhibitory activity of full-length recombinant LEKTI 
(rLEKTI) against several serine proteases in vitro, including plasmin, elastase, trypsin 
and subtilism A (Mitsudo et al. 2003). Full-length LEKTI is rapidly cleaved into active 
single and multi-domains intracellularly and secreted into the extracellular space at the 
interface between SG and SC by lamellar bodies (Bitoun et al. 2003; Ishida-Yamamoto 
et al. 2005; Jayakumar et al. 2005). Single or multi-domain LEKTI fragments exhibit 
strong inhibitory activity against KLKs. To date, the inhibitory activity of recombinant 
LEKTI domains against KLKs has been well established. For example, recombinant 
LEKTI domain D5, D6, D8-D11 and D9-D15 showed specific inhibition of KLK5, 
KLK7 and KLK14 (Egelrud et al. 2005; Deraison et al. 2007). Studies by other research 
groups confirmed the inhibitory efficiency of LEKTI D6-D9 and D9-D12 against KLK5 
and KLK7 respectively (Schechter et al. 2005). In addition, LEKTI D12-15 exhibited 
specific inhibition for KLK5 only (Vitzithum et al. 2008). 
	 41	
In healthy skin, the inhibition of KLKs activity by the serine protease inhibitors occurs 
through a dedicated balanced inhibitory pathway. However, imbalance between KLKs 
and their inhibitors can result in epidermal barrier defect. 
 
1.3.4 Up-regulation of KLKs in skin barrier dysfunction  
In the epidermis, the activities of KLKs are mainly regulated by LEKTI in combination 
with changes in microenvironmental pH (Deraison et al. 2007). Furthermore, the 
cleavage of the corneodesmosomal proteins by KLKs can be inhibited by LEKTI 
(Borgono et al. 2006).  
It has been revealed that KLK5, 7, and 14, together with their inhibitor LEKTI, are all 
produced in the SG of the epidermis, where the pH is almost neutral and LEKTI binds 
to KLKs to inhibit their proteolytic activities (Brattsand et al 2005). Recent research 
also showed that LEKTI is located separately from KLK5 and KLK7 in the lamellar 
bodies of granular keratinocytes, and secreted earlier than KLK5 and KLK7 to prevent 
the degradation of corneodesmosomal proteins by KLKs (Ishida-Yamamoto et al. 
2005). As KLK5 displays enzymatic activity at the neutral pH of the SG, it is assumed 
that KLK5 can activate itself in the SG, but its activity is quenched through immediate 
binding with its inhibitor LEKTI. As a result, KLK5 cannot further trigger the auto-
activation and the activation of other KLKs. Consequently, the KLKs activation cascade 
is quenched and KLKs-mediated proteolytic cleavage of corneodesmosomal proteins 
including corneodesmosin (CDSN), DSG1 and DSC1 is inhibited. 
During the transition of keratinocytes from SG to SC, the pH value drops from neutral 
to acidic due to the release of free fatty acids. It has been demonstrated that the binding 
of LEKTI and inactivation of KLKs are reversed by a decrease in pH to the range 4.5–
5.5 in vitro (Deraison et al. 2007), and SC maintains a pH in this range. Therefore, 
dissociation of the KLK5-LEKTI complexes and release of active KLK5 enzyme occur 
as they diffuse into the SC. KLK5 also exhibits enzymatic activity at acidic pH (4.5–
5.5) in the SC. Apart from auto-activation, KLK5 can activate KLK7/KLK14 in a 
cascade manner, and active KLK14 augments KLK5 activity in a feedback loop as 
shown in vitro using recombinant enzymes (Deraison et al. 2007) (Figure 1.5A). As a 
result, active KLK5, 7, and 14 cause the degradation of CDSN, DSG1 and DSC1, 
subsequently leading to dissociation of corneocytes and triggering epidermal 
desquamation  (Brattsand et al 2005). 
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In healthy skin, there is a fine-tuned balance between KLKs and their inhibitor LEKTI, 
thus normal skin desquamation and epidermal barrier function is delicately maintained 
(Figure 1.5B). However, the imbalance of KLKs and LEKTI induces over-degradation 
of intercellular adhesion molecules and leads to premature desquamation. As shown by 
both in vitro and in vivo studies, deficiency of LEKTI and unregulated proteolytic 
activity of KLKs can result in uncontrolled cleavage of corneodesmosomal proteins, 
subsequently exacerbating the epidermal barrier defect (Descargues et al. 2005).  
 
 
 
Figure 1.5. Regulatory roles of KLKs and LEKTI in epidermal desquamation. 
KLK5 can mediate the activation cascade of KLKs in skin desquamation. Apart from auto-activation, 
KLK5 can activate pro-KLK7 and pro-KLK14. Active KLK14 is able to activate pro-KLK5. The activated 
KLKs degrade corneodesmosomal proteins and cause the skin desquamation (A). KLKs and LEKTI are 
well balanced to maintain epidermal desquamation in normal skin. In comparison, LEKTI deficiency and 
up-regulated KLKs result in premature desquamation through over-degradation of corneodesmosomes, 
consequently leading to defective epidermal barrier (B).   
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KLKs are major proteases expressed in the skin and the key regulators of epidermal 
desquamation. Up-regulation of KLKs has been found in many skin disorders including 
AD, NS, and psoriasis, which are all characterised by compromised skin barrier 
function (Descargues et al. 2005, 2006; Hachem et al. 2006b; Komatsu et al. 2005, 
2007a, b; Voegeli et al. 2009). These findings suggest that up-regulation of KLKs may 
be correlated with epidermal barrier dysfunction. Therefore, we speculated that up-
regulated KLKs activity potentially contributed to the skin barrier defect in AD, 
consequently triggering the development of this skin disease. 
Up-regulation of KLKs including KLK5 has been found in the skin samples of AD and 
NS patients (Table 1.1). Previous studies show increased number of keratinocytes 
expressing KLK5 mRNA and elevated protein level of KLK5 in the AD skin (Komatsu 
et al. 2005, 2007b). Another study also revealed elevated proteolytic activity of KLK5 
in AD lesions (Voegeli et al. 2009). However, there are some controvertial findings 
showing that the mass level of KLK5 is not increased in the AD skin (Voegeli et al. 
2011). Hyperactivity of KLK5 is also found in NS patients with LEKTI deficiency 
(Descargues et al. 2005, 2006; Hachem et al. 2006b). In addition, reduced level of 
LEKTI has also been reported in AD patients (Roedl et al. 2009), indicating that 
insufficient inhibition of LEKTI could contribute to up-regulated activity of KLK5 in 
both AD and NS. Furthermore, the G1258A variant in SPINK5 gene, one of the most 
common polymorphisms in AD and NS, is proved to impact on the function of LEKTI 
through cleavage on D6-D7 domain. This prevents the formation of the LEKTI D6-D9 
fragment, which displays strong inhibition against KLK5, consequently resulting in 
unopposed activity of KLK5 (Fortugno et al. 2012). These findings suggest the 
importance of up-regulated KLK5 in the pathogenesis of AD.  
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Disease 
KLKs 
expression/activity 
Up/down-regulation Reference 
AD mRNA level 
KLK1, 4, 5, 6, 9, 10, 11, 13, 
14 ↑ 
Komatsu et al. 2005 
AD Protein level KLK5, 6, 7, 8, 10, 13, 14 ↑ 
Komatsu et al. 
2007b 
AD Proteolytic activity KLK5 ↑; KLK7 ↑ Voegeli et al. 2009 
AD Protein level 
KLK5 →; KLK7, KLK11 ↑; 
KLK14 → 
Voegeli et al. 2011 
NS 
Protein level and 
proteolytic activity 
KLK5 ↑; KLK7 ↑  
Descargues et al. 
2005, 2006 
NS Proteolytic activity KLK5 ↑; KLK7 ↑ 
Hachem et al. 
2006b 
 
Table 1.1. Dysregulation of KLKs in AD and NS.  
Up-regulation of KLKs including KLK5 has been reported in both AD and NS, whereas some study shows 
unchanged level of KLK5 in the AD skin. ↑: up-regulated. →: unchanged. 
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1.4 Kallikrein 5  
Among the above-mentioned KLKs, KLK5 is one of the major serine proteases 
abundantly expressed in the skin. It is also known as stratum corneum tryptic enzyme 
(SCTE) and accounts for most trypsin-like proteolytic activity in the epidermis 
(Brattsand et al. 2005). Apart from its typical role as a regulator of epidermal 
desquamation, recent studies have revealed that KLK5 may also involve in other 
functions of the epidermal barrier, such as modulation of inflammatory response and 
regulation of skin barrier formation (Briot el al. 2009; Bonnart et al. 2010). Up-
regulation of KLK5 has been found in AD (Komatsu et al. 2005, 2007b; Voegeli et al. 
2009). As a key epidermal protease and the regulator of skin barrier function, 
unopposed KLK5 activity may contribute to the epidermal barrier defect in AD, 
consequently promoting the development of this skin disorder. 
 
1.4.1 Protein structure and enzymatic activity  
KLK5 is originally identified as a novel human serine protease in keratinocytes and 
isolated from human epidermis, which is named as SCTE (Brattsand & Egelrud 1999). 
According to the new human kallikrein gene nomenclature, the official name is KLK5. 
Together with the other members of human KLKs family, KLK5 gene has been mapped 
on chromosome 19q13.4 and constitutes the largest contiguous serine protease cluster in 
the human genome. The gene is approximately 9.5kb in length, consisting of 6 exons 
and 5 introns (Brattsand & Egelrud 1999). 
KLK5 is a secreted serine protease. In human keratinocytes, KLK5 protein is 
synthesized as pre-pro-enzyme comprising 293 amino acids, which consists of a 
predicted signal peptide (29 amino acids), an activation peptide (37 amino acids) and 
the mature chain (227 amino acids), with 4 potential N-linked glycosylation sites. The 
serine protease catalytic domain of KLK5 is located in the mature chain. The 
synthesized pre-pro-enzyme is transported from the endoplasmic reticulum to Golgi 
apparatus, where the signal peptide is removed. Then they are delivered through trans-
Golgi network to lamellar granules, followed by being secreted into the extracellular 
space in the interface between granular layer and cornified layer as inactive zymogens. 
Consequently, pro-KLK5 is activated into mature form of the enzyme through 
proteolytic removal of the activation peptide. The activation of pro-KLK5 has been 
shown to require the cleavage of an arginine residue (Arg66-Ile67) (Brattsand & 
Egelrud 1999). KLK5 is capable of auto-activation. Besides of self-activation, pro-
	 46	
KLK5 could be activated by other serine proteases such as activated KLK14, matriptase 
and mesotrypsin (Brattsand et al., 2005; Sales et al., 2010; Miyai et al. 2014).  
After being activated, mature KLK5 can also activate other pro-KLKs in a cascade 
manner. Activated KLK5 exhibits potent trypsin-like proteolytic activity by cleaving 
after arginine or lysine residues in the targets (Michael et al. 2005). In this study using 
fluorogenic substrates, KLK5 shows preference for AMC conjugated Boc-Phe-Ser-Arg 
and Boc-Val-Pro-Arg (Michael et al. 2005).  
 
1.4.2 Tissue expression and biological function  
KLK5 is widely detected in human tissues and biological fluids. It has been shown to be 
estrogen/progestin-regulated and highly expressed in endocrine or hormone-responsive 
tissues, such as prostate, ovary, breast and skin. KLK5 has also been identified in 
various biological fluids, including seminal plasma, vaginal secretions and breast milk 
(Brattsand & Egelrud 1999). 
Recent studies have revealed that KLK5 is differentially regulated in a variety of 
hormone-dependent malignancies. KLK5 mRNA and protein levels are significantly 
increased in patients with ovarian cancer, especially in late stage and higher-grade 
tumors (Yousef et al. 2003b). Elevated expression of KLK5 is also detected in the 
serum of patients with breast cancer, and the KLK5 mRNA transcript is found to be an 
indicator of unfavorable prognosis (Yousef et al. 2003b, 2004). Furthermore, using a 
human KLK5-specific enzyme-linked immunosorbent assay method, KLK5 has been 
identified as a potential biomarker for ovarian and breast cancer (Yousef et al. 2003b). 
In addition, KLK5 mRNA is down-regulated in prostate cancer compared to normal 
prostatic tissues, and it is a favorable prognostic maker (Korbakis et al. 2009). Aberrant 
KLK5 expression in tumor tissue may be due to DNA methylation, as reported for 
KLK6 in breast cancer (Pampalakis and Sotiropoulou 2006). KLK5 splice variants 
could also result in premature stop of translation or the production of truncated non-
functional proteases (Dong et al. 2003; Yousef et al. 2004). However, the roles of 
dysregulated KLK5 in cancer pathogenesis are still obscure.  
KLK5 is involved in semen liquefaction. KLK5 has been shown to auto-activate, and in 
turn, activates pro-KLK3. Activated KLK3 may contribute to seminal clot liquefaction 
through hydrolysis of seminal vesicle proteins (Michael et al. 2006). In comparison, the 
involvement of KLK5 in skin physiology is relatively well established. KLK5 is 
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intensively detected in skin, where it precipitates in epidermal desquamation through 
cleavage of all three components of corneodesmosomes, including CDSN, DSG1 and 
DSC1 (Caubet et al. 2004). Although its roles are not completely elucidated, KLK5 may 
exert physiological functions in various tissues. Therefore, it is considered as one of the 
most attractive targets to study the pathogenesis of numerous diseases. 
 
1.4.3 KLK5 in the skin  
Apart from its well-established function in skin desquamation by degrading 
corneodesmosomal proteins, KLK5 is also implicated in the proteolytic processing of 
AMPs such as LL-37 in human skin. KLK5 cleaves the inactive cathelicidin precursor 
hCAP18 to generate mature peptide LL-37 (Yamasaki et al. 2006). As a result, LL-37 
can exert its protective function in defencing the skin against infectious agents from the 
surrounding environment (Yamasaki et al. 2006; Scott et al. 2007; McGrath & Uitto 
2008). Furthermore, accumulating evidences suggest that KLK5 can also promote the 
inflammatory response in the skin and induce the disrupted formation of epidermal 
barrier through its downstream molecules (Briot el al. 2009; Bonnart et al. 2010). These 
findings reveal that KLK5 is a potential regulatory molecule participating in numerous 
biological functions in the skin.  
 
1.4.3.1 KLK5 induces the activation of PAR2  
Protease activated receptors (PARs) are members of the transmembrane G-protein-
coupled receptor superfamily. It has been demonstrated that PARs can be activated by 
proteases through partial proteolytic cleavage on their extracellular domains. PAR2 is a 
member of PARs family. It is activated by trypsin-like proteases, whereas the other 
PARs are activated by thrombin (Oikonomopoulou et al. 2006). 
Trypsin-like proteases activate PAR2 through proteolytic cleavage at the N terminus 
R36/S37 activation site of the receptor, leading to the release of a newly formed N 
terminus (NH2-SLIGRL), which functions as a tethered ligand to activate the receptor 
itself (Figure 1.6). Irreversible activation of PAR2 by proteolytic cleavage renders the 
cleaved receptor unresponsive to further stimulation by activating proteases. Activated 
PAR2 then trafficks intracellularly, further influencing various biological functions in 
the cell. Like other G-protein coupled receptors, activated PAR2 is known to have a 
common signalling pathway, including coupling with G proteins and activation of 
phospholipase C (PLC). This induces the formation of ionsitol triphosphate (IP3), 
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consequently triggering the intracellular calcium mobilization (Kawabata 2002; 
Oikonomopoulou et al. 2006; Stefansson et al. 2008).  
 
Figure 1.6. Proteolytic activation of PAR2.  
Proteases enzymatically cleaves the N-terminal peptide of PAR2 at R36/S37 activation site (a), releasing 
a newly formed N terminus peptide (NH2-SLIGRL), which functions as a tethered ligand and triggers the 
activation of PAR2 (b). Activated PAR2 binds to G-protein and results in the formation of IP3 (c), further 
inducing the release of calcium from the endoplasmic reticulum (E.R.) and triggering intracellular 
calcium mobilization (d)(Reproduced from Kawabata 2002). 
 
PAR2 is present on the membrane of many cells types especially keratinocytes (Santulli 
et al. 1995; D'Andrea et al. 1998; Steinhoff et al. 1999). The endogenous activators of 
PAR2 in keratinocytes have been further identified. Potential candidates are 
(chymo)trypsin-like proteases KLKs, which are also abundantly expressed in 
keratinocytes. The ability of KLKs was examined with regard to their capacity to 
activate PAR2 in vitro. PAR2 activation was evaluated through measurements of 
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intracellular calcium mobilization. KLK5 and KLK14, which exhibit trypsin-like 
activity, are both able to trigger PAR2-dependent signaling (Stefansson et al. 2008). 
These results suggest that KLKs participate in the activation of PAR2 in keratinocytes. 
Since previous report implicated that PAR2 is involved in protease-mediated signalling 
in inflammation and immune response (Steinhoff et al. 2005), PAR2 could play a 
regulatory role in skin inflammatory reactions after being activated by KLKs. Later on, 
another study demonstrated that stimulation of human keratinocytes by recombinant 
KLK5 could induce the activation of PAR2, consequently resulting in up-regulation of 
proinflammatory cytokines such as thymic stromal lymphopoietin (TSLP) and 
interleukin-8 (IL-8) (Briot el al. 2009).  
TSLP is an epithelial cell-derived cytokine that is involved in the Th2 mediated allergic 
inflammation. It is a pro-Th2 cytokine that initiates differentiation of Th2 cells and 
promotes Th2 cytokine responses (Liu et al. 2007; Roan et al. 2012; Bell et al. 2013; 
Jang et al. 2013). TSLP is considered to be a novel proinflammatory mediator in AD. 
The importance of TSLP in AD was shown for the first time when increased level of 
TSLP was detected in lesional skin of AD patients but not in nickel-induced contact 
allergic dermatitis or in cutaneous lupus erythematosus lesions (Soumelis et al. 2002). 
Later, another study revealed that overexpression of TSLP in keratinocytes resulted in 
the development of an AD-like phenotype dominated by Th2 cytokines (Yoo et al. 
2005). Recently, the association of TSLP gene variants with AD has also been reported, 
suggesting TSLP could be a possible causative factor in AD (Gao et al. 2010; 
Duchatelet and Hovnanian 2014). IL-8 is a chemokine that primarily targets neutrophils, 
thus it is also known as neutrophil chemotactic factor. Keratinocyte-derived IL-8 has 
been shown to be a chemoattractant of human neutrophils and T cells, causing the 
migration of these cells toward the site of inflammation (Barker et al. 1991). 
Interactions between T cells, neutrophils, and keratinocytes are believed to play a 
central role in the pathophysiology of inflammatory cutaneous disorders such as AD. 
These findings provide evidence that keratinocytes could potentially play a key role in 
mediating the influx of neutrophils and T cells into the epidermis through IL-8 during 
skin inflammation of AD. In keratinocytes, PAR2 activation leads to increased secretion 
of IL-8, suggesting the potential role of PAR2 in inflammatory skin disorders (Hou et 
al. 1998).  
Recently, results from another study also indicate that exposure of human skin to 
irritants triggers up-regulation of KLK5 and activation of PAR2 (Underwood et al. 
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2013). These findings reveal the potential function of KLK5-PAR2 cascade in the 
inflammatory response in skin. In addition, PAR2 was also identified as a potential 
signalling molecule in the epidermal barrier function by regulating the lipid production 
in the epidermis (Hachem et al. 2006). The lipid bilayers in the SC are key components 
of the epidermal barrier. However, deficient lipid secretion has been detected in AD 
patients (Imokawa et al. 1991; Di Nardo et al. 1998; Hara et al. 2000). It has been 
demonstrated that serine proteases have a central role in the formation and maintenance 
of the epidermal lipid barrier by degrading the key lipid processing enzymes required 
for normal permeability barrier homeostasis and PAR2-mediated regulation of LB 
secretion. Acute barrier disruption leads to an increased pH in the SC, which results in 
the enhanced activity of serine proteases (Feingold et al. 2007; Demerjian et al 2008). 
Serine protease hyperactivity in SC can lead to a barrier abnormality via PAR2-induced 
down-regulation of LB secretion (Hachem et al. 2005, 2006a). As KLK5 is the one of 
the major serine proteases expressed in the SC, elevated activity of KLK5 could 
contribute to the impaired lipid processing and lipid barrier abnormalities in AD, 
consequently exacerbating the epidermal barrier dysfunction during the development of 
this skin disorder. Furthermore, PAR2 may function as a regulator of keratinocyte 
proliferation and differentiation (Derian et al. 1997). PAR2 activation is likely to be 
involved in pruritus of AD (Steinhoff et al. 2003a). PAR2 has been observed to be 
expressed at high levels in the lesional skin of patients with AD, and PAR2 agonist 
peptides induce pruritus in AD patients (Steinhoff et al. 2003b). These findings raise the 
possibility that KLK5 may trigger the inflammatory response and disturb the epidermal 
barrier formation through activation of PAR2.  
 
1.4.3.2 KLK5 cleaves corneodesmosomal protein DSG1 
KLK5 is a key serine protease involved in desquamation with trypsin-like activity 
(Egelrud and Lundström 1991; Egelrud 1993; Suzuki et al. 1994; Ekholm and Egelrud 
1998; Hansson et al. 2002). In healthy skin, KLK5 has been shown to cleave 
corneodesmosomal adhesion molecule DSG1. Both KLK5 and DSG1 are located in the 
outermost layers of epidermis, where KLK5 can specifically cleave the adhesive 
extracellular domain of DSG1 to maintain epidermal barrier integrity in the superficial 
layer (Caubet et al. 2004; Descargues et al. 2006). However, up-regulated KLK5 
activity can cause over-degradation of DSG1, leading to premature desquamation and 
epidermal barrier dysfunction. It has also been revealed that the activity of KLK5 is 
increased in NS patients and models with LEKTI deficiency, which leads to reduced 
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level of DSG1, consequently resulting in atopic manifestation (Descargues et al. 2005, 
2006; Di et al. 2009; Roedl et al. 2009). Moreover, over-degradation of DSG1 by up-
regulated KLK5 can be inhibited by LEKTI (Borgono et al. 2007; Fortugno et al. 2011). 
Recent study also demonstrated that SPINK5 and KLK5 double knockdown in 
organotypic human skin culture could restore the level of DSG1 (Wang et al. 2014). 
These findings indicate that up-regulated activity of KLK5 can result in progressive 
cleavage of DSG1, consequently leading to premature desquamation and deficient 
epidermal barrier integrity.  
In addition to serving as a rigid anchor between adjacent cells, recent study implicates 
DSG1 as a key component of a signalling axis governing epidermal morphogenesis. 
Distinct from other desmosomal cadherins, DSG1 is first expressed at the interface 
between basal and suprabasal layers, where keratinocytes commit to differentiation 
(Green and Simpson 2007; Garrod and Chidgey 2008). These findings raise the 
possibility that DSG1 could also serve as key morphoregulator in the epidermis. It has 
been demonstrated that DSG1 was required to down-regulate epidermal growth factor 
receptor (EGFR) signalling and promote epidermal differentiation, indicating DSG1 is 
also a potential regulator in keratinocyte morphogenesis (Getsios et al. 2009). DSG1 is a 
target molecule of KLK5. Although KLK5 is abundantly detected in the upper 
epidermis (Komatsu et al. 2005), there could also be KLK5 expression in the inner 
epidermal layers, where KLK5 may interact with DSG1 and further involve in the 
regulation of keratinocyte growth through DSG1. It has been reported that AD exhibits 
disorganized keratinocyte growth. Increased proliferation accompanied by disturbed 
differentiation has been found in AD skin (Proksch et al. 2006). These findings raised 
the possibility that up-regulated KLK5 might contribute to disrupted keratinocyte 
proliferation and differentiation in AD via DSG1.  
 
1.4.3.3 KLK5 participates in FLG and lipid processing via ELA2  
Recently, elastase 2 (ELA2), a novel epidermal protease, has been identified in human 
and mouse skin and is considered to be a potential trigger in NS pathogenesis through 
misprocessing of FLG and lipid. In a previous study, it has been confirmed that KLK5 
is able to activate ELA2 through proteolytic cleavage of pro-ELA2, and co-incubation 
of pro-ELA2 with KLK5 results in hyper-activity of ELA2 (Bonnart et al. 2010). 
Furthermore, hyper-active KLK5 could contribute to the enhanced activity of ELA2 in 
the LEKTI-deficient epidermis of both NS patients and SPINK5 knockout mice 
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(Bonnart et al. 2010). This study also suggested that LEKTI was able to inhibit the 
activity of ELA2 by down-regulating KLK5-mediated activation of pro-ELA2 (Bonnart 
et al. 2010). 
Moreover, ELA2 is found to be co-localized with (pro)-FLG in the epidermis, and it can 
directly proteolyze both pro-FLG and FLG monomers (Bonnart et al. 2010). FLG itself 
contributes to the epidermal barrier integrity by aggregating the keratin interfilaments to 
form the cornified cell envelope, thereby providing the structural support and 
mechanically resilient skin barrier. In addition, FLG can be degraded into highly 
hygroscopic amino acids, NMFs, and contribute to water retention within the SC layers, 
helping to maintain skin hydration (Scott et al. 1982; McGrath & Uitto 2008). 
Therefore, hyperactive KLK5 results in enhanced activity of ELA2, which could induce 
misprocessing of (pro)-FLG. As a result, FLG deficiency leads to defects in the 
formation of cornified envelope, a decreased hydration in the SC and a concomitant 
elevation of pH. In addition, ELA2 hyperactivity is sufficient to induce the disruption of 
the lipid lamellae formation (Bonnart et al. 2010). These findings suggested that up-
regulated KLK5 activity could contribute to the deficiency of FLG and lipid secretion 
through activation of ELA2, which leads to increased water loss and lipid lamellae 
defect. Many of the above-mentioned functional studies of KLK5 were carried out in 
NS model, where uncontrolled KLK5 activity potentially aggravates epidermal barrier 
dysfunction and results in AD-like lesions through PAR2, DSG1 and ELA2. Although 
the etiologies are different, NS and AD are both characterised with defective skin 
barrier and share several clinical features such as eczematous lesions and atopic 
manifestations. Therefore, the mechanisms of atopic manifestation in NS caused by up-
regulated KLK5 may also be implicated in the more mild and common disease, AD.  
 
1.4.4 Possible roles of up-regulated KLK5 in AD  
Up-regulation of KLK5 has been found in AD patients (Komatsu et al. 2005, 2007b; 
Voegeli et al. 2009). As AD is a chronic skin disorder, many genetic and enviromental 
factors may lead to persistent epidermal barrier defect in AD, consequently resulting in 
consistently up-regulation of KLK5. For instance, variants within LEKTI gene could 
induce lack of inhibition against KLK5 and lead to sustained up-regulation of KLK5 in 
AD. In addition, variations of FLG gene and overuse of soap both result in elevated pH 
in the epidermis (Ananthapadmanabhan et al. 2004; Brattsand et al. 2005), which could 
subsequently induce consistently increased KLK5 activity in the AD skin.  
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Despite the well-established functions of KLK5 in epidermal barrier through PAR2, 
DSG1 and ELA2, the association between KLK5 up-regulation and skin barrier defect 
is still obscure and needs to be fully elucidated. We speculated that up-regulated KLK5 
could contribute to the epidermal barrier dysfunction in AD through its downstream 
molecules (Figure 1.7). Previous studies have reported that single stimulation by KLK5 
triggers over-expression of proinflammatory cytokines in keratinocytes through PAR2 
(Stefansson et al. 2008; Briot et al. 2009). However, exposure to PAR2 stimuli at a 
supramaximal concentration or repeated stimulation could cause desensitization and 
impaired function of PAR2 (Dery, O. et al. 1998; Oikonomopoulou, K. et al. 2006). It 
remained unclear whether the function of PAR2 can be affected by repeated stimulation 
of consistently up-regulated KLK5 in AD, and what the potential influences on 
proinflammatory cytokines are. In addition, up-regulated KLK5 results in over-
degradation of DSG1 (Descargues et al. 2005, 2006; Di et al. 2009) and may also 
contribute to disorganized keratinocyte growth through DSG1. This could lead to 
impaired barrier integrity and disrupted barrier formation, consequently exacerbating 
skin barrier defect in AD. Furthermore, up-regulated KLK5 leads to FLG deficiency 
and lipid defect through activation of ELA2 (Bonnart et al. 2010), which may disturb 
the barrier integrity and subsequently aggravate the epidermal barrier dysfunction in 
AD. Therefore, KLK5 could be a potential therapeutic target in AD. More importantly, 
inhibition of up-regulated KLK5 may improve the skin barrier function, making it a 
promising therapeutic intervention for AD. 
 
Figure 1.7. Schematic diagram of the possible mechanisms underlying epidermal barrier defect in AD 
triggered by up-regulated KLK5.  
Consistent up-regulation of KLK5 may exacerbate the skin barrier dysfunction in AD through PAR2, 
DSG1 and ELA2. The epidermal barrier may be repaired through inhibition of unregulated KLK5 using 
potential inhibitor. 
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1.5 Treatment for AD  
AD can impact the quality of life of affected individuals significantly. Apart from the 
visible skin conditions, patients with AD suffer from intense itch, which can lead to 
sleep disturbances. Children with AD have daytime behavioural difficulties associated 
with insufficient sleep (Chamlin et al. 2005). Recent studies also reveal that quality of 
life can be affected by AD (Yaghmaie et al. 2013). These findings suggest the necessity 
to improve the quality of life of AD patients by managing this disease effectively. In 
addition, the financial impact of AD can also be great. Patients and their families are 
burdened with time-consuming treatments for the disease, as well as the dietary and 
household changes. Furthermore, treatments for AD require frequent application of 
topical medications, which also poses a significant economic burden for the healthcare 
system (Carroll et al. 2005). The general clinical situation is accentuated by the large 
population of patients with AD. Therefore, exploration of new therapeutic strategies for 
AD could be beneficial for patients, families and the society. The aim to get a precise 
understanding of the role of KLK5 up-regulation in skin barrier impairment is to find 
more effective therapeutic strategies for AD, such as inhibition of unopposed KLK5 
activity using potential inhibitor.  
 
1.5.1 Management and current therapies for AD 
Appropriate daily skin care is vital in the management of AD. Avoidance of exposure to 
environmental irritants and allergens is advised for the patients. All cotton clothing and 
bedding that is less irritating than synthetic or wool fabrics should be used for affected 
individuals (Mason 2008). Moisturizing cleansers are recommended while highly 
fragranced soaps should be avoided as they may irritate the skin (Watson and Kapur 
2011). After bathing, moisturizers and emollients should be applied liberally to help 
prevent moisture loss and drying of the skin (Watson and Kapur 2011). In addition, 
antihistamines may be helpful especially at night to control the intense itching 
associated with AD (Herman and Vender 2003). 
At present, most of the treatments for AD aim at reducing the clinical symptoms of the 
disease. Anti-inflammatory therapies such as utilization of steroids and 
immunomodulators remain the first-line pharmacologic treatments for AD, including 
topical and systemic application of corticosteroids. Recent studies reveal that topical 
application of immunomodulators could not only suppress immune function, but also 
compromise epidermal barrier function (Kao et al. 2003; Choi et al. 2006; Kim et al. 
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2010). However, the usage of topical immunosuppressants have raised safety concerns, 
such as increased risk of serious infectious complications and UV-induced skin cancer 
at sites of prolonged applications (Paller et al. 2001; Soter et al. 2001; Wahn et al. 2002 
Hickey et al. 2005; Elias and Wakefield, 2011). Xerosis is another clinical features of 
AD, and emollient moisturizers can also ease the symptoms of AD through 
moisturization (Rawling et al. 2004; Korting et al. 2010). Although these therapies can 
reduce the disease severity in AD, the primary barrier defect that ‘drives’ the 
development of AD is not completely corrected (Elias et al. 2008).  
Previous studies in animal models and patients of AD indicate that barrier repair 
interventions can improve epidermal barrier function and further reduce the skin 
inflammation (Elias 2008; Ong 2009). For instance, lipid replacement therapies have 
been used to repair the skin barrier in AD. However, the non-physiologic lipids in these 
moisturizers can impair the epidermal barrier rather than correcting the barrier function 
(Elias 2006). The defect of epidermal barrier in AD is characterized by deficient 
lamellar secretion and reduction of all three types of key lipids, cholesterol, free fatty 
acids, and ceramides, with a significant deficiency of ceramide content. Ceramide 
serves as the major water-holding molecule in the extracellular space of the SC, and 
reduced level of ceramide was found in AD patients (Imokawa et al. 1991; Di Nardo et 
al. 1998; Hara et al. 2000). Thus, correction of the barrier dysfunction in AD requires 
topical applications not only of sufficient quantities of lipids but also the lipids with a 
dominant proportion of ceramide (Elias 2006). Recent studies reveal restoration of 
epidermal barrier in AD by lipid replacement therapy with a ceramide-dominant form 
(Elias 2008).  
 
1.5.2 Development of AD treatments 
Apart from the existing treatments, potential therapeutic approaches for AD such as 
application of specific siRNA and inhibitors have also been evaluated. Previous report 
reveals that non-invasive delivery of anti-IL-10 siRNA into the epidermis significantly 
reduced the mRNA level of IL-10, which is elevated in AD skin lesions (Ohmen et al. 
1995; Kigasawa et al. 2010). Another study investigated the transdermal delivery of 
siRNA against the NFkB subunit RelA, a possible therapeutic target in AD (Uchida et 
al. 2011). Previous findings also suggest that specific inhibitors of serine proteases 
chymases and phosphatase calcineurin are potential therapeutic agents for AD (Imada et 
al. 2002; Terakawa et al. 2008; Carr 2013). In addition, UV phototherapy could be 
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beneficial for the adult patients of AD. However, the usefulness of this therapy is 
limited due to the potential toxicity of long-term UV therapy, inconvenience and 
expense (Watson and Kapur 2011).  
At present, the therapies of AD continue to be dominated by proof-of-concept studies of 
primarily anti-inflammatory medications. Although always effective, current treatments 
have the same problems in AD as they do in other chronic inflammatory dermatoses 
such as psoriasis: long-term effects associated with toxicity and potential serious side 
effects. The effective treatment of AD requires multi-pronged approaches, which 
include the combination of skin barrier repair, control of skin inflammation and 
elimination of exacerbating factors. Although much can be managed with existing 
therapy, AD continues to present an unmet need for safe and effective therapy 
(Arkwright et al. 2013). In order to explore the potential treatment options for patients 
suffering from this skin disorder, intensive studies are carried out to understand the 
mechanisms underlying the pathogenesis of AD, which is still not fully elucidated. As 
AD is increasingly ascribed to a primary epidermal barrier dysfunction, therapeutic 
strategies of AD should be first directed at improvement of the epidermal barrier. 
However, specific aspects of AD therapies such as restoration of skin barrier function 
remain largely untargeted. Therefore, the mechanisms underlying impaired epidermal 
barrier in AD need to be further investigated.  
 
1.5.3 Inhibition of up-regulated KLK5 as a potential therapy for AD 
As a chronic skin disorder, AD is characterized by persistent epidermal barrier defect, 
which may induce sustained up-regulation of KLK5. Considering the regulatory roles of 
KLK5 in skin barrier function through PAR2, DSG1 and ELA2 (Section 1.4.3), 
unopposed KLK5 activity might aggravate the epidermal barrier dysfunction in AD 
through its downstream molecules, consequently promoting the development of this 
disease. Therefore, KLK5 could be a promising therapeutic target in the treatments of 
AD. Recently, several proteases were selected as molecular targets for drug design. The 
inhibitors of numerous proteases such as MMPs, serine proteases and aspartic proteases 
have been exploited as therapeutics and eventually entered the pharmaceutical market 
(Sotiropoulou & Pampalakis 2012). As dysregulation of various proteases were 
implicated in the pathogenesis of numerous diseases such as HIV and cancer, proteases 
are attractive targets in the drug development for these diseases (Pandey et al. 2007; 
Fayard et al. 2009; Llibre 2009). Among these proteases, KLKs represent a major 
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proteolytic system operating in many tissues, but their biological roles are still not well 
defined. An increasing number of studies implicate that aberrant regulation of KLKs is 
associated with diverse diseases such as hypertension, skin disorders, inflammation and 
cancer and suggest their clinical applicability as disease biomarkers (Yousef et al. 
2003b; Michael et al. 2006; Pampalakis & Sotiropoulou 2007; Korbakis et al. 2009). In 
addition, KLKs have emerged as versatile signalling molecules. Therefore, KLKs 
represent attractive biomarkers for clinical applications and potential therapeutic targets 
for common human pathologies (Sotiropoulou & Pampalakis 2012). Identification of 
potent specific and selective inhibitors of KLKs mainly through high-throughput 
screening platforms and substrate-guided design will aid the development of novel 
KLKs activity-modulating agents and the discovery of presently unidentified pathways 
mediated by KLKs in vivo (Swedberg et al. 2009; 2011; De Veer et al. 2013). In 
conclusion, inhibition of up-regulated KLKs, such as KLK5, for the treatments of 
diseases including AD represents a largely unexploited area that will be considerably 
developed in the future.  
Sunflower trypsin inhibitor (SFTI-1) is a 14 amino acid cyclic peptide extracted from 
the sunflower seeds. It exhibits exceptionally potent trypsin-inhibitory activity. SFTI-1 
and SFTI-1-derived analogues are known to act upon a wide range of serine proteases 
including cathepsin G7, matriptase and KLKs (Long et al. 2001; Swedberg et al. 2009; 
De Veer et al. 2013; Tan et al. 2013). In this thesis, Dr. Macmillan’s group at UCL 
Chemistry Department demonstrated that the circular peptides could be prepared via a 
native chemical ligation-type process. This strategy was utilised for the first time to 
produce the analogues of SFTI-1. Ile10 in the scaffold of SFTI-1 was substituted with 
glycine, which had been demonstrated to give rise to a folded SFTI-1 analogue. The 
synthesised peptide was designated as SFTI-G and exhibited inhibitory activity towards 
commercial recombinant KLK5 in spectrofluorimetric assay. Further experiments were 
conducted in this project to evaluate the influences of SFTI-G on the biological 
functions of KLK5 in human keratinocytes. Previous findings suggest that up-regulated 
KLK5 could exacerbate the epidermal barrier dysfunction in AD. An improved 
understanding of the contribution of KLK5 up-regulation to skin barrier defect and the 
development of AD could facilitate the drug development for this skin disorder. 
Therefore, restoration of epidermal barrier function through inhibition of unopposed 
KLK5 activity is a promising therapeutic intervention for AD. 
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1.6 Hypothesis and objectives  
1.6.1 Hypothesis 
In this project, it was hypothesized that up-regulation of KLK5 could exacerbate the 
epidermal barrier dysfunction in AD through affecting the cytokine production and cell 
growth in keratinocytes. If this is the case, inhibition of unopposed KLK5 activity might 
improve the skin barrier function, which is a promising therapeutic intervention for AD.  
 
1.6.2 Objectives 
The major objectives of this project are as follow,  
1. To compare the epidermal morphology, expression/activity of KLK5 and levels of 
relevant barrier-related proteins in normal and AD skin.  
2. To investigate the contribution of up-regulated KLK5 to skin barrier defect, 
keratinocytes ectopically overexpressing KLK5 (KLK5-cells) could be generated using 
lentiviral vector.  
3. To further study the influences of overexpressed KLK5 on epidermal barrier 
function, using in vitro skin-equivalent organotypic cultures (OTCs) and in vivo skin 
grafts generated from KLK5-cells.  
4. To investigate the effects of consistently up-regulated KLK5 on cytokine production 
and cell growth in keratinocytes, expression of related genes and proteins in KLK5-
cells. 
5. To verify whether the impairments caused by up-regulated KLK5 can be reversed 
through inhibition of unopposed KLK5 activity in KLK5-cells treated with SFTI-G. 
Specific studies have been planned for each chapter, and a brief description is added per 
chapter.  
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CHAPTER 2: METHODS 
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2.1 Recruitment of patient samples 
Clinical material was obtained with written informed consent from patients attending 
dermatology clinics at Great Ormond Street Hospital; ethical approval was granted by 
the local research ethics committee. Skin biopsies were taken from the nonlesional and 
lesional sites of five AD patients and five age-matched healthy donors. Each individual 
was given written informed consent before the biopsy was taken. The skin samples were 
fixed in 4% paraformaldehyde (Sigma-Aldrich, Poole, UK) overnight at 4°C and 
embedded in paraffin. All paraffin-embedded tissue was cut into skin sections (5µm 
thickness) and collected onto Superfrost plus slides (Fisher Scientific, Loughborough, 
UK). For the skin cryosections, the samples were snap frozen in liquid nitrogen in 
Tissue-Tek O.C.T. (Thermo Fischer Scientific, Loughborough, UK) and cut into 
sections (5µm thickness). 
 
2.2 Staining of skin biopsies 
2.2.1 Histological staining  
Hematoxylin and eosin staining (H&E staining) was performed on paraffin-embedded 
sections using standard histological techniques. The skin sections were deparaffinized in 
two changes of 100% xylene for 5 minutes each. Then the sections were rehydrated in 
100% ethanol twice and 70% ethanol twice for 5 minutes each. The slides were then 
kept in tap water for 5 minutes. The sections were stained with hematoxylin (GHS1128, 
Sigma-Aldrich, Poole, UK) for 10 minutes and briefly rinsed in tap water. Excess 
staining was removed by quickly dipping the slides in acidic ethanol (1% HCl in 70% 
ethanol) and rinsed again in tap water. Then the sections were stained in eosin (E4009, 
Sigma-Aldrich, Poole, UK) for 2 minutes. Stained sections were dehydrated in two 
washes of 70% ethanol, 100% ethanol, 100% xylene for 5 minutes each and mounted 
with DPX solution (Leica Biosystems, Newcastle, UK). 
 
2.2.2 Immunostaining  
Immunostaining for KLK5, PAR2 and FLG was performed on paraffin-embedded 
sections. The skin sections were dewaxed in two washes of 100% xylene for 5 minutes 
each. Then the sections were immersed in 100% ethanol twice and 70% ethanol twice 
for 5 minutes each. Antigen retrieval was achieved by microwave treatment in freshly 
prepared 10mM sodium citrate (pH 6.0) for 5 minutes 3 times. Endogenous peroxidase 
activity was blocked using 3% hydrogen peroxide in 1 x phosphate buffered saline 
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(PBS). Tissues were then incubated in fetal calf serum (FCS) for 30 minutes at room 
temperature. The sections were incubated with primary antibodies in a humid chamber 
overnight at 4°C. All the primary antibodies were diluted in PBS, and information and 
the dilutions of the primary antibodies used for immunostaining were listed in Table 2.1 
(Section 2.17). Negative controls were included for each sample by omitting the 
primary antibody.  
Next day, primary antibodies were removed by three washes with PBS for 5 minutes 
each. Tissues were incubated with appropriate biotinylated secondary antibodies (Dako, 
Cambridgeshire, UK) in blocking buffer (1 x PBS with 0.1% Triton X-100 (Sigma-
Aldrich, Poole, UK) and 3% FCS) with the dilution factor of 1:100.  Tissues were 
rinsed in PBS for three times and incubated with VECTASTAIN Elite ABC reagent that 
contains equal amount of Reagent A and B (Vector Laboratories, Peterborough, U.K.) 
for 30 minutes, and then developed with Vector DAB Peroxidase Substrate (Vector 
Laboratories, Peterborough, U.K.). Nuclei were counterstained with hematoxylin. 
Stained sections were dehydrated and mounted with DPX solution (Leica Biosystems, 
Newcastle, UK). 
Immunostaining of DSG1 was performed on skin cryosections. Prior to fixation, 
sections were air-dried and washed twice in PBS. Fixation of the tissue samples was 
performed by immersing the sections in ice-cold acetone (Sigma-Aldrich, Poole, UK) 
for 10 minutes. After fixation, the sections were washed three times in PBS. Then 
tissues were incubated in blocking buffer for 30 minutes at room temperature prior to 
incubation with primary antibodies overnight at 4°C. The following day, after several 
rinses with PBS, sections were incubated with appropriate Alexa-Fluor 488 or 568 
conjugated secondary antibody (1:500, Molecular Probes, Eugene) in dark for 1 hour at 
room temperature. All negative controls were incubated in the presence of secondary 
antibody alone. Nuclei were counter-stained with DAPI (Vector Laboratories, 
Peterborough, U.K.). After rinsing with PBS, the sections were mounted using Mowiol 
solution containing 10% Mowiol D488 (Calbiochem, Nottingham, U.K.), and the slides 
were kept at -20°C.  
Stained sections were visualized using a Leica DMLB Microscope. Images were 
captured by a microscope-mounted CCD camera (Cool-SNAP-Pro; Media Cybernetics, 
USA) controlled by Image-Pro Plus, version 6.0 (Media Cybernetics, USA). All images 
were taken with the same setting and saved as 24-bits color images or 8-bit gray-scale 
images.  
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2.2.3 Quantification of staining intensity  
Quantification of protein expression in the epidermis of stained skin sections was 
performed using computerised software Image-Pro Plus v6.0 (Media Cybernetics 
Corporation, USA). The images of three non-overlapped but adjacent regions in each 
skin section were recorded and saved digitally. In order to ensure the relative reliability, 
the light level on the microscope was set to a fixed value and the camera acquisition 
settings were kept constant to capture the images.  
The intensity threshold of positive staining for each antibody was defined and adjusted 
using the eyedropper tool provided in the software, and DAB-stained dots with brown 
color were selected (Figure 2.1). Color signal above the threshold for each antibody was 
considered to be positive, whereas any signal below the threshold was regarded as 
negative. The defined color threshold was saved and further applied for the stained skin 
sections. Before automate counting, the epidermis in each region was highlighted 
manually as an area of interest (AOI) using the irregular tool (Figure 2.1). The optical 
counts of positive staining within AOI were measured based on the defined threshold. 
The staining intensity in each AOI was shown as mean density, which was calculated as 
integrated optical density (IOD)/area. Average intensities of the positive staining in 
normal, AD nonlesional and AD lesional skin were analyzed using one-way ANOVA. 
The differences were considered statistically significant at p<0.05.  
 
 
Figure 2.1 Quantification of staining intensity using Image-Pro Plus.  
The images were recorded and saved digitally (A). The threshold of positive staining was defined using 
the eye-drop tool provided in the software. The epidermis was highlighted manually as an area of interest 
using the irregular tool. The optical counts of positive staining within AOI were measured based on 
intensity threshold (B). 
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2.2.4 In situ zymography 
The activity of total epidermal proteases was examined by in situ zymography using 
casein-derived substrate. This casein derivative is extensively labelled with fluorogenic 
dye BODIPY TR-X, which results in the formation of intramolecularly quenched 
substrate and leads to a quenching of the fluorescent dye. Protease-catalyzed hydrolysis 
on the casein substrate releases the fluorescent dye-labelled peptides, allowing for the 
detection of protease activity. Briefly, the skin cryosections were air-dried and rinsed 
using 1x PBS with 0.1% Triton X-100 (Sigma-Aldrich, Poole, UK). Then the skin 
sections were incubated with 10 µg/ml BODIPY TR-X conjugated casein substrate 
(Life Technologies, Paisley, UK) in the developing buffer (10 mM Tris-HCl, pH=7.8) 
in a humid chamber at 37°C for two hours. After rinsing with PBS, nuclei were counter-
stained with DAPI. Sections were again rinsed several times with PBS and mounted 
into Mowiol solution. The stained sections were kept at -20°C before being visualized 
using a Leica DMLB Microscope. 
 
2.3 Construction of lentiviral vector and production of lentivirus 
2.3.1 Construction of lentiviral vector 
The full-length cDNA encoding human KLK5 was amplified by RT-PCR with forward 
primer (5'-GGGTGGTTATAACTCAGGCC-3'), and reverse primer (5'-
GTGCATATCGCAGCAGTCGGTGG-3') (Invitrogen, Paisley, UK). The cDNA was 
cloned into pGEM-T vector (Promega, Hampshire, UK). Ligated vectors were 
transformed into E. coli competent cells JM109 (Promega, Hampshire, UK). Positive 
clones containing recombinant DNA were selected by white-blue screening using IPTG 
and X-gal (Sigma-Aldrich, Poole, UK). Presence of KLK5 gene insertion and the 
orientation of the insertion in the integrated vector were further confirmed using 
restriction digestion. The sequences of the recombinant pGEM-KLK5 plasmids were 
also checked using direct DNA sequencing (DNA sequencing services, Wolfson 
Institute for Biomedican Research, UCL), and the sequences were analyzed using 
Sequencher v5.2 (Gene Codes Corporation, USA).  
Amplified KLK5 gene was further cloned to a HIV-1 based, self-inactivating lentiviral 
vector. The vector contains upstream spleen focus-forming virus (SFFV) promoter and 
downstream enhanced green fluorescent protein (eGFP) reporter gene. The vector 
encoding eGFP alone was used as negative control (Figure 2.2). SFFV promoter is 
known to mediate high levels of transgene expression in a diverse variety of target 
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tissues. Lentiviral vector was digested using BamHI site, and pGEM-KLK5 vector was 
digested using SacI and SacII sites. All the restriction endonucleases used in this 
experiments were purchased from New England Biolabs (Hertfordshire, UK). Both 
digested lentiviral vector and KLK5 fragment were blunted. KLK5 gene was then 
cloned into the lentiviral vector using blunt end ligation to generate SFFV-KLK5-eGFP 
construct. Ligated vectors were transformed into E. coli competent cells. Clones with 
presence of KLK5 gene and correct orientation of insertion were selected using 
restriction digestion and direct DNA sequencing.  
 
Figure 2.2 Construction of lentiviral vector.  
KLK5 overexpression vector was constructed by cloning of KLK5 gene into a lentiviral vector containing 
upstream SFFV promoter and downstream eGFP reporter gene. KLK5 and eGFP genes were separated 
by an internal ribosome entry site (IRES). The vector containing eGFP only was used as control. 
 
2.3.2 Production and titration of lentivirus 
The 293T human renal epithelial cell line is a convenient source of recombinant virus. 
293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, 
Paisley, UK) containing 200 mM L-glutamine, 10 mM MEM non-essential amino acids, 
500 µg/ml geneticin and 100 mM sodium pyruvate, supplemented with 10% fetal calf 
serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were maintained 
in culture at 37oC with 5% CO2.  
Lentivirus were produced by co-transfecting 293T cells with a packaging plasmid 
(pCMV8.74) encoding viral gag, pol and accessory proteins and an envelope plasmid 
(pMDG2) encoding the envelope of vesicular stomatitis virus. Twenty-four hours prior 
to transfection, 12 x 106 cells were seeded in each T175 flask. The following day, 293T 
cells cultured in T-175 flask were transfected with 25 µg of KLK5/eGFP or eGFP 
plasmid, 17.5 µg of pMDG2 plasmid and 25 µg of pCMV8.74 plasmid. Plasmid vectors 
and 1 × 10−7 mol/l of polyethylenimine (Sigma-Aldrich, Gillingham, UK) were diluted 
in OptiMEM (Invitrogen, Paisley, UK) and filtered through 0.22-µm pore cellulose 
acetate filters. Then the solution was gently mixed before being added to the cells. 
Infectious lentiviruses were harvested 48 and 72 hours post-transfection. The culture 
supernatants were collected and centrifuged at 2,000 R.P.M. for 5 minutes to get rid of 
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the cell debris, followed by being filtered through 0.45-µm pore filters. The filtered 
supernatants were concentrated by ultracentrifugation at 23,000 R.P.M for 2 hours. The 
final viral pellets were resuspended in OptiMEM for 30 minutes on ice and aliquots of 
viral stocks were kept at −80 °C until further use. 
For the titration of lentivirus, 1x105 of 293T cells were seeded on 24 wells plate and 
infected with serial dilutions of KLK5/eGFP or eGFP lentiviral stock. Multiplicity of 
infection (MOI) used for the lentiviral infection ranged from 10 to 0.0032. Transduced 
cells were identified by eGFP fluorescence using flow cytometry. Briefly, a suspension 
of non-fixed cells was analyzed on a BD LSRII FACS machine (BD, San Jose, CA, 
USA). Forward and side scatter were used to exclude debris and aggregates, and eGFP 
fluorescence was measured by filter 530/30 nm. Transduced cells were identified by 
eGFP fluorescence. For each sample, 10,000 eGFP positive cells were collected. 
Analysis was performed using FlowJo (Tree Star, Stanford University, San Francisco, 
CA, USA). Transducing activity was expressed in transducing units (TU). The titers of 
the virus in transducing units per ml (TU/mL) was determined using the following 
formula: virus titers = [(cells at starting time) x (percentage of transduced 
cells)]/(volume of virus solution added expressed in mLs). Titres of eGFP and 
KLK5/eGFP lentivirus were 8x108 and 4x108 TU/mL respectively. 
 
2.4 Human keratinocytes culture and lentiviral transduction 
2.4.1 Culture of human keratinocytes 
Human keratinocytes were co-cultured with lethally irradiated 3T3 mouse fibroblasts 
and grown in the keratinocyte culture media. The culture media was consisted of equal 
amount of DMEM and DMEM/Ham F12 (DMEM/F12, 3:1 mixture) (Invitrogen, 
Paisley, UK) supplemented with 10% FCS and Pen/Strep (100 IU/ml of penicillin, 100 
µg/ml of streptomycin). Human keratinocyte growth supplement (Invitrogen, Paisley, 
UK) was added to the culture media, and the final concentrations of the components in 
the supplemented medium were: 0.2% bovine pituitary extract, 5 µg⁄ml bovine insulin, 
0.18 µg⁄ml hydrocortisone, 5 µg⁄ml bovine transferrin, 0.2 ng⁄ml human epidermal 
growth factor. Keratinocytes were maintained in culture at 37oC, 5% CO2 and passaged 
every 3-4 days at subconfluence and fresh 3T3 feeder cells were added when needed. 
Three types of human keratinocytes were used: NIKS, NTERT and primary human 
keratinocytes. NIKS is a spontaneously immortalized human keratinocyte cell line 
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(Allen-Hoffmann et al. 2000). NTERT cells are immortalized human keratinocytes by 
ectopically expressing of the telomerase catalytic subunit hTERT (Dickson et al. 2000). 
Both cell lines become immortal but still retain normal growth and differentiation 
characteristics. As cell lines are easy to be handled and cultured, they are important 
tools for the in vitro study. However primary cell cultures mimic the physiological state 
of cells more closely and are more suitable for the in vitro and in vivo function study. 
Therefore, primary human keratinocytes were also used in this study. 
In order to isolate human primary keratinocytes, sterile skin biopsies were obtained by 
punch biopsy from healthy volunteer donors or AD patients. Each individual has been 
given written informed consent initially when the biopsy was taken. The biopsies were 
then washed in PBS and excess dermis together with underneath connective tissues 
were removed using sterile blade. The skin samples were cut into small pieces and 
immersed in the Dispase solution (50U/mL, BD Biosciences, Plymouth, UK) at 4oC 
overnight. Next day, the epidermis was mechanically separated from the dermis using 
forceps after the enzymatic treatment with Dispase. The epidermis was cut into small 
pieces and incubated with 0.25% trypsin/EDTA at 37oC for 40 minutes with agitating 
every 10 minutes. Equal volumes of 10% FCS/DMEM were then added into the 
digested contents to neutralise the trypsin. The contents were filtered through sterile 
100µM cell strainer (BD Biosciences, Plymouth, UK) and the filtered suspension was 
centrifuged at 2,000 R.P.M. for 10 minutes. The cell pellet was resuspended in 
keratinocyte culture media and seeded in the flask with 3T3 feeder layer.  
2.4.2 Lentiviral transduction of human keratinocytes 
For lentiviral transduction, 2x105 of human keratinocytes were seeded on 12 wells plate 
24 hours prior to transduction. On the following day, cells were infected with 
KLK5/eGFP or eGFP lentiviral stock without addition of a cationic polymer. Following 
exposure to one round of lentiviral infection at MOI 10, transduced cells with eGFP 
fluorescence were visualized under Leica DM IL inverted fluorescent microscope and 
transduction efficiencies were assessed at different time points. Percentage of GFP 
positive cells in transduced keratinocytes was also evaluated using flow cytometry. 
Briefly, cultured cells were trypsinized and resuspended in PBS with 5% FCS. The 
suspension of non-fixed cells was analyzed on a BD LSRII FACS machine (BD, San 
Jose´, CA, USA). Forward and side scatter were used to exclude debris and aggregates, 
and eGFP fluorescence was measured by filter 530/30 nm. Transduced cells were 
identified by eGFP fluorescence. In all cases, 10,000 eGFP positive cells were 
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collected. Analysis was performed using FlowJo (Tree Star, Stanford University, San 
Francisco, CA, USA).  
2.5 Immunocytostaining 
Over twenty-four 13mm glass coverslips were immersed in 70% alcohol (IMS) in a 
sterile petri dish for approximately ten minutes. Then the coverslips were taken out 
from the petri dish and left to dry in the hood. Each coverslip was transferred into an 
individual well of a 24-well plate. 2x105 cells were seeded in each well and the plate 
was stored in an incubator at 37oC, 10% CO2 for 2 days. Prior to fixation, all cells were 
washed twice with PBS. For fixation and permeablilization of cells, the coverslips were 
immersed in 4% paraformaldehyde solution with 0.1% Triton X-100 for 10 minutes, 
after which the coverslips were transferred into 35mm petri dishes. Then the cells were 
washed three times using PBS. After the third wash, the cells were left in PBS and 
stored at 4°C before staining.  
Immunofluorescence staining was performed by adding 30µl of diluted anti-KLK5 
antibody to each coverslips, proceeded by immediate coverage using a small piece of 
parafilm. Then the cells were incubated with the primary antibody in a humid chamber 
at 4°C overnight. Negative controls were included for each sample by omitting the 
primary antibody. Following by three repeated washes with PBS, each coverslip was 
incubated with Alexa Fluor 568–coupled goat anti-mouse IgG in dark at room 
temperature for one hour. The cells were then washed three times in PBS and left in the 
final wash for 15 minutes. Nucleus was counterstained with DAPI, followed by further 
washing of the cells twice in PBS. The coverslips were mounted onto glass slides using 
Mowiol solution (Calbiochem, Nottingham, U.K.) and stored at -20°C. Images were 
recorded using a LSM 510 UV confocal laser scanning microscopy (Zeiss, Germany) 
and processed using ZEN 2009 Light Edition (Zeiss, Germany). 
2.6 Western blotting 
2.6.1 Protein assay 
The cell pellets were resuspended in ice-cold lysis buffer, pH 8.0. The final 
concentrations of the components in the lysis buffer were:  50 mmol/L Tris-HCl, 150 
mmol/L NaCl, 5 mmol/L EDTA, 1x protease inhibitor cocktail (Roche, Mannheim, 
Germany), 1mmol/L phenylmethanesulfonylfluoride and 1% Triton. Samples were 
incubated on ice for 15 minutes. To lyse the cells completely, the solution was pipetted 
up and down for several times, prior to being centrifuged at 12,000 R.P.M. for 15 
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minutes at 4oC to pellet the insoluble material. The total protein concentration in both 
cell lysates and culture supernatants were determined using Bio-Rad protein assay kit 
(Hertfordshire, UK). Two-fold serial dilutions of protein standard bovine serum 
albumin (BSA) that cover the range from 3.125 µg/ml to 50 µg/ml were used to 
generate the standard curve. Serial dilutions of both the protein supernatant and BSA 
protein were then prepared, after which the absorbance of each sample was read at a 
wavelength of 595nm. The concentration of total protein was calculated in reference to 
serial dilutions of BSA falling within the linear part of the standard curve. 
2.6.2 SDS-PAGE and protein transfer 
The cell lysates or culture supernatants were diluted in 5x sample buffer containing 
0.5mmol/l Tris-HCl, 100mmol/l dithiothreitol, 10% sodium dodecyl sulfate (SDS), 30% 
glycerol and 0.001% bromophenol blue, pH 6.8. The samples were heated at 95oC for 5 
minutes. The gels were prepared according to the recipe (Table 2.1). Once the gels were 
prepared, 5µl of full range Rainbow molecular weight marker (GE Healthcare, 
Buckinghamshire, UK) was loaded. Equal amount of total protein in appropriate 
volumes of each sample were also loaded in sodium dodecyl sulfate polyacrylamide gel 
electrophoresis. The gels were then run at 100V in running buffer for approximately 
three hours, until the samples had run to the end of the gel. The components of the 
running buffer were: 25 mmol/L Tris-base, 190 mmol/L glysine and 0.1% SDS in 
dH2O. 
 Company	 8%		 10%		 12%		 Stacking	gel	
H2O	 -	 4.71	mL	 4.05	mL	 3.35	mL	 3.05	mL	
1.5	M	Tris-HCl,	pH	8.8	 Sigma	 2.5	mL	 2.5	mL	 2.5	mL	 -	
0.5	M	Tris-HCl,	pH	6.8	 Sigma	 -	 -	 -	 1.25	mL	
30%	Acrylamide/Bis-
acrylamide		 Sigma	 2.64	mL	 3.3	mL	 4	mL	 0.65	mL	
20%	(w/v)	SDS	 Sigma	 100	µl	 100	µl	 100	µl	 50	µl	
10%	ammonium	
persulfate	(APS)	 VWR	 150		µl	 150		µl	 150		µl	 37.5	µl	
TEMED	 Sigma	 30	µl	 15	µl	 15	µl	 7.5	µl	
Table 2.1: Recipe of the separating and stacking gels for SDS-PAGE.  
 
After electrophoresis, proteins were transferred to Hybond-P polyvinylidene fluoride 
membranes (GE Healthcare, Buckinghamshire, UK) at 100V for 1 hour and 30 minutes. 
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Prior to transfer, a nitrocellulose membrane, several pieces of filter paper and sponges 
were all soaked in transfer buffer for at least 15 minutes. The stacking gel was removed 
and the remaining gel transferred to the saturated membrane stacked on top of the moist 
sponge and filter paper. The gel was covered with a second piece of soaked filter paper 
and sponge, all of which were contained within a plastic enclosed grid and transferred 
into the transfer chamber filled with transfer buffer. The components of the transfer 
buffer were: 25 mmol/L Tris-base, 190 mmol/L glysine, 20% methanol in dH2O. The 
chamber was kept within an ice bucket.  
2.6.3 Detection 
The membrane was washed for 3 times by soaking in wash buffer that contains PBS 
with 0.05% Tween 20 on a shaker. After washing, the membrane was blocked with 
block solution containing 5% dried skimmed milk in wash buffer for 1 hour. This was 
followed by three washes, each for 5 minutes in wash buffer. The membrane was then 
incubated with primary antibodies in a sealed plastic bag on a vigorous shaker 
overnight. All the primary antibodies were diluted in 3% BSA in PBS. Information of 
the primary antibodies used for western blot analysis was listed in Table 2.1 (section 
2.17). On the next day, the membranes were washed by 3 times and further incubated 
with sheep anti-mouse immunoglobulin G antibody conjugated with horseradish 
peroxidase (HRP) (GE Healthcare, Buckinghamshire, UK) or mouse anti-rabbit 
immunoglobulin G antibody conjugated with HRP (Sigma-Aldrich, Gillingham, UK) in 
a sealed bag for 1 hour. The secondary antibodies were diluted in 3% dried skimmed 
milk in wash buffer. This was followed by three consecutive washes in wash buffer 
each for 10-15 minutes. Signals were detected using the ECL Prime Western Blotting 
Detection System (GE Healthcare, Buckinghamshire, UK) following by the instruction 
of the manufacturer. All experiments were performed in duplicate, and densitometry 
analysis was carried out on scanned immunoblot images. 
 
2.7 Casein gel zymography 
NIKS and NTERT cells were cultured in serum free keratinocyte culture media for 48 
hours. The culture media were collected and concentrated using Amicon centrifugal 
filter devices (Millipore, Watford, UK). Concentrated samples were mixed in a non-
reducing Novex® Tris-Glycine SDS Sample Buffer (Life Technologies, Paisley, UK). 
And then the samples were loaded onto polyacrylamide gels copolymerized with casein 
substrate (12% acrylamide, 0.1% casein, Life Technologies, Paisley, UK) for 
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electrophoresis. After electrophoresis, the gels were soaked in renaturing buffer 
containing 50 mM Tris, pH 8 and 2.5% Triton X-100 (Life Technologies, Paisley, UK) 
for 1 hour at room temperature to remove SDS. Then the gels were incubated at 37°C in 
developing buffer containing 50 mM Tris, pH 8 (Life Technologies, Paisley, UK) for 24 
hours. Gels were stained with 1% Coomassie Brilliant blue (Sigma-Aldrich, Poole, UK) 
for 1 hour. Casein degrading activity could be visualized when the gels were stained 
with Coomassie Blue. Areas with caseinolytic activity showed as clear bands against the 
dark blue background, revealing the digestion of substrate on the gel. 
2.8 Intracellular calcium mobilization assay 
Measurement of intracellular [Ca2+] mobilization was performed using the FluoForte 
Calcium Assay kit (Enzo Life Sciences, Exeter, UK). Mobilization of intracellular 
calcium was detected utilizing a fluorogenic calcium-binding dye. The dye is provided 
to the cells as an acetoxymethyl ester, which is cell-permeable. Once inside the cells, 
the dye is hydrolyzed by intracellular esterases, leading to the formation of a cell 
membrane impermeable form of this dye. In the absence of calcium, the calcium-
binding moiety portion of the dye quenches the fluorescence of its fluorophore portion. 
The self-quenching of this dye was relieved upon binding of mobilized calcium, 
resulting in an increased fluorescence signal. 
Human keratinocytes were plated in 96-well plates at the density of 1 × 104 cells/100 µl 
per well. After 24 hours, the growth medium was completely removed. Dye-loading 
solution was prepared by reconstituting one vial of Reagent A in assay buffer 
containing 1mL of Reagent B and 9mL of Reagent C, and 100 µl of dye-loading 
solution was added per well. The cells were further incubated with the dye-loading 
solution for 45 min at 37°C and then 15 min at room temperature. The cells were 
stimulated with 25µM of recombinant human KLK5 (rKLK5) from commercial source 
(R&D Systems, Oxfordshire, UK) or 100µM of PAR2 activating peptide (SLIGKV-
NH2, H-5024, Bachem, Switzerland), and a time-response curve of intracellular [Ca2+] 
signal was recorded via real-time monitoring of fluorescence intensity at excitation = 
530 nm and emission = 570 nm in a microplate reader (FLUOstar, OPTIMA). For the 
inhibitory study, during the incubation of the cells, concentrated culture media of 
KLK5-cells containing recombinant KLK5 was pre-incubated with SFTI-G at different 
concentrations at 37°C for 10 minutes. Normal keratinocytes were challenged with the 
mixtures of pre-incubated KLK5 and SFTI-G. Cells injected with KLK5 alone were 
used as control. The response curve of intracellular [Ca2+] mobilization was recorded. 
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Intracellular calcium mobilization was shown as an increase of fluorescence intensity in 
relative fluorescence units (RFU), and the RFU values were plotted against the time. 
 
2.9 Three-dimensional organotypic cultures (OTCs) 
Following a single passage, primary keratinocytes were cultivated in vitro on de-
epidermalized dermal (DED) matrix. Briefly, glycerol-preserved DED matrix (Euro 
Skin Bank, Beverwijk, Netherlands) was incubated in PBS containing antibiotic mix 
(600 units/mL penicillin-G, 600 µg/mL streptomycin sulfate, 250 µg/mL gentamicin 
sulfate, and 2.5 µg/mL fungizone) at 37°C for up to 10 days and then cut into 1.5 × 
1.5 cm2. Dermal fibroblasts derived from normal human skin biopsies (passages 3–7) 
were used for the culture. Primary human fibroblasts were seeded onto the reticular side 
of the DED matrix overnight. Next day, the keratinocytes were seeded on the papillary 
side of the DED matrix (Figure 2.3).  
After keratinocytes reached confluence (about 2–3 days), the culture was lifted and then 
cultivated at the air-liquid-interface for 14 days to allow keratinocyte differentiation. 
The mature cultures were fixed in 4% paraformaldehyde at 4°C overnight, following by 
being embedded in paraffin or snap frozen in liquid nitrogen in Tissue-Tek O.C.T. All 
paraffin-embedded or snap frozen tissues were cut into skin sections (5µm thickness) 
and collected onto glass slides. For histological examination, paraffin-embedded 
sections were stained with hematoxylin and eosin. Immunostaining for KLK5, FLG and 
DSG1 was performed on paraffin-embedded sections or cryosections. 
 
Figure 2.3: In vitro assessment using three dimensional organotypic cultures.  
Primary keratinocytes were cultured in vitro on DED matrix at the air–liquid interface for 14 days 
(Adapted from Martins et al. 2009). 
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2.10 Bioengineered skin preparation and grafting to immunodeficient	
mice 
Primary normal human keratinocytes infected with lentiviral vectors encoding eGFP or 
KLK5/eGFP genes were seeded on top of a fibrin matrix populated with live primary 
human fibroblasts (Figure 2.4 A). After keratinocytes reached confluence, the 
bioengineered skin constructs were grafted onto the dorsum of six-weeks old female 
immunodeficient nude/nude mice (NMRI strain, Elevage-Janvier, France) (Figure 2.4 
B). Eight weeks after grafting, skin samples from grafts were taken postmortem, 
embedded in paraffin or snap frozen and sectioned for histological and 
immunohistochemical examination. 
 
 
Figure 2.4: In vivo evaluation using a humanized mouse model.  
(A) Formation of the skin-equivalent constructs (Di Nunzio et al. 2008). 
(B) Keratinocytes were grafted onto nude mice based on two independently conducted experiments (a), 
and scar was formed and peeled off about 2 weeks post-grafting (b). Regenerated skin grafts were 
examined 8 weeks after grafting (c).  
 
2.11 RT2 profiler Human EGF PCR array  
The SYBR-Green fluorescence-based human EGF PCR array (Qiagen, Manchester, 
UK) was used to evaluate the expression of 82 genes related to EGF-mediated signal 
transduction in keratinocytes transduced with KLK5/eGFP or eGFP only vector. The 
experiment was conducted by following the instruction of manufacturer. Total RNA 
was extracted using Trizol reagent (Sigma-Aldrich, Gillingham, UK). cDNA was 
synthesized using the RT² First Strand Kit according to the protocol provided by the 
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manufacturer. cDNA template was mixed with the appropriate ready-to-use PCR master 
mix, and equal volumes were aliquot to each well of the same plate. Then the plate was 
run using the real-time PCR cycling program on a real-time thermal cycler (7300, 
Applied Biosystems). PCR conditions consist pre-heating of the thermal sensitive 
HotStart DNA polymerase at 94ºC for 10 minutes, followed by 40 cycles of PCR 
performed at 95ºC for 15 seconds, 60ºC for 1 minute.The expression of target genes was 
normalized to the housekeeping genes. Fold change was calculated as the normalized 
gene expression (2^(- Delta Ct)) in KLK5-cells divided by the normalized gene 
expression in eGFP-cells. Fold-Regulation represents fold-change results in a 
biologically meaningful way. Fold-change values greater than one indicate a positive- 
or an up-regulation, and the fold-regulation is equal to the fold-change. Fold-change 
values less than one indicates a negative or down-regulation, and the fold-regulation is 
the negative inverse of the fold-change. Three-fold change was used as the threshold. 
 
2.12 Reverse transcription-PCR (RT-PCR) 
Total RNA was isolated from samples using Trizol reagent (Sigma-Aldrich, 
Gillingham, UK).  cDNA was synthesized from RNA template using first strand cDNA 
synthesis kit for RT-PCR (Roche, Mannheim, Germany). The reverse transcription 
reaction was performed using 1µg RNA diluted in 1µL nuclease free water, 2µL first 
strand buffer, 4µL MgCl2 solution, 1µL random primers, 8µL dNTPs, 1µL RNase 
inhibitor and 1µL reverse transcriptase. The sample was incubated at room temperature 
for 30 minutes. After that, 1 cycle of PCR was performed at 42ºC for 45 mins, 99ºC for 
5 mins and 5ºC for 5 mins in a PCR cycler. The expression of KLK5 and GSK-3b was 
determined using PCR. A 25 µL reaction was performed using 100ng of cDNA 
template, 12.5µL of PCR mastermix, 2.5µL of upstream primer, 2.5µL of downstream 
primer, 0.625U of Taq polymerase and nuclease free water.  
All the primers were purchased from Invitrogen, and primer sequences were as 
follows:KLK5: forward primer (5'-GGGTGGTTATAACTCAGGCC-3'); and reverse 
primer (5'-GTGCATATCGCAGCAGTCGGTGG-3'); GSK-3b: forward primer 
(5'CAGTTTTCCTGGCCAGGAGC-3'); and reverse primer (5'-
CCCAAAGAGGTAAGCGCTAC-3'). PCR conditions consist pre-heating of the 
thermal sensitive Taq polymerase at 94 ºC for 2 minutes, followed by 40 cycles of PCR 
performed at 94ºC for 30 seconds, 60ºC for 30 seconds and 72ºC for 30 seconds and 72 
ºC for 10 minutes in a PCR cycler. The expression of KLK5 and GSK-3b was 
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normalized to the housekeeping gene GAPDH.  
 
2.13 Human phospho-kinase antibody array 
The Human Phospho-Kinase Antibody Array (R&D Systems, Oxfordshire, UK) was 
used to probe 43 phospho-kinases and 2 related total proteins heat shock protein 60 
(HSP60) and β-catenin in the cell lysates of cultured keratinocytes. The experiment was 
conducted by following the procedures recommended by manufacturer. Briefly, the 
array membranes were first incubated in the block buffer for 1 hour. In the meantime, 
cells were lysed in the by incubating in the lysis buffer on ice for 15 minutes. The 
samples were then centrifuged at 12,000 R.P.M. for 15 minutes to pellet the insoluble 
material. The total protein concentration in the cell lysate was determined using Bio-
Rad protein assay kit (Hertfordshire, UK). Desired quantity of cell lysates were diluted 
with the blocking buffer. After being removed from the block buffer, the array 
membranes were incubated with the diluted cell lysates at 4 ºC overnight. After 
incubation, the membranes were washed 3 times with wash buffer containing PBS and 
0.05% Tween 20 for 5 minutes each and incubated with the detection antibody cocktail 
at room temperature for 1 hour. Following incubation, the membranes were washed 
with 3 changes of wash buffer that contains PBS and 0.05% Tween 20 for 5 minutes 
each and then incubated with the steptavidin-HRP solution at room temperature for 30 
minutes. The membranes were finally washed with wash buffer for 3 times at room 
temperature and the bound antibodies were detected by chemiluminescence using the 
reagents provided by manufacturer. The intensities of the blots were quantified by 
densitometry. As each reference or target protein was blotted in duplicate, mean pixel 
density of each pair of duplicate blots was calculated as a result of the protein level of 
each reference or target. 
 
2.14 Human cytokine antibody array 
The Human Cytokine Antibody Array Panel A (R&D System, Oxfordshire, UK) was 
used to probe 36 cytokines in the culture supernatants collected from keratinocytes. The 
experiment was conducted by following the procedures recommended by manufacturer. 
Briefly, the array membranes were first incubated in the block buffer for 1 hour. In the 
meantime, desired quantity of culture media was mixed with the detection antibody 
cocktail and incubated at room temperature for 1 hour. After removing the block buffer, 
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the sample/antibody mixture were added to the array membranes and incubated at 4 ºC 
overnight. Followed by the incubation, the membranes were washed 3 times with wash 
buffer that contains PBS and 0.05% Tween 20 for 5 minutes each and then incubated 
the steptavidin-HRP solution at room temperature for 30 minutes. The membranes were 
finally washed with wash buffer for 3 times at room temperature and the bound 
antibodies were detected by chemiluminescence using the reagents provided by 
manufacturer. The intensities of the blots were quantified by densitometry. As each 
reference or target protein was blotted in duplicate, mean pixel density of each pair of 
duplicate blots was calculated as a result of the protein level of each reference or target. 
 
2.15 Enzyme linked immunosorbent assay (ELISA) 
Culture supernatants were collected 48 hours after the cells reached confluence, 
followed by centrifugation at 1,200 R.P.M for 7 min at 4°C to remove the cellular 
debris. The total protein concentration in culture supernatant was quantified using Bio-
Rad protein assay kit (Section 2.5.1). The samples were then stored at −80°C until being 
subjected to ELISA. Expression of IL-8 in the culture supernatants was measured by 
ELISA using mouse monoclonal antibody to human IL-8 (BD Biosciences, San Diego, 
CA, USA). Immunoreactive TSLP and IL-10 within the supernatants were also 
quantified using ELISA kits containing mouse monoclonal antibodies against human 
TSLP and IL-10 (eBioscience, Hatfield, UK). These antibodies had no measurable cross 
reactivity with high concentrations of other known cytokines as claimed by the 
manufactures. Serial dilutions of recombinant standards and samples were carried out 
according to the instructions provided by the manufacturers. The standard curves were 
generated using the recombinant standards within certain range. The expression of 
protein was quantified in reference to serial dilutions of recombinant standards falling 
within the linear part of the standard curve. The levels of IL-8, TSLP and IL-10 were 
normalized to the concentration of total protein in each sample. Data represent the 
results from three independent experiments performed in duplicate. 
 
2.16 Statistical analysis  
Each experiment was performed independently for two or three times. Data were 
expressed as mean ± standard error of the mean (SEM) of one experiment performed in 
duplicate or triplicate. The appropriate statistical tool was used as described in each 
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chapter. For comparison of protein expression in normal, AD nonlesional and AD 
lesional skin, data were analyzed statistically using one-way ANOVA with post-hoc 
Tukey tests. The levels of different proteins in untransduced cells, eGFP-cells and 
KLK5-cells were compared by one-way ANOVA with post-hoc Tukey tests. For 
comparison of SFTI-G treated and untreated groups, student’s t-test was used to 
determine the statistically significant differences between the treated and untreated 
groups. Statistical evaluation of data was performed using SPSS 16.0 (SPSS Inc., 
Chicago, USA). Differences with p-value less than 0.05 were considered as statistically 
significant. 
 
2.17 Antibodies 
The information and dilutions of the antibodies used in immunostaining and western 
blotting were listed in Table 2.2.  
Antibody  Raised species Clone 
Product 
code Company 
Dilution for 
staining 
Dilution for 
western blotting 
KLK5 mouse - H00025818-B01P 
Abnova, 
Taiwan,  
China 
1:500 1:5000 
DSG1  
(extracellular) mouse P124 
10R-
D104A 
Fitzgerald, 
Cambridge, 
UK 
1:100 
 
1:100 
 
PAR2 mouse Sam11 sc-13504 
Santa Cruz, 
Heidelberg, 
Germany 
1:50 1:200 
FLG mouse 
 
15C10 
NCL-
FILAGG
RIN 
Leica 
Microsystem, 
Newcastle, UK 
 
1:100 
 
- 
Involucrin Mouse 
 
SY5 19018 
Sigma-aldrich, 
St. Louis, 
USA 
1:10000 - 
 
GSK-3β 
 
rabbit 
 
Y174 ab32391 
Abcam, 
Cambridge, 
UK 
- 1:5000 
Phospho-p53 rabbit - AF2996 
R&D, 
Oxfordshire, 
UK 
 
- 
 
1:2000 
HSP60 mouse 
 
264233 MAB 
1800 
R&D, 
Oxfordshire, 
UK 
 
- 
 
1:1000 
Actin mouse 
 
AC-15 A5441 
Sigma-aldrich, 
St. Louis, 
USA 
 
- 
 
1:10000 
 
Table 2.2 List of antibodies used for immunostaining and western blotting. 
	 77	
 
 
 
 
 
 
 
 
 
CHAPTER 3: RESULTS 
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3.1 Disturbed epidermal barrier in AD 
Epidermal barrier dysfunction is considered as the initial event in AD. Various genetic 
and environmental factors can contribute to enhanced activity of epidermal proteases, 
consequently exacerbating the skin barrier defect and promoting the development of 
AD. KLK5 is one of the key epidermal proteases accounting for most of the trypsin-like 
proteolytic activity (Brattsand et al. 2005). It is also involved in the regulation of 
epidermal barrier function through DSG1, PAR2 and ELA2 (Caubet et al. 2004; 
Descargues et al. 2006; Briot el al. 2009; Bonnart et al. 2010). It was speculated that up-
regulation of KLK5 might play an important role in skin barrier dysfunction in AD. 
Although previous reports showed increased expression and elevated proteolytic 
activity of KLK5 in AD lesions (Komatsu et al. 2005, 2007b; Voegeli et al. 2009), there 
were few studies evaluating the expression of KLK5 protein in skin samples obtained 
from a group of AD patients by comparing to a group of age-matched healthy donors. In 
this study, the epidermal morphology, the expression of KLK5 and the levels of 
relevant barrier-related proteins were examined in the AD and normal skin. Skin 
biopsies were taken from the nonlesional and lesional sites of five AD patients and five 
age-matched healthy donors (Section 2.2.1).  
 
3.1.1 Impaired epidermal morphology in the AD skin 
The epidermal morphology in AD and normal skin was examined by H&E staining 
(Section 2.2.1). The lesional skin from all five AD patients exhibited morphological 
changes by comparing to the normal skin (Figure 3.1, k-o vs. a-e). Histopathological 
features of AD lesion consisted of acanthosis (thickening of the epidermis), 
parakeratosis (retention of nucleus in the cornified layer), elongated rete ridges of the 
epidermis and superficial dermal perivascular inflammatory infiltrate. In contrast, the 
conified layer remained relatively intact in the nonlesional skin compared to the lesional 
skin. However, the nonlesional skin already exhibited some AD-like histopathological 
characteristics (Figure 3.1, f-j), but far less prominent than those observed in the 
lesional skin.  
In addition, keratinocytes were tightly connected in the normal skin under higher 
magnification, whereas enlarged intercellular space between neighboring keratinocytes 
was observed in the AD lesional skin, as well as the nonlesional sites of some AD 
patients (Figure 3.2).  
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Figure 3.1. Impaired epidermal barrier in the AD skin.  
H&E staining was performed on the normal and AD skin. The AD lesional skin exhibited hyperplasia, 
parakeratosis, elongated rete ridges and lymphocyte infiltration compared to the normal skin (k-o vs. a-
e). The nonlesional skin also showed thickened epidermis and parakeratosis, but not as obvious as those 
in the lesional skin (f-j). Bar= 100µm.  
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Figure 3.2. Enlarged intercellular space in the AD skin.  
H&E stained sections were further checked under microscope at higher magnification. Enlarged 
intercellular space was observed in the AD lesional skin (k-o) as well as the nonlesional skin from three 
subjects (h-j) compared to the normal skin (a-e). Bar= 50 µm. 
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3.1.2 Up-regulation of KLK5 in AD  
The expression of KLK5 was examined in the normal and AD skin by 
immunohistochemistry staining using anti-human KLK5 antibody (Section 2.2.2). 
The results showed that KLK5 was mainly localised in lower cornified layer of the 
epidermis in normal skin, whereas the staining of KLK5 was extended to deeper layers 
with increased intensity in the AD lesional skin (Figure 3.3, a-e vs. k-o). Enlarged 
staining zone and enhanced staining intensity of KLK5 were already observed in the 
nonlesional sites of some AD patients (Figure 3.3, h and j), but not as prominent as 
those detected in the lesional skin.  
The intensity of KLK5 staining was quantified using computer-assisted image analysis 
(Section 2.2.3). The results indicated that there was significantly elevated expression of 
KLK5 in the AD lesional skin compared to the normal skin (p<0.05) (Figure 3.4). In 
contrast, the increase of KLK5 staining in the nonlesional skin was not significant 
(p>0.05). These results revealed up-regulated expression of KLK5 in AD skin 
especially in the lesional sites. 
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Figure 3.3. Aberrant expression of KLK5 in the AD skin.  
Immunohistochemistry staining of KLK5 was carried out in the normal and AD skin. Brown color 
represents the staining of KLK5. Blue color represents hematoxylin-stained nuclei. Extended staining of 
KLK5 in the deeper layers of the epidermis with increased intensity was found in the lesional skin (k-o) 
compared to the normal skin (f-j). There was also extended expression of KLK5 in the nonlesional skin, 
but not as prominent as the lesional skin. Bar= 100 µm. 
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Figure 3.4. Quantification of KLK5 expression in normal and AD skin.  
The expression of KLK5 was quantified according to the intensity of KLK5 staining in the skin biopsies. 
The images of three non-overlapped but adjacent regions in each skin section were recorded and saved 
digitally. The epidermis in each region was highlighted manually as AOI. The staining intensity in each 
AOI was shown as mean density, which was calculated as integrated optical density (IOD)/area. The 
results showed significantly increased expression of KLK5 in the AD lesional skin (n=5), while there was 
no significant difference in KLK5 expression between nonlesional skin (n=5) and normal skin (n=5). 
Error bars represent the standard error. * indicates results significant at p<0.05.  
 
3.1.3 Up-regulated activity of epidermal proteases in the AD skin 
KLK5 is a major contributor to trypsin-like proteolytic activity and the initiator of 
protease activation cascade in the epidermis. A study from another research group has 
showed increased activity of the extractable trpsin-like proteases in the tape strips 
obtained from AD lesions, which could be attributed to unregulated activity of KLK5 
(Voegeli et al. 2009). Although the staining results in our study showed up-regulated 
expression of KLK5 in the AD skin, the activity of KLK5 in AD still needed to be 
further investigated. However, there is no in situ approach available to evaluated the 
proteolytic activity of KLK5 in the skin at present. Therefore, the activity of total 
epidermal proteases was examined by in situ zymography using the casein-derived 
substrate labelled with fluorogenic dye. Protease-catalyzed hydrolysis on the substrate 
releases the fluorescent dye-labelled peptides, allowing for the detection of protease 
activity (Section 2.2.4). As KLK5 is one of the main contributors to epidermal 
proteolytic activity, the results from this assay could partially represent the activity of 
KLK5. 
The results showed that the epidermal proteolytic activity was low and mainly restricted 
to the cornified layer in the normal skin. In contrast, the activity was extended from the 
cornified layer to the deeper layers in the AD lesional skin with increased intensity, 
indicating enhanced activity of epidermal proteases in AD (Figure 3.5 i-l vs. a-d). In the 
	 84	
nonlesional skin, diffused proteolytic activity was also detected with slightly increased 
intensity (Figure 3.5 e-h), but not as prominent as that observed in the lesional skin. 
These results revealed enhanced proteolytic activity in the AD skin. Although we 
cannot exclude substrate processing by other proteases, these results could still partially 
represent increased activity of KLK5 in AD. As the initiator of proteolytic cascade in 
the epidermis, uncontrolled KLK5 activity might also promote the amplification of 
protease activation cascade and consequently contribute to the elevated proteolytic 
activity in AD. Furthermore, the activity of epidermal proteases was extended to deeper 
layer of the AD skin, where diffused expression of KLK5 was also observed, suggesting 
the abberent proteolytic activity in AD could be attibuted to dysregulation of KLK5.  
 
Figure 3.5. Unregulated activity of epidermal proteases in the AD skin.  
The activity of total epidermal proteases in the normal and AD skin was examined by in situ zymography. 
Red color represents total epidermal proteolytic activity. Blue color represents DAPI-stained nuclei.  The 
proteolytic activity was extended to the deeper layers in the AD lesional skin with increased intensity (i-l) 
compared to the normal skin (a-d). There was slightly increased protease activity in the AD nonlesional 
skin (e-h). Bar= 50 µm.  
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3.1.4 Over-degradation of DSG1 in the AD skin  
As KLK5 can cause the proteolytic cleavage of corneodesmosomal protein DSG1, the 
expression of DSG1 was examined in the AD skin. The antibody that recognizes the 
extracellular domain of DSG1 was used. 
DSG1 was detected in the suprabasal layers of the normal skin with a strong 
membranous pattern of staining. In contrast, there was decreased staining intensity of 
DSG1 in the AD lesional skin compared to the normal skin, especially in the granular 
layer, where the activity of KLK5 might be up-regulated (Figure 3.6 A, a-d vs. i-l). The 
staining pattern of DSG1 in the nonlesional skin was similar to that in the normal skin, 
but reduced intensity of DSG1 staining was already detected in the granular layer of 
nonlesional skin from two subjects (Figure 3.6 A, f and g).  
The intensity of DSG1 staining was further quantified. The results showed significant 
decrease of DSG1 staining intensity in the lesional skin compared to the normal skin 
(p<0.05) (Figure 3.6 B). In contrast, the level of DSG1 was not significantly reduced in 
the nonlesional skin (p>0.05).  
It has been reported that as a secreted protease, KLK5 is able to degrade the 
extracellular adhesion domain of DSG1 through proteolytic cleavage and further induce 
the epidermal desquamation (Caubet et al. 2004; Descargues et al. 2006). Up-regulation 
of KLK5 can lead to over-degradation of DSG1 and further result in premature 
desquamation (Descargus et al. 2006). Combined with these previous findings, reduced 
level of DSG1 in AD skin indicated the over-degradation of DSG1 potentially caused 
by the progressive cleavage by up-regulated KLK5.  
	 86	
 
Figure 3.6. Over-degradation of DSG1 in the AD skin.  
Immunofluorescence staining of DSG1 was carried out in the normal and AD skin. Green color 
represents the staining of DSG1. Red color represents PI-stained nuclei. The intensity of DSG1 staining 
was reduced in the lesional skin (i-l) compared to the normal skin (a-d). Slightly decreased intensity of 
DSG1 staining was also observed in the nonlesional skin of two subjects (f,g). Bar= 100 µm (A). 
Quantification of DSG1 expression in the normal and AD skin was performed (B). Intensity of DSG1 
staining was reduced in the lesional skin (n=4) compared to the normal skin (n=4), but there was no 
significant decrease in the nonlesional skin (n=4). Error bars represent the standard error. * indicates 
results significant at p<0.05.  
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3.1.5 Expression of PAR2 in normal and AD skin 
Since KLK5 is an endogenous activator of PAR2, the expression of PAR2 was 
evaluated in the AD skin. The results showed that PAR2 was localised in the upper 
granular layer of the epidermis in normal skin. Some non-specific staining was observed 
within the cornified layer, which was also seen in the negative controls. In comparison, 
the expression of PAR2 was extended to inner layers of epidermis in the AD skin 
(Figure 3.7A).  
The expression of PAR2 was quantified according to the intensity of PAR2 staining. 
There were no significant differences in PAR2 expression among normal, AD 
nonlesional and lesional skin (p>0.05) (Figure 3.7B). As the antibody cannot distinguish 
the active form from the non-active form of PAR2, the results from immunostaining 
only reflected the total protein level of PAR2 but not the PAR2 function. Therefore, it 
still remained unclear whether the function of PAR2 is affected by dysregulated KLK5 
in AD, which required further investigation.    
 
3.1.6 Reduced level of FLG in the AD skin 
Previous study has revealed that up-regulated KLK5 activity is able to trigger the 
hyperactivity of ELA2, an epidermal serine protease which directly proteolyse both 
profilaggrin and filaggrin monomers. This results in the deficiency of FLG and 
consequenly lead to the skin barrier impairment (Bonnart et al. 2010). Therefore, the 
expression of FLG was also examined in the AD skin, however, the patients recruited in 
our study have not been genotyped for FLG mutations. 
As shown by immunostaining, FLG was expressed in the granular and lower cornified 
layer in the normal skin. In contrast, the intensity of FLG staining was decreased in the 
AD lesional skin compared to the normal skin. In addition, the level of FLG was also 
reduced in the nonlesional skin, but not as prominent as the reduction in lesional skin 
(Figure 3.8). The intensity of FLG staining was further quantified. The results revealed 
that the level of FLG was significantly decreased in the lesional skin compared to the 
normal skin (p<0.05), and the intensity of FLG staining was also reduced in the 
nonlesional skin (p<0.05) (Figure 3.9).  
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Figure 3.7. The expression of PAR2 in normal and AD skin.  
Immunohistochemistry staining of PAR2 was carried out in the normal and AD skin. Brown color 
represents the staining of PAR2. Blue color represents hematoxylin-stained nuclei. PAR2 expression was 
extended to the deeper layers of the epidermis in the lesional skin (i-l) compared to the normal skin (a-d). 
Bar= 50 µm (A). Quantification of PAR2 expression in the epidermis of normal and AD skin was 
performed (B). The results showed that there was no significant difference of PAR2 expression among the 
normal skin (n=4), AD nonlesional (n=4) and lesional skin (n=4). Error bars represent the standard 
error.  
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Figure 3.8. Reduced level of FLG in the AD skin.  
Immunohistochemistry staining of FLG was carried out in the normal and AD skin. Brown color 
represents the staining of FLG. Blue color represents hematoxylin-stained nuclei. The expression of FLG 
was decreased in the lesional skin (k-o) compared to the normal skin (a-e), there was also reduced FLG 
expression in the nonlesional skin (f-j), but not as prominent as that in the lesional skin. Bar= 50 µm.  
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Figure 3.9. Quantification of FLG expression in normal and AD skin.  
The expression of FLG was quantified according to the intensity of FLG staining in the skin biopsies. The 
results indicated decreased expression of FLG in the lesional skin (n=5) compared to the normal skin 
(n=5), and there was reduced level of FLG in the nonlesional skin (n=5) as well. Error bars represent the 
standard error. * indicates results significant at p<0.05.  
 
3.1.7 Summary 
The AD lesional skin exhibited disturbed epidermal morphology, which was 
characterised by acanthosis, parakeratosis and enlarged intercellular space. Acanthosis 
is also known as diffused epidermal hyperplasia and characterised by thickened spinous 
and granular layers, indicating an increased cell number or proliferation of 
keratinocytes. Parakeratosis is usually seen in diseases of increased cell turnover and is 
associated with disturbed terminal differentiation. Thus, these histological features 
implicated disrupted proliferation/differentiation of keratinocytes in AD lesions. 
Moreover, enlarged intercellular space in the lesional skin could be attributed to lack of 
adhesion between adjacent keratinocytes or intercellular edema in the epidermis 
(spongiosis) in AD. Furthermore, reduced levels of barrier-related proteins DSG1 and 
FLG were also detected in the lesional skin. In addition, the results suggested increased 
expression and enhanced activity of KLK5 in the AD lesional skin, indicating up-
regulated KLK5 might be correlated with the barrier disruption in AD. In the 
nonlesional skin, impairments of epidermal morphology and dysregulations of KLK5, 
DSG1, FLG were already observed, but far less prominent than those observed in the 
lesional skin.  
As a secreted protease, KLK5 cleaves extracellular adhesion domain of DSG1 to trigger 
the epidermal desquamation. In this study, reduced intensity of DSG1 staining was 
found in the AD skin especially in the granular layer, where the activity of KLK5 might 
be up-regulated. These results suggested that unopposed KLK5 activity could result in 
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over-degradation of DSG1 and subsequently contribute to deficiency of intercellular 
adhesion in AD. 
Recent studies by other research groups showed that single stimulation by recombinant 
KLK5 (rKLK5) triggered the activation of PAR2 (Stefansson et al. 2008; Briot et al. 
2009). However, exposure to PAR2 stimuli at a supramaximal concentration or repeated 
stimulation could cause the desensitization and impaired function of PAR2 (Dery et al. 
1998; Oikonomopoulou et al. 2006). As a chronic skin disorder, AD is characterized by 
persistent epidermal barrier defect, which may induce consistent up-regulation of KLK5 
(Section 1.4.4). In addtion, the results suggested that increased expression and enhanced 
activity of KLK5 already existed in the nonlesional skin of some AD pateints. These 
observations indicated that up-regulation of KLK5 could be sustained in the AD skin, 
thus the function of PAR2 might be affected by continuous stimulation of consistently 
up-regulated KLK5 in AD. Currently, there is no in situ approach available to examine 
PAR2 function in the skin, thus an in vitro cell model overexpressing KLK5 would be 
useful to further investigate the influences of sustained KLK5 up-regulation on the 
function of PAR2.  
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3.2 Generation and characterization of human keratinocytes 
overexpressing KLK5   
Further experiments were conducted to investigate the contribution of sustained KLK5 
up-regulation to the skin barrier impairment in AD. Human keratinocytes ectopically 
overexpressing KLK5 were generated using lentiviral expression vector. This cell 
model could mimic the consistent up-regulation of KLK5 in AD and eliminate other 
causative factors of epidermal barrier defect. KLK5 gene was cloned into the vector 
containing spleen focus-forming virus (SFFV) promoter and internal ribosome entry site 
(IRES) linked eGFP reporter gene (KLK5/eGFP). The vector expressing eGFP alone 
(eGFP) was used as control (Section 2.3). Human keratinocyte cell lines NIKS, 
NTERT, and primary human keratinocytes were transduced with eGFP vector (eGFP-
cells) or KLK5/eGFP vector (KLK5-cells), and untransduced cells (UT) were used as 
negative control (Section 2.4). The influences of overexpressed KLK5 on its 
downstream molecules such as DSG1 and PAR2 were evaluated.  
 
3.2.1 Keratinocytes ectopically overexpressing KLK5   
Following the exposure to one round of lentiviral infection at multiplicity of infection 
(MOI) 10, transduction efficiencies in keratinocytes were assessed on the basis of eGFP 
expression using both fluorescent microscope and flow cytometry. Expression of eGFP 
was visualised under fluorescent microscope, and eGFP positive cells were found in all 
three types of keratinocytes transduced with eGFP or KLK5/eGFP vector (Figure 3.10). 
The transduction efficiencies were 75% for eGFP-cells and 67% for KLK5-cells in 
NIKS keratinocytes, 72% for eGFP-cells and 69% for KLK5-cells in NTERT 
keratinocytes, and 64% for eGFP-cells and 62% for KLK5-cells in primary 
keratinocytes. These results revealed that high transduction efficiencies were achieved 
in all types of keratinocytes using lentiviral vectors.  
The transgene expression in transduced keratinocytes was evaluated on the basis of 
eGFP expression during the propagation of cells in a period of up to 21 days. The 
proportions of eGFP positive cells were examined using flow cytometry at indicated 
time points (Figure 3.11). There was no significantly reduced percentage of eGFP 
positive cells in both NIKS and NTERT cells transduced with eGFP or KLK5/eGFP 
vector. As primary keratinocytes cannot be cultured for a long period, the expression of 
eGFP was only assessed for 12 days. Similarly, the proportion of eGFP positive cells 
was not significantly decreased in primary cells transduced with eGFP or KLK5/eGFP 
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vector. These results revealed stable transgene expression in keratinocytes mediated by 
lentiviral transduction. Transduced keratinocytes with over 50% eGFP positive cells 
were used for further experiments. 
 
Figure 3.10. Transduction efficiencies in keratinocytes transduced with lentiviral vectors.  
The expression of eGFP in transduced NIKS, NTERT and primary human keratinocytes (primary KC) 
were evaluated using fluorescent microscope and flow cytometry on Day 6 post-transduction. Green 
color represents GFP fluorescence. eGFP positive cells with green colour were found in all three types of 
keratinocytes transduced with eGFP or KLK5/eGFP vector. UT: untransduced cells. Bar=100 µm (A).  
 
 
Figure 3.11. The expression of eGFP in transduced keratinocytes. 
Percentages of eGFP positive cells in transduced NIKS, NTERT and primary keratinocytes were assessed 
for a period of up to 21 days using flow cytometry. Stable expression of eGFP was detected in three types 
of keratinocytes transduced eGFP or KLK5/eGFP vector.  
 
3.2.2 Characterization of KLK5-cells  
The expression of KLK5 in transduced NTERT cells was examined using 
immunocytostaining (Section 2.5). The intensity of KLK5 staining was increased in 
KLK5-cells compared to untransduced cells and eGFP-cells, suggesting ectopically 
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overexpressed KLK5 in human keratinocytes transduced with KLK5/eGFP vector 
(Figure 3.12). The results also showed co-localisation of KLK5 and eGFP in cells 
transduced with KLK5/eGFP vector, whereas no co-expression of KLK5 and eGFP was 
observed in eGFP-cells. 
 
 
Figure 3.12. Overexpression of KLK5 in keratinocytes transduced with KLK5/eGFP. 
The expression of KLK5 in transduced NTERT cells was examined using immunocytostaining. Red color 
represents the staining of KLK5. Green color represents GFP fluorescence. Blue color represents DAPI-
stained nuclei. Increased KLK5 expression was detected in KLK5-cells (KLK5/eGFP) compared to 
untransduced cells (UT) and eGFP-cells (eGFP). Bar=10 µm.  
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The levels of KLK5 in transduced NIKS, NTERT and primary keratinocytes were also 
evaluated by western blotting (Section 2.6). A band at ~38kDa was detected in the cell 
lysates obtained from untransduced cells, eGFP-cells and KLK5-cells with increased 
level in KLK5-cells. Protein levels were quantified by densitometry and normalized to 
β-actin. The results showed significantly increased expression of KLK5 in cells 
transduced with KLK5/eGFP vector (p<0.05) (Figure 3.13).  
 
 
Figure 3.13. Increased expression of KLK5 in the lysates of KLK5-cells. 
The expression of KLK5 in transduced NIKS, NTERT and primary keratinocytes was examined using 
western blotting. A band at ~38kDa was detected in all the cells with increased level in KLK5-cells. β-
Actin was used as loading control. Representative western blot out of three independent experiments 
(n=3) are shown (A). Protein levels were quantified by densitometry as shown in the corresponding bar 
chart. There was significantly increased expression of KLK5 in the lysates of keratinocytes transduced 
with KLK5/eGFP vector compared to untransduced cells (UT) and eGFP cells (B). Error bars represent 
the standard error. * indicates results significant at p<0.05.  
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As KLK5 is a secreted protein, the expression of KLK5 in the culture media collected 
from NIKS, NTERT and primary keratinocytes was also examined using western 
blotting. A band at ~34kDa was detected in the culture media collected from 
untransduced cells, eGFP-cells and KLK5-cells with elevated intensity in KLK5-cells. 
Protein levels were quantified by densitometry and normalized by Ponceau red staining. 
The expression of KLK5 was also significantly increased in the culture media of KLK5-
cells compared to untransduced cells and eGFP-cells (p<0.05) (Figure 3.14). The results 
of immunocytostaining and western blotting both revealed ectopically overexpressed 
KLK5 in human keratinocytes transduced with KLK5/eGFP vector. 
 
 
 
Figure 3.14. Ectopically overexpressed KLK5 in the culture media of KLK5-cells. 
The expression of KLK5 in the culture media obtained from NIKS, NTERT and primary keratinocytes was 
examined using western blotting. A band at ~34kDa was detected in all the cells with increased level in 
KLK5-cells (A). Ponceau red staining was used as loading control (B). One representative experiment 
out of three (n=3) is shown. Similar results were obtained from three independent experiments. Protein 
levels were quantified by densitometry as shown in corresponding bar chart. The expression of KLK5 was 
significantly increased in the culture media of KLK5-cells compared to untransduced cells (UT) and 
eGFP-cells (C). Error bars represent the standard error. * indicates results significant at p<0.05.  
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Furthermore, the sizes of KLK5 protein in the cell lysates and culture media were 
compared. KLK5 showed bands at ~38kDa and ~34kDa in the cell lysates and culture 
media respectively (Figure 3.15). These two bands might correspond to pro-KLK5 in 
the cell lysates and active form of KLK5 in the culture media. 
 
Figure 3.15. The sizes of KLK5 protein in the cell lysates and culture media. 
The sizes of KLK5 protein in the cell lysates and culture media collected from NIKS keratinocytes were 
compared using western blot. The band of KLK5 protein predominantly detected in the culture media was 
~4kDa less than that in the cell lysates.  
 
 
In order to further confirm there was active form of KLK5 in the culture media, the 
activity of KLK5 in both culture media and cell lysates obtained from NIKS and 
NTERT keratinocytes was evaluated by casein zymography (Section 2.7). Commercial 
rKLK5 (active form) was used as positive control. 
A digestion band was detected in the culture media collected from KLK5-cells at 
~34kDa, which is the same size as the digestion band of commercial rKLK5 (Figure 
3.16A, b and d). Meanwhile, same samples were examined by western blotting (Figure 
3.16A, a and c). The results confirmed that the size of digestion bands in zymography 
was consistent with the size of KLK5 bands in western blotting (Figure 3.16A). In 
contrast, no KLK5 activity was detected in the cell lysates of keratinocytes transduced 
with KLK5/eGFP vector (Figure 3.16B). The results showed that secreted KLK5 in the 
culture media of KLK5-cells exhibited proteolytic activity, indicating it was the active 
form of KLK5. 
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Figure 3.16 Active KLK5 in the culture media of KLK5-cells. 
The activities of KLK5 in both culture media and cell lysates were examined using casein zymography 
and the same samples were also examined by western blotting. Secreted KLK5 in the culture media of 
KLK5-cells showed bands at the same size as commercial rKLK5 (active form) in both western blotting 
and zymography (a,b for NIKS cells and c,d for NTERT cells) (A). In comparison, no caseinolytic activity 
of KLK5 was detected in the cell lysates (B).  
 
 
3.2.3 The influences of up-regulated KLK5 on DSG1 and PAR2 
As both DSG1 and PAR2 are predominantly expressed in differentiated keratinocytes, 
primary keratinocytes, which possess better potential to undergo proliferation and 
differentiation in vitro, were used to investigate the influences of up-regulated KLK5 on 
DSG1 and PAR2.  
The expression of DSG1 in primary keratinocytes transduced with KLK5/eGFP was 
examined by western blotting. An antibody recognizing extracellular domain of DSG1 
was used. The results showed a specific band of full-length DSG1 at ~165kDa in all the 
cells with reduced level in KLK5-cells. Protein levels were quantified by densitometry 
and normalized to β-Actin. There was decreased intensity of DSG1 band in KLK5-cells 
compared to untransduced cells and eGFP-cells (Figure 3.17), suggesting the over-
degradation of DSG1 in keratinocytes overexpressing KLK5. 
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Figure 3.17. Reduced level of DSG1 in KLK5-cells.  
The expression of DSG1 in transduced primary keratinocytes was examined using western blotting. A 
specific band of full-length DSG1 was detected at ~165kDa with reduced intensity in KLK5-cells. β-actin 
was used as loading control. Representative western blot out of two independent experiments are shown 
(A). Protein levels were quantified by densitometry as shown in the corresponding bar chart. There was 
decreased intensity of DSG1 band in KLK5-cells compared to untransduced cells (UT) and eGFP-cells 
(B).  
 
The expression of PAR2 was examined using anti-PAR2 antibody. Two major bands at 
~71kDa and ~55kDa were detected in western blotting. These bands were reported 
previously, due to considerable N-linked glycosylation of PAR2 on Asn63 and Asn555 
(Koo et al. 2002; Compton et al. 2009; Aman et al. 2010). Protein levels were 
quantified by densitometry and the expression of PAR2 was evaluated as a sum of these 
two bands (71 + 55 kDa). The results showed that PAR2 expression was not changed in 
KLK5-cells compared to untransduced cells and eGFP-cells (Figure 3.18).  
 
Figure 3.18. Unchanged expression of PAR2 in KLK5-cells.  
The expression of PAR2 in keratinocytes was examined using western blotting. Two bands at 71 and 
55kDa were detected, corresponding to different glycosylated forms of PAR2. β-Actin was used as 
loading control. One representative western blot out of two is shown (A). Similar results were obtained 
from two independent experiments. Protein levels were quantified by densitometry as shown in the 
corresponding bar chart. PAR2 expression remained unchanged in KLK5-cells compared to 
untransduced cells (UT) and eGFP-cells (B).  
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Although the expression of PAR2 was unchanged in KLK5-cells, the influences of 
consistently overexpressed KLK5 on PAR2 function remained unknown and were 
further investigated. It has been reported that activated PAR2 can trigger intracellular 
calcium mobilization and further exert its regulatory function in the cell (Dery et al. 
1998; Gardell et al. 2008). Therefore, the function of PAR2 in KLK5-cells was 
evaluated by measuring the level of PAR2-dependent intracellular calcium mobilization 
using calcium mobilization assay (Section 2.8).  
PAR2 can be activated by its specific agonist peptide (PAR2-AP, SLIGKV-NH2). In 
order to validate whether this assay can be used to detect PAR2-dependent intracellular 
calcium mobilization, normal keratinocytes were stimulated with 100µM PAR2-AP and 
calcium mobilization was measured in time course. The results showed that intracellular 
calcium mobilization was initiated immediately following by the injection of 100µM 
PAR2-AP. Maximal response appeared at ~50 seconds post-injection and calcium 
mobilization returned to the baseline ~240 seconds post-injection (Figure 3.19). 
Therefore, PAR2-dependent calcium mobilization could be measured using this assay to 
reflect the function of PAR2 in keratinocytes. 
 
Figure 3.19. Intracellular calcium mobilization in normal keratinocytes followed by the injection of 
PAR2-AP. 
Normal human keratinocytes were injected with 100µM PAR2-AP, and the intracellular calcium 
mobilization was examined. There was mobilization of intracellular calcium in keratinocytes stimulated 
with PAR2-AP. Cells injected with PBS only were used as negative control. Similar results were obtained 
from two independent experiments. 
  
	 101	
In addition, since single stimulation of KLK5 can also trigger the activation of PAR2, 
normal keratinocytes were challenged with rKLK5 and calcium mobilization was 
measured in time course. The results showed that 25µM rKLK5 could stimulate the 
intracellular calcium mobilization in normal keratinocytes potentially through the 
activation of PAR2. The mobilization of intracellular calcium was initiated immediately 
following by the injection of rKLK5. Maximal response appeared at ~110 seconds post-
injection and calcium mobilization returned to the baseline ~240 seconds post-injection 
(Figure 3.20). It was noticed that the response of calcium mobilization was relatively 
slower in normal keratinocytes challenged with rKLK5 compared to those challenged 
with PAR2-AP. This could be attributed to the different activating mechanisms of 
PAR2 mediated by PAR2-AP and KLK5.  
 
Figure 3.20. Intracellular calcium mobilization in normal keratinocytes stimulated by rKLK5. 
Normal human keratinocytes were injected with rKLK5, and the intracellular calcium mobilization was 
examined. There was mobilization of intracellular calcium in keratinocytes challenged with 25µM 
rKLK5. Cells injected with PBS only were used as negative control. Similar results were obtained from 
two independent experiments. 
 
 
Although single stimulation of KLK5 caused activation of PAR2 in normal 
keratinocytes, the effects of consistently overexpressed KLK5 on the function of PAR2 
still needed to be investigated. Therefore, PAR2-dependent intracellular calcium 
mobilization was evaluated in KLK5-cells followed by the stimulation of PAR2-AP. 
Untransduced cells and eGFP-cells were used as controls. PAR2-dependent calcium 
mobilization was immediately initiated in untransduced cells and eGFP-cells stimulated 
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with PAR2-AP, and the shape of the response curve was similar. However, the level of 
PAR2-dependent intracellular calcium mobilization was reduced in KLK5-cells 
compared to the controls (Figure 3.21), indicating the function of PAR2 could be 
impaired under the repeated stimulation of endogenously overexpressed KLK5. 
 
 
Figure 3.21. Reduced level of PAR2-dependent intracellular calcium mobilization in KLK5-cells. 
PAR2-AP was used to challenge untransduced cells, eGFP-cells and KLK5-cells, and the mobilization of 
intracellular calcium was examined. Decreased PAR2-dependent intracellular calcium mobilization was 
found in KLK5-cells compared to untransduced cells (UT) and eGFP-cells. Similar results were obtained 
from two independent experiments.  
 
 
 
Thus, our results showed that single stimulation by exogenous PAR2-AP or rKLK5 
could trigger the mobilization of intracellular calcium in normal keratinocytes through 
the activation of PAR2. However, the level of PAR2-dependent intracellular calcium 
mobilization was decreased in KLK5-cells, where endogenous KLK5 was consistently 
overexpressed, suggesting sustained up-regulation of KLK5 might result in impaired 
PAR2 function in keratinocytes. As exposure to the stimuli at a supramaximal 
concentration or continuous stimulation could lead to the desensitization of PAR2 (Dery 
et al. 1998; Oikonomopoulou et al. 2006), it could be theorized that PAR2 was 
desensitized under the repeated stimulation by overexpressed KLK5, which 
consequently induced the function impairment of PAR2 in KLK5-cells. 
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3.2.4 KLK5 overexpression resulted in histopathological features of AD in in vitro 
organotypic cultures 
In order to further study the potential influences of overexpressed KLK5 on 
keratinocytes, organotypic culture (OTC) was used as a skin-equivalent model to 
evaluate the keratinocyte growth and epidermal formation in vitro. OTCs were 
generated using primary keratinocytes transduced with KLK5/eGFP vector (Section 
2.9). Cultures of untransduced cells and eGFP-cells were used as controls. Matured 
cultures were sectioned to examine the epidermal morphology as well as the protein 
levels of KLK5, DSG1 and FLG. 
The results showed fully developed epidermal structures in the cultures of untransduced 
cells, eGFP-cells and KLK5-cells (Figure 3.22 a,e,i). eGFP fluorescence could be 
visualized directly in sections of cultures generated from eGFP-cells and KLK5-cells, 
particularly within the most superficial cornified layers of the epidermis (Figure 3.22 
f,i). eGFP was actually expressed in every layer of the OTCs, however, due to the 
accumulation of eGFP in the uppermost layers, the eGFP intensity in these layers could 
result in bleaching effects across other compartments. These results indicated that the 
SFFV promoter could mediate stable transgene expression in all epidermal 
compartments with pronounced accumulation of eGFP in the cornified layers.  
The culture generated from KLK5-cells exhibited histopathological features of AD by 
comparing to the normal and eGFP cultures, such as mild parakeratosis and enlarged 
intercellular space. Furthermore, increased cell sizes of suprabasal keratinocyte was 
found in the KLK5 cultures (Figure 3.22 a,e,i). KLK5 was localised in the lower 
cornified layers of the normal and eGFP cultures, whereas the staining of KLK5 was 
extended throughout the whole epidermis in KLK5 culture. There was increased 
intensity of KLK5 staining in the culture generated from KLK5-cells, indicating 
lentiviral-mediated overexpression of KLK5 (Figure 3.22 b,f,j). In addition, DSG1 and 
FLG were detected in the suprabasal layers of the OTCs of untransduced cells and 
eGFP-cells. Reduced intensities of DSG1 and FLG staining were found in the cultures 
generated from KLK5-cells, which were consistent with the decreased levels of these 
barrier-related proteins in the AD skin (Figure 3.22 c,g,k and d,h,l).  
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Figure 3.22. Impaired epidermal morphology and disturbed expression of barrier-related proteins in 
OTCs generated from KLK5-cells. 
The skin morphology and the expression of KLK5, DSG1, FLG were examined in the cultures generated 
from untransduced cells (UT) (a-d), eGFP-cells (eGFP) (e-h) and KLK5-cells (KLK5/eGFP) (i-l) in two 
independent experiments. b,f,j:Brown color represents the staining of KLK5. Blue color represents 
hematoxylin-stained nuclei. c,g,k:Red color represents the staining of DSG1. Green color represents 
GFP fluorescence. Blue color represents DAPI-stained nuclei. d,h,l:Brown color represents the staining 
of FLG. Blue color represents hematoxylin-stained nuclei. KLK5 cultures exhibited AD-like 
histopathological features, overexpression of KLK5 and reduced levels of DSG1 and FLG. Bars: (a,e,i 
and c,g,k) = 100µm; (b,f,j and d,h,l) = 50µm.  
 
 
3.2.5 KLK5 up-regulation induced AD-like manifestations in in vivo skin 
engraftment model  
In order to investigate whether KLK5 overexpression could result in AD-like 
manifestations, function study of KLK5-cells was also performed using an in vivo 
mouse/human skin engraftment model (Section 2.10). eGFP-cells, KLK5-cells and AD 
keratinocytes were used to generate the skin grafts. The examination of living mice 
under fluorescence light revealed eGFP expression as a sign of sustained engraftment 
(Figure 3.23A, a). At postmortem, no macroscopic abnormalities were detected and 
histological analysis of the graft and surrounding murine tissue was undertaken (Figure 
	 105	
3.23A, b). Staining for human involucrin allowed areas of human and murine epidermis 
to be clearly delineated (Figure 3.23B). 
 
 
Figure 3.23. In vivo assessment of KLK5-cells using humanized mouse model.  
Function study of KLK5-cells was further performed using an in vivo mouse/human skin engraftment 
model. eGFP-cells, KLK5-cells and AD keratinocytes were used to generate the skin grafts in two 
independent experiments. A real-time eGFP expression of the graft was evaluated under 488nm light and 
macroscopic appearance of the graft was examined under transmit light (A). Examination of animals 
under fluorescence light revealed eGFP expression as a sign of sustained engraftment (a). At 
postmortem, no macroscopic abnormalities were detected, and histological analysis of the graft and 
surrounding murine tissue was undertaken (b). Human involucrin expression could indicate mouse (Mo)-
human (Hu) skin boundary in all the grafts (B). Brown color represents the staining of involucrin. Blue 
color represents hematoxylin-stained nuclei. Bar= 100µm.  
 
 
Histological appearance of the skin grafts was examined using H&E staining. In the 
skin grafts generated from eGFP-cells, the epidermis exhibited normal architecture 
(Figure 3.24 a, d). In contrast, the skin grafts generated from KLK5-cells were found to 
possess histopathological features of AD, including acanthosis, mild parakeratosis and 
enlarged intercellular space (Figure 3.24 b, e). Similarly, the grafts generated from AD 
keratinocytes also exhibited similar morphological disruptions as KLK5 grafts (Figure 
3.24 c, f). Furthermore, increased cell sizes of suprabasal keratinocytes were also 
detected in both KLK5 and AD grafts. 
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Figure 3.24. AD-like morphological disruptions in the grafts generated from KLK5-cells and AD 
keratinocytes.  
Histological appearance of grafts generated from normal keratinocytes transduced with eGFP (a,d), 
KLK5/eGFP (b,e) and AD keratinocytes (c,f) in two independent experiments were examined using H&E 
staining. Both KLK5 and AD grafts exhibited histological features of AD, including acanthosis, 
parakeratosis and enlarged intercellular space. Bars: a-c=100µm, d-f=50µm. 
 
 
 
Furthermore, the expression of KLK5 in the skin grafts was evaluated by 
immunostaining, and the activity of epidermal proteases was also examined using in 
situ zymography. The results showed that KLK5 was mainly localised in the cornified 
layer of eGFP grafts, whereas the staining of KLK5 was diffused throughout the whole 
epidermis with increased intensity in KLK5 grafts. The expression of KLK5 was also 
elevated and extended to the deeper layers in skin grafts generated from AD 
keratinocytes (Figure 3.25, a-c). In addition, the results showed that the epidermal 
proteolytic activity was low and mainly restricted to the cornified layer in eGFP grafts. 
In comparison, the activity of epidermal proteases was enhanced and extended to the 
deeper layers in both KLK5 and AD grafts (Figure 3.25, d-f). These results were 
consistent with the up-regulation of KLK5 and enhanced activity of epidermal proteases 
observed in the AD skin (Section 3.1.2 and 3.1.3). 
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Figure 3.25. Increased expression of KLK5 and enhanced activity of epidermal proteases in the grafts 
generated from KLK5-cells and AD keratinocytes.  
Elevated expression of KLK5 (a-c) and increased activity of epidermal proteases (d-f) were found in both 
KLK5 and AD grafts compared to eGFP grafts in two independent experiments. One representative 
experiment out of two is shown. a-c:Brown color represents the staining of KLK5. Blue color represents 
hematoxylin-stained nuclei. d-f:Red color represents total epidermal proteolytic activity. Blue color 
represents DAPI-stained nuclei. Bars: a-c=50µm, d-f=100µm.  
 
The expression of DSG1 and FLG was also examined in the skin grafts using 
immunostaining. DSG1 was detected in the suprabasal layers of eGFP grafts with a 
strong membranous pattern of staining. The expression of FLG was restricted to the 
granular and lower cornified layers. There were decreased intensities of DSG1 and FLG 
staining in both KLK5 and AD grafts compared to eGFP grafts (Figure 3.26). These 
results were consistent with the reduced levels of DSG1 and FLG in the AD skin 
(Section 3.1.4), suggesting the skin barrier impairment caused by overexpressed KLK5.  
 
 
Figure 3.26. Reduced levels of DSG1 and FLG in KLK5 and AD grafts. 
Immunostaining for DSG1 (a-c) and FLG (d-f) were performed on the skin grafts generated from two 
independent experiments. One representative experiment of two is shown. a-c:Red color represents the 
staining of DSG1. Blue color represents DAPI-stained nuclei. d-f:Brown color represents the staining of 
FLG. Blue color represents hematoxylin-stained nuclei. Reduced intensities of DSG1 and FLG staining 
were found in both KLK5 and AD grafts compared to eGFP grafts. Bar = 100 µm.  
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3.2.6 Summary 
 
Keratinocytes ectopically overexpressing KLK5 were generated using lentiviral vector. 
High transduction efficiency and stable transgene expression were achieved in 
transduced keratinocytes. There was increased expression of KLK5 in both cell lysates 
and culture media collected from KLK5-cells. Casein zymography confirmed that 
secreted KLK5 in the culture media of KLK5-cells was the active form. Furthermore, 
the results revealed that consistent up-regulation of KLK5 in keratinocytes resulted in 
over-degradation of DSG1 and impaired function of PAR2. Both in vitro OTCs and in 
vivo skin grafts generated from KLK5-cells exhibited histopathological features of AD 
including acanthosis, parakeratosis and enlarged intercellular space. In addition, the 
results showed overexpression of KLK5, enhanced activity of epidermal proteases and 
reduced levels of DSG1, FLG in the OTCs and skin grafts of KLK5-cells, which were 
also observed in the AD skin previously (Section 3.1). Therefore, up-regulation of 
KLK5 in keratinocytes showed the potential to result in AD-like epidermal barrier 
abnormalities in the skin.  
It was noticed that the suprabasal keratinocytes in OTCs and skin grafts generated from 
KLK5-cells exhibited increased cell sizes compared to eGFP-cells. It has been 
previously reported that increased sizes of suprabasal cells could reflect disrupted 
morphological transformation of keratinocytes transitioning into the suprabasal 
epidermis (Getsios et al. 2009). Combined with these findings, our results indicated that 
the switch from basal to suprabasal keratinocytes might be disturbed in KLK5-cells. In 
addition, less flattened cell shape and retention of nuclei in the cornified layer were also 
found in OTCs and skin grafts generated from KLK5-cells, indicating the impaired 
keratinocyte differentiation possibly caused by overexpressed KLK5. Abnormal 
suprabasal morphology and poorly differentiated appearance in OTCs and skin grafts of 
KLK5-cells suggested that up-regulation of KLK5 might result in disorganised 
keratinocyte proliferation and differentiation.  
Previous studies by other research groups have revealed that single stimulation by 
KLK5 could activate PAR2 and consequently trigger the overexpression of 
proinflammatory cytokines (Stefansson et al. 2008; Briot et al. 2009). However, 
repeated stimulation by endogenously overexpressed KLK5 resulted in impaired 
function of PAR2 in KLK5-cells. Whether the production of proinflammatory cytokines 
was affected in KLK5-cells remained unclear and required further investigation.   
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3.3 Influences of up-regulated KLK5 on keratinocyte growth and 
cytokine production  
It is well established that KLK5 can cause degradation of DSG1 and activation of PAR2 
(Caubet et al. 2004; Stefansson et al. 2008). However, results from our in vitro and in 
vivo studies using KLK5-cells indicated that consistently up-regulated KLK5 not only 
induced over-degradation of DSG1, but also showed potential to result in disrupted 
keratinocyte growth and impaired PAR2 function, which has not been previously 
reported. As revealed by other studies, single stimulation by recombinant KLK5 could 
trigger the activation of PAR2 (Stefansson et al. 2008; Briot et al. 2009). Furthermore, 
activated PAR2 is able to induce the up-regulation of proinflammatory cytokines in 
keratinocytes (Briot el al. 2009). Actually, up-regulation of KLK5 tends to be consistent 
in the AD skin. Therefore, single stimulation by KLK5 may not truly reflect the 
situations in this disease. In contrast, our cell model with sustained overexpression of 
KLK5, which mimics the situations in AD more closely, could be suitable for studying 
the roles of up-regulated KLK5 in AD pathogenesis. In order to further investigate the 
influences of consistent KLK5 up-regulation on keratinocyte growth and cytokine 
production, expression of relevant genes and proteins in KLK5-cells were examined.  
 
3.3.1 Expression of epidermal growth factor (EGF)-related genes in KLK5-cells 
It has been reported that DSG1 is not only a transmembrane adhesion protein serving as 
a rigid anchor between adjacent cells, but also a potential signalling molecule involved 
in the regulation of keratinocyte growth (Getsios et al. 2009). DSG1 is required for 
proper down-regulation of EGF-extracellular signal-regulated kinase 1/2 (Erk1/2) 
signalling, thereby repressing the proliferation and facilitating the differentiation of 
keratinocyte. This regulatory function of DSG1 on EGF-pathway relies on its 
intracellular domain (Getsios et al. 2009). In my previous results, KLK5 from cell 
lysates showed no proteolytic activity (Section 3.2.2), suggesting the inactive form of 
KLK5 inside the cell may not interact with the intracellular domain of DSG1. However, 
KLK5 is activated after being secreted into the extracellular space and active KLK5 is 
able to degrade the extracellular domain of DSG1. Previous studies have revealed that 
after the cleavage on extracellular domain, some transmembrane proteins undergo 
regulated intramembrane proteolysis, which results in the release of intracellular domain 
fragments from the membrane and further influence the intracellular signalling (Lal & 
Caplan 2011; Houri et al. 2013). This regulatory event may also occur in DSG1 after the 
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cleavage of its extracellular domain by KLK5. It was hypothesized that over-
degradation of DSG1 extracellular domain by up-regulated KLK5 might affect the 
stability of DSG1 intracellular domain, consequently interfering its regulatory function 
on EGF-mediated signal transduction. In order to test this hypothesis, the expression of 
82 genes related to EGF signalling was examined in keratinocytes overexpressing 
KLK5 using PCR array (Section 2.11). 
Primary human keratinocytes transduced with KLK5/eGFP or eGFP vector with the 
transduction efficiencies around 60-70% were harvested 6 days post-transduction. The 
expression of relevant genes was examined in KLK5-cells and compared to that in 
eGFP-cells. Fold-change values were calculated (Section 2.11). Fold-change values 
greater than one indicated a positive- or an up-regulation, and fold-change values less 
than one indicated a negative or down-regulation.  
The results showed that 19 genes were up-regulated, whereas 63 genes were down-
regulated in KLK5-cells (Appendix 2). Three-fold change was used as the threshold for 
selection of differential gene expression. The expression of most genes showed no 
difference between eGFP-cells and KLK5-cells, including EGF and epidermal growth 
factor receptor (EGFR). The expression of the gene encoding glycogen synthase kinase 
3 beta (GSK-3β) was down-regulated by ~6-fold in KLK5-cells compared to eGFP-cells 
(Figure 3.27). GSK-3β is a protein kinase implicated in the regulation of keratinocyte 
proliferation and differentiation (Hampton et al. 2012; Chen et al. 2013). It is a regulator 
in serine/threonine protein kinase Akt pathway, which is involved in EGF-mediated 
signalling (Galbaugh et al. 2006).  
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Figure 3.27. Expression of EGF-related genes in KLK5-cells and eGFP-cells. 
Human EGF signalling pathway RT2 profiler PCR array was performed to examine the expression of 82 
EGF-related genes in KLK5-cells and eGFP-cells. The scatter plot allowed the visualization of up and 
down fold-regulation of all genes investigated. The line in the middle indicates fold change of 1 and the 
other two lines represents fold change of 3. The experiment was performed once. The results showed that 
the expression of GSK3β was down-regulated by ~6-fold in KLK5-cells compared to eGFP-cells.  
 
 
 
 
3.3.2 Evaluation of GSK-3β expression in KLK5-cells 
In order to confirm the findings of PCR array, mRNA level of GSK-3β in KLK5-cells 
was further examined using RT-PCR (Section 2.12). Untransduced cells and eGFP-cells 
were used as controls. The results confirmed increased mRNA level of KLK5 in 
keratinocytes transduced with KLK5/eGFP vector compared to untransduced cells and 
cells transduced with control vector. However, the mRNA level of GSK-3β remained 
unchanged in KLK5-cells (Figure 3.28B). The results from RT-PCR were not consistent 
with the down-regulated mRNA level of GSK-3β in the PCR array.  
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Figure 3.28. mRNA levels of KLK5 and GSK-3β in KLK5-cells.  
mRNA levels of GSK-3β and KLK5 were measured by RT-PCR. The band intensities were quantified by 
densitometry and normalized to GAPDH. Increased mRNA level of KLK5 was detected in KLK5-cells, 
whereas the mRNA level of GSK-3β B in KLK5-cells was not changed compared to untransduced cells 
(UT) and eGFP-cells. One representative experiment out of three (n=3) is shown. Error bars represent 
the standard error. * indicates results significant at p<0.05.  
 
The protein level of GSK-3β was also examined using western blotting. There was a 
band of GSK-3β at ~46kDa in untransduced cells, eGFP-cells and KLK5-cells. Protein 
levels were quantified by densitometry and normalized to β-actin. The expression of 
GSK-3β was not changed in KLK5-cells compared to untransduced cells and eGFP-
cells (Figure 3.29).  
 
 
Figure 3.29. Unchanged expression of GSK-3β in KLK5-cells.  
The expression of GSK-3β in KLK5 cells was examined using western blotting. A band at ~46kDa was 
detected in all the cells. Representative western blots out of two independent experiments are shown. 
Protein levels were quantified by densitometry and normalized to β-Actin. The results showed that the 
expression of GSK-3β remained unchanged in KLK5-cells compared to untransduced cells (UT) and 
eGFP-cells.  
 
The results of RT-PCR and western blotting suggested that both mRNA and protein 
levels of GSK-3β were not changed in KLK5-cells, which were not consistent with the 
reduced expression of GSK-3β in the PCR array. Thus down-regulation of GSK-3β in 
KLK5-cells detected by the array may be false positive. The reason could be low 
reaction efficiency caused by the technical errors or primers degradation, which resulted 
in decreased level of GSK-3β in the PCR array. Therefore, these results indicated that 
up-regulated activity of KLK5 in keratinocytes might not affect the expression of GSK-
3β. 
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3.3.3 Expression of protein kinases in KLK5-cells 
The growth of keratinocytes is regulated by various signaling pathways, which involve 
large amount of protein kinases (Calautti et al. 1995, 2005; Dahler et al. 2001; Eckert et 
al. 2002; Mammucari et al. 2005). Up-regulated KLK5 may affect the process of 
keratinocyte growth through certain kinases. However, only a limited number of kinase 
genes related to EGF-mediated signaling were evaluated in the PCR array (Section 
3.3.1). Therefore, human phospho–kinase antibody array that contains numerous 
kinases relevant to keratinocyte growth such as Akt, Fyn, JNK, p38 was also performed 
(Calautti et al. 1995, 2005; Eckert et al. 2002). The levels of 43 phospho-kinases and 2 
related total proteins heat shock protein 60 (HSP60) and β-catenin were examined in 
KLK5-cells and compared to those in eGFP-cells (Section 2.13).  
Primary human keratinocytes were transduced with KLK5/eGFP or eGFP vector. 
KLK5-cells and eGFP-cells with transduction efficiencies about 50%-60% were 
harvested 6 days post-transduction. Cell lysates were prepared and subjected to the 
antibody array. The results showed that 7 proteins were abundantly expressed in both 
eGFP-cells and KLK5-cells, including p53, CREB, β-catenin, STAT3, WNK1, PRAS40 
and HSP60 (Figure 3.30A). The intensities of the blots were quantified using 
densitometry (Appendix 3). The expression of the target proteins was normalized to the 
reference protein. Normalized protein levels of phospho-kinases in eGFP-cells and 
KLK5-cells were compared. The results showed that the expression of phospho-p53 and 
HSP60 was increased in KLK5-cells compared to eGFP-cells (Figure 3.30B).  
The kinases involved in EGF-mediated signalling such as EGFR and Erk1/2 were also 
included in the antibody array. Binding of EGF triggers the phosphorylation and 
activation of EGFR and Erk1/2. However, there were no significant differences of 
phospho-EGFR and phospho-Erk1/2 between KLK5-cells and eGFP-cells, indicating 
the activities of these EGF-related kinases were not affected by overexpressed KLK5. 
Together with unchanged expression of EGF and EGFR in KLK5-cells detected by the 
PCR array (Section 3.1.1), these results suggested EGF-mediated signalling was not 
influenced by up-regulated KLK5 in keratinocytes.   
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Figure 3.30. The levels of phospho-kinases in KLK5-cells and eGFP-cells. 
The expression of 43 phospho-kinases and 2 related total proteins HSP60 and β-catenin in KLK5-cells 
were examined by comparing to those in eGFP-cells using human phospho-kinase array. Each 
reference/target was blotted in duplicate. Abundant expression of 7 phospho-kinases was detected in both 
cells (A). Mean pixel density of each reference/target was calculated. The expression of the target kinases 
was normalized to the reference protein. Increased expression of p53 and HSP60 was found in KLK5-
cells compared to eGFP-cells (B).  
 
 
3.3.4 Up-regulation of p53 may contribute to disturbed keratinocyte growth in 
KLK5-cells 
The level of phospho-p53 in KLK5-cells was further evaluated using western blotting. 
The antibody recognizes p53 phosphorylated at S392, same as the one used in the 
phospho-kinase antibody array (Section 2.17). A band at ~53kDa was detected in 
untransduced cells, eGFP-cells and KLK5-cells, and the intensity of this band was 
quantified by densitometry and normalized to β-actin. The results showed increased 
expression of phospho-p53 in KLK5-cells compared to untransduced cells and eGFP-
cells (Figure 3.31). Overexpression of KLK5 in keratinocytes induced elevated level of 
phospho-p53, which was consistent with the results of human phospho-kinase antibody 
array. 
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Figure 3.31. Up-regulation of phospho-p53 in KLK5-cells. 
The expression of phospho-p53 in KLK5-cells was examined using western blotting. A band at ~53kDa 
was detected in all the cells with increased level in KLK5-cells. β-Actin was used as loading control. 
Representative western blot out of two independent experiments are shown (A). Protein levels were 
quantified by densitometry as shown in the corresponding bar chart (B). Elevated expression of p53 was 
found in KLK5-cell compared to untransduced cells (UT) and eGFP-cells. Error bars represent the 
standard error.  
 
p53 is a transcription factor that regulates the cell cycle by targeting numerous growth-
related genes, therefore it is implicated in multiple processes such as growth arrest and 
apoptosis (Piette et al. 1997; Schwartz et al. 1997; Freedman et al. 1999). p53 is also 
known as tumour protein p53, and the association between p53 and cancer has been 
well established. In normal cells, the p53 protein is continually produced, but p53 levels 
are kept low due to continuous degradation by MDM2 (Piette et al. 1997; Freedman et 
al. 1999). MDM2 is one of the transcriptional targets of p53, which can inactivate p53 
protein by forming the complex with it in a negative feedback loop, consequently 
triggering the degradation of p53 by the proteasome through ubiquitin system and in 
turn down-regulating p53 (Piette et al. 1997; Freedman et al. 1999). In response to 
oxidative stress, deregulated oncogene expression and DNA damage induced by UV 
irradiation or chemical agents, p53 starts to dissociate with MDM2. Then p53 becomes 
accumulated and activated (Piette et al. 1997; Freedman et al. 1999). Once activated, 
p53 exerts three major functions: growth arrest, DNA repair and apoptosis. It induces 
cell growth arrest by holding the cell cycle at the G1/S regulation point to stop the 
progression of cell cycle, preventing replication of damaged DNA (Piette et al. 1997; 
Schwartz et al. 1997). During the growth arrest, p53 may activate the transcription of 
proteins involved in DNA repair. It can also initiate the apoptosis to discard the cells 
containing damaged DNA (Piette et al. 1997; Schwartz et al. 1997; Freedman et al. 
1999). Mutations of p53 have been found in most skin cancers and in more than 50% of 
all human malignancies, where its role of defencing against cancer is lost (Bieging et al. 
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2014). The regulatory role of p53 in normal tissue homeostasis has also been revealed. 
Previous study has reported that maximum expression of p53 was found in proliferating 
keratinocytes, and down-regulation of p53 was detected in keratinocytes undergoing the 
transition from proliferation to differentiation (Dazard et al. 2000). These findings 
suggested that p53 might be abundantly expressed in proliferating keratinocytes, and the 
level of p53 was down-regulated when cells start to differentiate. Therefore, the level of 
p53 is delicately maintained during the growth of keratinocytes. Up-regulated level of 
p53 could be correlated with increased proliferation and disturbed differentiation in 
keratinocytes overexpressing KLK5. 
  
3.3.5 Elevated HSP60 could induce aberrant cytokine production in KLK5-cells  
3.3.5.1 Increased expression of HSP60 in KLK5-cells  
The protein level of HSP60 in KLK5-cells was also examined by western blot analysis. 
The antibody was same as the one used in the phospho-kinase antibody array (Section 
2.17). A band at ~60kDa was detected in untransduced cells, eGFP-cells and KLK5-
cells with increased level in KLK5-cells. Protein levels were quantified by 
densitometry, and the expression of HSP60 was increased in KLK5-cells compared to 
untransduced cells and eGFP-cells (Figure 3.32). These results confirmed the up-
regulation of HSP60 in KLK5-cells detected by the antibody array.  
 
 
Figure 3.32. Elevated expression of HSP60 in KLK5-cells. 
The expression of HSP60 in KLK5-cells was examined using western blotting. A band at ~60kDa was 
detected in all the cells with elevated level in KLK5-cells. β-Actin was used as loading control. Western 
blot represented the results of two independent experiments (A). Protein levels were quantified by 
densitometry as shown in the corresponding bar chart (B). Increased expression of HSP60 was found in 
KLK5-cells compared to untransduced cells (UT) and eGFP-cells. Error bars represent the standard 
error.  
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HSP60 is a mitochondrial chaperonin, which is implicated in the maintenance and 
transport of mitochondrial proteins (Henderson & Pockley 2010). It also plays a 
potential role as a “danger signal” in the immune response, which is able to trigger the 
cytokine secretion and initiate inflammatory response in numerous cell types including 
macrophages, monocytes and cardiomyocytes (Srivastava 2002; Kang et al. 2013; Tian 
et al. 2013). Stimulation by exogenous HSP60 can be sensed by toll-like receptor 4 
(TLR4), which triggers the activation of various protein kinases such as p38 and MAPK 
kinase 3, consequently stimulating NFkB-mediated signalling and promoting the 
production of proinflammatory molecules such as TNFa, IL-12, IL-15, IL-6 and IL-1b 
(Srivastava 2002; Kang et al. 2013; Tian et al. 2013). Furthermore, in macrophages and 
dendritic cells, TLR4-mediated signalling is activated and inflammatory cytokines are 
up-regulated not only in response to exogenous HSP60 but also to endogenous HSP60 
produced by stressed cells (Bulut et al. 2002; Quintana & Cohen 2005; Osterloh et al. 
2007). It still remained unclear whether HSP60 is involved in the regulation of cytokine 
secretion in keratinocytes. However, several studies have revealed that TLR4 is 
expressed in human keratinocytes (Song et al. 2002; Pivarcsi et al. 2003; Lebre et al. 
2007). These findings raise the possibility that HSP60 might trigger the production of 
inflammatory cytokines in keratinocytes through TLR4-mediated signalling. Up-
regulation of KLK5 could result in increased level of endogenous HSP60 in 
keratinocytes and consequently affect the production of cytokines.  
 
3.3.5.2 Elevated production of IL-8, TSLP and IL-10 in KLK5-cells 
Both PAR2 and HSP60 are involved in the regulation of cytokine production. KLK5 
could affect the secretion of cytokines in keratinocytes through PAR2 or HSP60. In 
order to investigate the profile of cytokine production in KLK5-cells, the levels of 36 
cytokines were evaluated and compared to those in eGFP-cells using human cytokine 
antibody array (Section 2.14).  
Culture media collected from both KLK5-cells and eGFP-cells were subjected to the 
array. The results showed that expression of 6 cytokines were abundantly detected in 
the culture media obtained from KLK5-cells and eGFP-cells, including GROa, IL-1ra, 
IL-8, IL-10, MIF and Serpin E1 (Figure 3.33A). The intensities of the blots were 
quantified using densitometry (Appendix 4). The expression of the target proteins was 
normalized to the reference protein. Normalized protein levels of the cytokines in 
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eGFP-cells and KLK5-cells were compared. There was increased expression of IL-8 
and IL-10 in KLK5-cells compared to that in eGFP-cells (Figure 3.33B). 
 
 
Figure 3.33. Expression of cytokines in KLK5-cells and eGFP-cells. 
The expression of cytokines in KLK5-cells was examined using human cytokine array. eGFP-cells were 
used as control. Each reference/target was blotted in duplicate. Abundant expression of 6 cytokines was 
detected in both cells (A). Mean pixel density of each reference/target was calculated. The expression of 
the target cytokines was normalized to the reference protein. Increased expression of IL-8 and IL-10 was 
found in KLK5-cells compared to eGFP-cells (B). 
 
 
Expression of IL-8 and IL-10 in KLK5-cells was further examined in samples from 
three independent experiments using ELISA (Section 2.14). In addition, TSLP is a 
proinflammatory cytokine involved in the inflammatory response in many skin 
disorders (Soumelis et al. 2002; Roan et al. 2012). Up-regulation of TSLP is associated 
with AD-like phenotype, and increased level of TSLP was also found in the lesional 
skin of AD patients (Yoo et al. 2005; Briot et al. 2009; Sano et al. 2013). These findings 
suggest TSLP is potential mediator involved in the pathogenesis of AD. As TSLP is not 
included in the human cytokine antibody array, the level of TSLP in KLK5 cells was 
evaluated by ELISA as well.  
The results showed significantly increased levels of IL-8 and IL-10 in KLK5-cells 
compared to untransduced cells and eGFP-cells (p<0.05) (Figure 3.34 A&C). These 
results were consistent with the up-regulation of IL-8 and IL-10 in KLK5-cells in 
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human cytokine antibody array. The production of TSLP in KLK5-cells was also 
significantly elevated compared to that in untransduced cells and eGFP-cells (p<0.05) 
(Figure 3.34 B).  
 
Figure 3.34. Increased levels of IL-8, TSLP and IL-10 in KLK5-cells. 
The expression of IL-8 (A), TSLP (B) and IL-10 (C) in the culture media collected from KLK5-cells was 
examined using ELISA. Untransduced cells (UT) and eGFP-cells were used as controls. Increased 
expression of IL-8, TSLP and IL-10 was detected in KLK5-cells compared to untransduced cells and 
eGFP-cells. Data represent mean±s.e.m. from three independent experiments (n=3). Error bars represent 
the standard error. * indicates results significant at p<0.05.  
 
As both PAR2 and HSP60 can regulate the cytokine secretion, dysregulations of PAR2 
and HSP60 in KLK5-cells may affect the production of cytokines. It has been reported 
that KLK5 can trigger overexpression of proinflammatory cytokines such as IL-8 and 
TSLP in keratinocytes through PAR2-mediated signalling (Briot et al. 2009). However, 
my previous data revealed that the function of PAR2 was impaired under the repeated 
stimulation by endogenously overexpressed KLK5 (Section 3.2.3), which could not 
result in the up-regulation of IL-8 and TSLP in KLK5-cells. Therefore, increased levels 
of IL-8 and TSLP in KLK5-cells might be attributed to other factors such as up-
regulated HSP60.  
Keratinocyte-derived IL-8 functions as a chemoattractant to cause the migration of 
human neutrophils and T cells toward the site of inflammation (Barker et al. 1991). 
Previous studies implicate the production of IL-8 is regulated by TLR4-NFkB 
signalling (Pivarcsi et al. 2003; Sawa et al. 2008). It is possible that overexpressed 
KLK5 causes up-regulation of HSP60 in keratinocytes, which could stimulate TLR4-
NFkB-mediated signal transduction, consequently result in elevated level of IL-8 and 
contributing to the inflammatory infiltrate in skin.  
TSLP is a pro-Th2 cytokine. It can initiate the differentiation of Th2 cells and promote 
the production of Th2 cytokines (Liu et al. 2007; Roan et al. 2012; Jang et al. 2013). 
Overexpression of TSLP has been found in AD lesions (Sano et al. 2013), which could 
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contribute to the Th2 immune response in this skin disease. It has been reported that 
TLR4-NFkB pathway potentially involves in the expression of TSLP (Li et al. 2011). It 
was speculated that overexpression of KLK5 could trigger TLR4-NFkB signalling 
through up-regulating HSP60, subsequently leading to increased level of TSLP in 
keratinocytes. This may trigger the Th2 response and contribute to the immune 
dysregulation. As a result, up-regulated Th2 cytokines possibly leads to reduced level of 
lipid production and decreased amount of corneodesmosomes in the epidermis (Sawada 
et al. 2012; Hatano et al. 2013), consequently abrogating the intercellular cohesion and 
exacerbating the epidermal barrier dysfunction.  
IL-10 is a cytokine primarily produced by monocytes and Th2 cells, and expression of 
IL-10 is also found in keratinocytes. It has been reported that IL-10 exerts its anti-
inflammatory function by suppressing the production of Th1 proinflammatory cytokines 
such as interferon-γ (IFN-γ) (Fiorentino et al. 1991; D'Andrea et al. 1993). Previous 
study revealed that apart from its inhibition on the Th1 response, IL-10 was also able to 
promote the Th2 response in allergic skin inflammation (Laouini et al. 2003a). 
Increased level of IL-10 has been detected in the AD skin (Ohmen et al. 1995; Howell 
et al. 2005).  In immune cells, the level of IL-10 can be regulated by groups of 
transcription factors including NFkB, STATs, GATA3 and SMAD4 (Saraiva & O'Garra 
2010). It is not clear whether the IL-10 production in keratinocytes is regulated through 
the same pathways. Up-regulated KLK5 in keratinocytes may stimulate the activation of 
transcription factors such as NFkB through HSP60-mediated signalling, consequently 
resulting in elevated secretion of IL-10 and promoting Th2 immune response. 
Sustained overexpression of KLK5 induced increased production of IL-8, TSLP and IL-
10 in keratinocytes possibly through up-regulating HSP60. In order to confirm the 
speculation, future experiments need to be carried out to elucidate this potential 
signalling mediated by KLK5 and HSP60. 
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3.3.6 Summary 
The expression/activity of EGF, EGFR and Erk1/2 remained unchanged in KLK5 cells, 
suggesting DSG1-EGF signalling and its regulatory role in keratinocyte growth was not 
affected by up-regulated KLK5. However, there was increased level of p53 in 
keratinocytes overexpressing KLK5. However, p53 up-regulation in KLK5-cells could 
also be a response to in vitro culture. Therefore, whether p53 is up-regulated in a 
KLK5-dependent manner still needs to be confirmed. As p53 is down-regulated during 
the switch of keratinocytes from proliferation to differentiation, up-regulation of p53 
could be correlated with disrupted cell proliferation and differentiation, consequently 
contributing to disturbed keratinocyte growth in KLK5-cells. The level of HSP60 was 
also elevated in keratinocytes with sustained KLK5 overexpression. Since HSP60 is 
able to promote the production of inflammatory cytokines, up-regulation of HSP60 may 
contribute to increased secretion of IL-8, TSLP and IL-10 in KLK5-cells.  
These results indicated that up-regulation of KLK5 not only induced over-degradation 
of corneodesmosomes, but also showed potential to result in disorganised keratinocyte 
growth through p53 and lead to aberrant cytokine production in keratinocytes through 
HSP60. These abnormalities could lead to disturbed epidermal barrier formation and 
contribute to the immune dysregulation, consequently exacerbating skin barrier defect. 
Therefore, inhibition of unregulated KLK5 activity in keratinocytes using potential 
inhibitor might be an effective strategy for the restoration of epidermal barrier function. 
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3.4 Inhibition of up-regulated KLK5 reversed the abnormalities in 
barrier-related proteins  
Sustained overexpression of KLK5 induced over-degradation of DSG1 and up-
regulation of p53 in keratinocytes, which could consequently result in the impaired 
epidermal barrier integrity. Consistent up-regulation of KLK5 also caused increased 
expression of HSP60 and further resulted in aberrant secretion of inflammatory 
cytokines in keratinocytes, subsequently contributing to the immune dysregulation. The 
abnormalities in these barrier-related proteins caused by overexpressed KLK5 could 
exacerbate skin barrier defect and promote the development of AD. Therefore, KLK5 
appeared to be a potential target for the therapeutic approaches of AD. It was speculated 
that inhibition of up-regulated KLK5 might correct the aberrant expression/activity of 
its downstream molecules, further improving the function of epidermal barrier and 
reversing the disease phenotype in AD.  
SFTI-1 is a cyclic peptide and the smallest natural serine protease inhibitor. It shows 
exceptionally potent trypsin-inhibitory activity. SFTI-1 and its analogues exhibit 
inhibition upon a range of serine proteases including cathepsin G7, matriptase and 
KLKs (Long et al. 2001; Tan el al. 2013). SFTI-1 is considered as a natural template 
and a promising peptide-based drug bioscaffold that can be modified to produce highly 
specific inhibitors (Boy et al. 2010; Lesner et al. 2011). For instance, previous studies 
have reported that the SFTI-1-derived peptides can selectively block the proteolytic 
activity of KLK4 and KLK7 (Swedberg et al. 2009, 2011; De Veer et al. 2013). These 
findings raised the possibility that SFTI-1 could be used as a natural scaffold to generate 
potential KLK5-specific inhibitors.  
In this project, we collaborated with Dr. Macmillan’s group at UCL Chemistry 
Department. They demonstrated that the circular peptides could be prepared via a native 
chemical ligation-type process. This strategy was used for the first time to produce the 
analogue of SFTI-1, which was designated as SFTI-G. The inhibitory activity of SFTI-
G against KLK5 was confirmed by spectrofluorimetric assay. SFTI-G exhibited 
inhibition towards KLK5-catalyzed proteolysis of fluorogenic substrate (Boc-Val-Pro-
Arg-AMC), and IC50 was ~15 µM. Further experiments were conducted in this project 
to inhibit the unopposed activity of endogenously overexpressed KLK5 using SFTI-G 
and to investigate whether the impairments in KLK5-cells could be reversed once the 
KLK5 activity is inhibited. Synthesized SFTI-G was purified and freeze-dried at UCL 
Chemistry Department. Mass spectrometry analyses showed successful synthesis of 
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SFTI-G analogue (Shariff et al 2014). Lyophilised peptides were reconstituted in 
ultrapure water to make the stock solutions, which were then sterilized by filtration 
through 0.22 µm porous Millipore filters. The stock solutions were aliquoted and kept 
frozen. At the time of treatment, the solutions were diluted in pre-warmed culture 
medium to the final concentrations used for the experimental treatments. 
 
3.4.1. The activity of KLK5 was inhibited by SFTI-G 
3.4.1.1 SFTI-G inhibited the activity of exogenous recombinant KLK5  
Previous results in this study suggested that single stimulation by recombinant active 
KLK5 was able to induce PAR2-dependent intracellular calcium mobilization in normal 
keratinocytes (Section 3.2.3). In addition, recombinant KLK5 secreted by cells 
overexpressing KLK5 (mKLK5) was proven to be the active form (Section 3.2.2), thus 
mKLK5 should also be able to trigger the intracellular calcium mobilization in normal 
keratinocytes. The serum-free culture media collected from KLK5-cells was 
concentrated (Section 2.7). This concentrated media containing mKLK5 was able to 
trigger calcium mobilization in normal keratinocytes (Figure 3.35). If the activity of 
mKLK5 can be inhibited by SFTI-G, mKLK5-stimulated intracellular calcium 
mobilization in keratinocytes should be reduced in the presence of SFTI-G. In order to 
confirm this, concentrated culture media containing mKLK5 was pre-incubated with 
SFTI-G (concentrations ranged from 10nM to 100 µM) at 37oC for 10 minutes. The 
intracellular calcium mobilization was measured in normal keratinocytes followed by 
the injection of pre-incubated mixtures of mKLK5 and SFTI-G. Cells injected with 
mKLK5 alone were used as control. 
The results showed that intracellular calcium mobilization was initiated immediately 
followed by the injection of mKLK5 alone. SFTI-G did not affect KLK5-induced 
intracellular calcium mobilization at the concentration of 10nM. Calcium mobilization 
in keratinocytes induced by KLK5 was suppressed by SFTI-G at or above the 
concentration of 100nM. As the concentration of SFTI-G continuously increased, the 
suppression of calcium mobilization was more obvious. KLK5-induced intracellular 
calcium mobilization in keratinocytes was effectively suppressed by SFTI-G at the 
concentration of 100 µM.  
It could be theorized that SFTI-G inhibited the activity of KLK5, which prevented the 
proteolytic cleavage and activation of PAR2 by KLK5. Consequently, reduced PAR2 
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activation resulted in decreased PAR2-dependent intracellular calcium mobilization in 
normal keratinocytes, which was observed in the presence of SFTI-G. In addition, 
SFTI-G with higher concentration was able to inhibit the activity of KLK5 with 
stronger efficacy. As a result, less PAR2 were activated by KLK5 as the dose of SFTI-
G increased, and the reduction of PAR2-dependent intracellular calcium mobilization 
was more obvious. These results suggested that SFTI-G was able to inhibit the activity 
of KLK5 in a does-dependent manner. 100 µM SFTI-G could effectively inhibit KLK5 
and this concentration was used for further experiments. Therefore, SFTI-G inhibited 
the activity of exogenous recombinant KLK5, but the influence of SFTI-G on 
endogenously overexpressed KLK5 in live cells remained unknown and was further 
investigated.  
 
 
Figure 3.35. KLK5-stimulated intracellular calcium mobilization in normal keratinocytes was inhibited 
by SFTI-G. 
Normal human keratinocytes were stimulated with the mixture of mKLK5 and SFTI-G at serial 
concentrations. Injection of mKLK5 alone triggered intracellular calcium mobilization in normal 
keratinocytes. The calcium mobilization was reduced in the presence of SFTI-G, and the reduction was 
more obvious as the concentration of SFTI-G increased, indicating SFTI-G could inhibit the activity of 
KLK5 in a does-dependent manner. 
 
 
3.4.1.2 SFTI-G inhibited the activity of endogenously overexpressed KLK5 without 
affecting its expression 
In order to study the influence of SFTI-G on endogenously overexpressed KLK5, 
KLK5-cells in culture were treated with SFTI-G. SFTI-G was used at 100 µM final 
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concentration and the treatment of SFTI-G lasted for 48 hours. Untransduced cells and 
eGFP-cells were treated in parallel with KLK5-cells. Untreated cells were used as 
controls. No visible cell death was observed in all three types of cells treated with SFTI-
G. Cell lysates and culture media were harvested 48 hours post-treatment and were 
subjected to further analysis.  
SFTI-1 inhibits the activity of serine proteases by directly binding to its trypsin-like 
serine protease catalytic domain (Shariff et al 2014). As an SFTI-1-derived analogue, 
SFTI-G may exert its inhibitory activity in the same way as SFTI-1. As a result, the 
expression of KLK5 in KLK5-cells should not be affected by SFTI-G treatment. In 
order to confirm this, expression of KLK5 in the culture media of KLK5-cells treated 
with SFTI-G was examined using western blot analysis. Untransduced cells and eGFP-
cells were treated in parallel. Untreated cells were used as controls. The levels of KLK5 
in treated and untreated groups were compared using paired t-test and p<0.05 was 
considered as significant. The expression of KLK5 was detected in the culture media of 
KLK5-cells, whereas the levels of KLK5 in untransduced cells and eGFP-cells were not 
detectable. The intensity of KLK5 band remained unchanged in KLK5-cells treated 
with SFTI-G compared to untreated KLK5-cells (p>0.05) (Figure 3.36). Therefore, the 
expression of KLK5 was not affected by SFTI-G treatment, suggesting that SFTI-G 
could inhibit the activity of KLK5 by interacting with its trypsin-like serine protease 
catalytic domain but not causing the degradation of KLK5. 
 
 
Figure 3.36. The expression of KLK5 was not affected by SFTI-G. 
The expression of KLK5 in the cells with (+) or without (-) the treatment of SFTI-G was examined by 
western blot analysis. Ponceau red staining was used as loading control. Representative western blot out 
of three independent experiments (n=3) are shown (A). Protein levels were quantified by densitometry as 
shown in the corresponding bar chart (B). The expression of KLK5 was not affected in KLK5-cells after 
the treatment of SFTI-G. Error bars represent the standard error.  
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Previous experiments in this study indicated that consistent up-regulation of KLK5 in 
keratinocytes lead to impaired PAR2 function without affecting the expression of PAR2 
(Section 3.2.3). Thus the expression of PAR2 in KLK5-cells treated with SFTI-G was 
examined using western blotting (Figure 3.37). Untransduced cells and eGFP-cells were 
treated with SFTI-G as well. Protein levels of PAR2 were quantified by densitometry 
and normalized to β-actin. The results revealed unchanged intensity of PAR2 blots in 
cells treated with SFTI-G compared to untreated cells, indicating the expression of 
PAR2 was not affected by SFTI-G treatment. Although the expression of PAR2 was not 
influenced by SFTI-G, the function of PAR2 in KLK5-cells treated with SFTI-G 
remained unclear and was further evaluated. 
 
 
Figure 3.37. Expression of PAR2 in KLK5-cells treated with SFTI-G. 
Expression of PAR2 in KLK5-cells treated with SFTI-G was evaluated by western blot analysis. 
Untransduced cells (UT) and eGFP-cells were treated in parallel with KLK5-cells. Untreated cells were 
used as controls. β-Actin was used as loading control. One representative experiment out of two is shown 
(A). Similar results were obtained from two independent experiments. Protein levels were quantified by 
densitometry as shown in the corresponding bar chart (B). The expression of PAR2 in KLK5-cells was 
not affected by SFTI-G.  
 
The level of PAR2-dependent intracellular calcium mobilization was reduced in 
keratinocytes consistently overexpressing KLK5, indicating the function of PAR2 was 
impaired in KLK5-cells (Section 3.2.3). This could be attributed to the desensitization 
of PAR2 under the repeated stimulation by consistently overexpressed KLK5. If the 
activity of endogenously overexpressed KLK5 could be inhibited by SFTI-G, the 
repeated stimulation of PAR2 by KLK5 might be prevented and the desensitization of 
PAR2 could be relieved. As a result, the impaired function of PAR2 should be restored 
and the level of PAR2-dependent intracellular calcium mobilization should be 
recovered in KLK5-cells followed by SFTI-G treatment. In order to confirm this, 
KLK5-cells were incubated with 100 µM SFTI-G overnight. The following day, treated 
KLK5-cells were stimulated with specific PAR2 agonist peptide (PAR2-AP) and 
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PAR2-dependent intracellular calcium mobilization was measured in time-course. 
eGFP-cells were treated in parallel with KLK5-cells. Untreated cells were used as 
controls. 
There was reduced level of PAR2-dependent intracellular calcium mobilization in 
untreated KLK5-cells compared to eGFP-cells, which was consistent with the previous 
results. Once KLK5-cells were treated with SFTI-G, the PAR2-dependent intracellular 
calcium mobilization was restored compared to untreated KLK5-cells (Figure 3.38). 
There was no obvious difference in PAR2-dependent intracellular calcium mobilization 
between treated and untreated eGFP-cells.  
 
 
 
Figure 3.38. Recovered PAR2-dependent intracellular calcium mobilization in KLK5-cells treated with 
SFTI-G. 
PAR2-dependent intracellular calcium mobilization in KLK5-cells treated with SFTI-G was examined. 
eGFP-cells were treated in parallel. Untreated cells were used as controls. All the cells were challenged 
with PAR2-AP. PAR2-dependant intracellular calcium mobilization was restored in KLK5-cells treated 
with SFTI-G compared to untreated KLK5-cells. There was no obvious difference of PAR2-dependent 
intracellular calcium mobilization between treated and untreated eGFP-cells. Similar results were 
obtained from two independent experiments. 
 
 
These results revealed that PAR2-dependent intracellular calcium mobilization was 
recovered in KLK5-cells treated with SFTI-G, indicating the impaired function of 
PAR2 was restored after SFTI-G treatment. It could be theorized that SFTI-G inhibited 
the up-regulated activity of endogenously overexpressed KLK5, which protected PAR2 
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from being repeatedly stimulated by consistently overexpressed KLK5. As a result, the 
desensitization of PAR2 was relieved and the function of PAR2 was restored, which 
caused recovered PAR2-dependent intracellular calcium mobilization in KLK5-cells 
treated with SFTI-G. The results indicated that the activity of endogenously 
overexpressed KLK5 could also be inhibited by SFTI-G. Further experiments were 
conducted to examine whether the abnormalities in relevant barrier-related proteins 
caused by overexpressed KLK5 could be reversed by SFTI-G treatment.  
 
3.4.2 The abnormalities in barrier-related proteins caused by up-regulated KLK5 
were reversed by SFTI-G treatment 
3.4.2.1 Restored level of DSG1 in KLK5-cells treated with SFTI-G 
Up-regulation of KLK5 resulted in over-degradation of corneodesmosomal protein 
DSG1 in keratinocytes (Section 3.2.3). If the activity of KLK5 could be inhibited by 
SFTI-G, the level of full-length DSG1 in KLK5-cells should be restored followed by 
the treatment of SFTI-G. In order to confirm this, the expression of DSG1 in KLK5-
cells treated with SFTI-G was examined using western blot analysis. Untransduced cells 
and eGFP-cells were treated with SFTI-G in parallel. Untreated cells were used as 
controls. Protein levels of DSG1 were quantified by densitometry and normalized to β-
actin.  
The band of full-length DSG1 was detected at ~165kDa. The intensity of DSG1 band 
was decreased in untreated KLK5-cells compared to untransduced cells and eGFP-cells, 
which was consistent with the previous results. After SFTI-G treatment, the intensity of 
DSG1 band in KLK5-cells was increased (Figure 3.39), suggesting the restoration of 
full-length DSG1 in KLK5-cells treated with SFTI-G. The levels of DSG1 in both 
untransduced cells and eGFP-cells were not affected by SFTI-G treatment. These results 
indicated that SFTI-G could inhibit the uncontrolled activity of KLK5 in keratinocytes 
overexpressing KLK5, further preventing the over-degradation of DSG1 by unregulated 
KLK5.  
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Figure 3.39. Restored level of DSG1 in KLK5-cells treated with SFTI-G.  
Expression of DSG1 in KLK5-cells with (+) or (-) SFTI-G treatment was examined by western blotting. 
Untransduced cells (UT) and eGFP-cells were treated with SFTI-G as well. Untreated cells were used as 
controls. β-Actin was used as loading control. Representative western blot out of two independent 
experiments are shown (A). Protein levels were quantified by densitometry as shown in the corresponding 
bar chart (B). There was a restored level of full-length DSG1 in KLK5-cells treated with SFTI-G 
compared to untreated KLK5-cells. The level of DSG1 was not changed in untransduced cells and eGFP-
cells after the treatment of SFTI-G.  
 
3.4.2.2 Reduced expressions of phospho-p53 and HSP60 in KLK5-cells followed by 
the treatment of SFTI-G 
Overexpressed KLK5 also resulted in the up-regulation of phospho-p53 and HSP60 in 
keratinocytes (Section 3.3.3). If the activity of KLK5 could be inhibited by SFTI-G, the 
expressions of phospho-p53 and HSP60 in KLK5-cells should be reduced after the 
treatment of SFTI-G. However, inhibition of KLK5 should not affect the levels of other 
kinases. In order to confirm this, the expression of relevant kinases in KLK5 cells 
treated with SFTI-G was examined using human phospho-kinase array as previously 
described (Section 2.13). eGFP-cells were treated in parallel with KLK5-cells. 
Untreated cells were used as controls. The intensities of the blots were quantified using 
densitometry (Appendix 5). The expression of the target proteins was normalized to the 
reference proteins. Normalized protein levels of phospho-kinases were compared.  
The results showed that the blot intensities of phospho-p53 and HSP60 were increased 
in untreated KLK5-cells compared to untransduced cells and eGFP-cells. Once KLK5-
cells were treated with SFTI-G, the levels of phospho-p53 and HSP60 were reduced 
(Figure 3.40). The expression of phospho-p53 and HSP60 in eGFP-cells was not 
influenced by SFTI-G. In addition, the levels of other phospho-kinases were not 
affected by SFTI-G. These results indicated that the up-regulation of phospho-p53 and 
HSP60 in KLK5-cells was inhibited after SFTI-G treatment.  
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Figure 3.40. Reduced levels of phospho-p53 and HSP60 in KLK5-cells treated with SFTI-G. 
The expression of 43 phospho-kinases and 2 related total proteins in KLK5-cells treated with SFTI-G was 
examined using human phospho-kinase array. eGFP-cells were treated in parallel with KLK5-cells. 
Untreated cells were used as controls. The expression of 22 phospho-kinases was detected in both cells 
(A). The expression of the target proteins was normalized to the reference protein (B). Reduced 
expression of p53 and HSP60 was found in KLK5-cells treated with SFTI-G compared to untreated 
KLK5-cells. There were no differences of p53 and HSP60 between treated and untreated eGFP-cells. 
 
 
The levels of phospho-p53 and HSP60 were further examined using western blot 
analysis. Untransduced cells and eGFP-cells were treated in parallel with KLK5-cells. 
Untreated cells were used as controls. The bands of phospho-p53 and HSP60 were 
detected at ~53kDa and ~60kDa respectively. The expression of phospho-p53 and 
HSP60 was increased in untreated KLK5 cells compared to untransduced cells and 
eGFP-cells. After SFTI-G treatment, the intensities of phospho-p53 and HSP60 bands 
in KLK5-cells were decreased (Figure 3.41&3.42), which was consistent with the 
results in kinase antibody array. The levels of phospho-p53 and HSP60 in untransduced 
cells and eGFP-cells were not affected by SFTI-G treatment. These results suggested 
that SFTI-G controlled the unregulated activity of KLK5 in KLK5-cells, further 
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inhibiting the up-regulation of phospho-p53 and HSP60 caused by overexpressed 
KLK5. As increased phospho-p53 could be correlated with disorganized keratinocyte 
proliferation and differentiation, SFTI-G inhibited the up-regulation of phospho-p53 
and might further correct the keratinocyte growth in KLK5-cells. In addition, 
overexpressed KLK5 might induce aberrant production of inflammatory cytokines in 
keratinocytes through up-regulating HSP60. Since the up-regulation of HSP60 was 
inhibited by SFTI-G treatment, the production of cytokines in KLK5-cells might be 
further affected.  
 
Figure 3.41. Decreased level of phospho-p53 in KLK5-cells treated with SFTI-G. 
The expression of phospho-p53 in KLK5-cells treated with SFTI-G was examined using western blotting. 
β-Actin was used as loading control. One representative experiment out of two is shown (A). Similar 
results were obtained from two independent experiments. Protein levels were quantified by densitometry 
as shown in the corresponding bar chart (B). Up-regulated expression of p53 was inhibited in KLK5-cells 
treated with SFTI-G compared to untreated KLK5-cells. The level of p53 was not changed in 
untransduced cells (UT) and eGFP-cells after the treatment of SFTI-G.  
                  
Figure 3.42. Reduced expression of HSP60 in KLK5-cells after the treatment of SFTI-G. 
The expression of HSP60 in KLK5-cells treated with SFTI-G was examined using western blot analysis. 
β-Actin was used as loading control. Representative western blot out of two independent experiments are 
shown (A).  Protein levels were quantified by densitometry as shown in the corresponding bar chart (B). 
Elevated expression of HSP60 was reduced in KLK5-cells treated with SFTI-G compared to untreated 
KLK5-cells. The level of HSP60 was not changed in untransduced cells (UT) and eGFP-cells treated with 
SFTI-G.  
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3.4.2.3 Decreased secretion of IL-8, TSLP and IL-10 in KLK5-cells treated with 
SFTI-G 
Previous results revealed that overexpressed KLK5 resulted in up-regulation of 
inflammatory cytokines IL-8, TSLP and IL-10 in keratinocytes (Section 3.3.5). If the 
activity of KLK5 could be inhibited by SFTI-G, the production of IL-8, TSLP and IL-
10 in KLK5-cells should be reduced after the treatment of SFTI-G, but the levels of 
other cytokines should not be affected. In order to confirm this, the levels of cytokines 
in KLK5 cells treated with SFTI-G were examined using human cytokine array as 
previously described (Section 2.14). eGFP-cells were treated in parallel with KLK5-
cells. Untreated cells were used as controls. The intensities of the blots were quantified 
using densitometry (Appendix 6). The expression of the target proteins was normalized 
to the reference proteins. Normalized protein levels of cytokines were compared 
(Section 2.14).  
The results showed that the blot intensities of IL-8 and IL-10 were elevated in untreated 
KLK5-cells compared to untransduced cells and eGFP-cells. Once KLK5-cells were 
treated with SFTI-G, the levels of IL-8 and IL-10 were decreased (Figure 3.43). The 
production of IL-8 and IL-10 in eGFP-cells was not influenced by SFTI-G. In addition, 
the expression of other cytokines was not affected by SFTI-G. These results indicated 
that the increased levels of IL-8 and IL-10 in KLK5-cells were inhibited by SFTI-G 
treatment.  
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Figure 3.43. Reduced expression of IL-8 and IL-10 in KLK5-cells followed by the treatment of SFTI-
G. 
The expression of 36 cytokines in KLK5-cells treated with SFTI-G was examined using human cytokine 
antibody array. eGFP-cells were treated in parallel with KLK5-cells. Untreated cells were used as 
controls. The expressions of 6 cytokines were detected in both cells (A). Pixel density of each blot was 
calculated. The expression of the target proteins was normalized to the reference protein (B). Reduced 
expression of IL-8 and IL-10 was found in KLK5-cells treated with SFTI-G compared to untreated KLK5-
cells. There was no difference of IL-8 and IL-10 between treated and untreated eGFP-cells. 
 
 
The levels of IL-8, TSLP and IL-10 were further evaluated in samples from three 
independent experiments using ELISA. Untransduced cells and eGFP-cells were treated 
with SFTI-G as well. There was elevated production of these inflammatory cytokines in 
untreated KLK5-cells compared to untransduced cells and eGFP-cells. After SFTI-G 
treatment, the levels of IL-8, TSLP and IL-10 in KLK5-cells were significantly reduced 
(p<0.05) (Figure 3.44), which was consistent with the results in cytokine antibody array. 
The secretion of these inflammatory cytokines in untransduced cells and eGFP-cells 
was not affected by SFTI-G treatment. The results from both human cytokine antibody 
array and ELISA indicated that SFTI-G inhibited the activity of endogenously 
overexpressed KLK5, further preventing the up-regulation of IL-8, TSLP and IL-10 in 
KLK5-cells.  
Previous findings in this study suggested that overexpression of KLK5 resulted in up-
regulated HSP60 in keratinocytes, consequently leading to elevated secretion of IL-8, 
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TSLP and IL-10 in KLK5-cells. Reduced level of HSP60 together with decreased 
production of these inflammatory cytokines was detected in KLK5-cells treated with 
SFTI-G. It was speculated that SFTI-G might control the activity of KLK5, further 
inhibiting the up-regulation of HSP60 caused by overexpressed KLK5 and reversing the 
aberrant secretion of IL-8, TSLP, IL-10 in KLK5-cells.  
 
Figure 3.44. Reduced levels of IL-8, TSLP and IL-10 in KLK5-cells treated with SFTI-G. 
The expression of IL-8 (A), TSLP (B) and IL-10 (C) in KLK5-cells treated with SFTI-G was evaluated 
using ELISA. Untransduced cells (UT) and eGFP-cells were treated in parallel with KLK5-cells. 
Untreated cells were used as controls. Up-regulation of IL-8, TSLP and IL-10 was inhibited in KLK5-
cells treated with SFTI-G but not in untreated KLK5-cells. The cytokines levels were not changed in 
untransduced cells and eGFP-cells after the treatement of SFTI-G. Error bars represent the standard 
error. Data represent mean±s.e.m. from three independent experiments (n=3). Error bars represent the 
standard error. * indicates results significant at p<0.05.  
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3.4.3 Summary 
SFTI-G was able to inhibit the activity of KLK5, further reversing the abnormalities in 
its down-stream molecules such as DSG1, p53, HSP60 and inflammatory cytokines, 
which are key regulators of the epidermal barrier function. SFTI-G may interact with 
KLK5 through binding to its trypsin-like serine protease catalytic domain rather than 
causing the degradation of KLK5. These results suggested that inhibition of up-
regulated KLK5 could prevent the dysregulations of these barrier-related proteins, 
further contributing to the restoration of skin barrier. 
The results in this study serve as a useful starting point for the development of a potent 
and selective inhibitory peptides towards KLK5. Therefore, SFTI-1 could be used as a 
scaffold to generate the specific inhibitor for KLK5. Application of the potential KLK5-
specific inhibitor may inhibit the up-regulation of KLK5 in AD, further reversing the 
abnormalities in relevant barrier-related proteins and improving the function of 
epidermal barrier. This may prevent the development of AD and could be a promising 
therapeutic intervention for this skin disorder. 	 	
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CHAPTER 4: DISCUSSION  	 	
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4.1 Discussion 
This work sought to investigate the contribution of up-regulated KLK5 to epidermal 
barrier dysfunction in AD and validate the inhibitory activity of SFTI-1 analogue 
towards KLK5. Several noteworthy findings from this study will be discussed. 
 
Epidermal barrier defect in AD patients 
The formation and function of epidermal barrier can be evaluated using noninvasive 
techniques including tape strips and invasive methods such as skin biopsy analysis. 
Tape stripping has been used to evaluate the barrier function in AD skin (Komatsu et al. 
2007b; Voegeli et al. 2009, 2011). Although tape stripping is a relatively milder 
technique especially for children, it still has some limitations. For instance, tape strips 
are able to remove the outermost cells from the epidermis, which are corneocytes. As a 
result, only those molecules that are abundantly expressed in the cornified layer can be 
evaluated using this technique. Although many key components of epidermal barrier 
can be detected in corneocytes, the formation of skin barrier is a dynamic process that 
occurs during the transition from granular keratinocytes to corneocytes. Some barrier-
related proteins such as DSG1 and FLG are already expressed in the granular layer, but 
the levels of these proteins cannot be properly measured using tape strips. In 
comparison, skin biopsy is a powerful tool for morphological examination of the entire 
epidermal barrier, and it can reflect the expression of barrier-related proteins more 
precisely. Therefore, biopsy analysis can help the dermatologists to identify the skin 
conditions and make diagnosis for skin diseases. However, since no specific 
histological features can be used to distinguish AD from other skin diseases with similar 
symptoms and most of the affected individuals are children, biopsies are not routinely 
taken from AD patients for diagnosis.  
As AD is characterized by primary skin barrier dysfunction, biopsy analysis is 
necessary for the investigation of barrier defect in AD skin. Studies using skin biopsies 
from AD patients have already been performed by other research groups. For example, 
to investigate the localization of KLKs in AD skin, biopsy from one AD patient has 
been taken and subjected to immunostaining (Stefansson et al. 2008). In addition, to 
examine the expressions of antimicrobial protein and keratins in AD, skin biopsies 
obtained from four and seven AD patients were analyzed by immunohistochemical 
	 138	
staining respectively (Komatsu et al. 2005; Gläser et al. 2009). Levels of barrier-related 
proteins including keratins were evaluated in skin biopsies obtained from twenty-five 
AD patients (Jensen et al. 2004). The staining results in one patient can well indicate the 
distribution of barrier proteins in AD skin. However, these findings could not reflect the 
protein levels in AD patients accurately, since the variation among different individuals 
is considerable. Therefore, in order to evaluate the protein expression in AD skin, 
average protein levels should be examined in biopsies obtained from a group of AD 
patients, which can reflect the trend of protein expression in AD skin and represent the 
real situation in AD more precisely. In this project, skin biopsies obtained from five AD 
patients and five age-matched healthy controls were subjected to histological and 
immunohistological analysis.  
The levels of barrier-related proteins including KLK5, DSG1, PAR2 and FLG in skin 
biopsies were evaluated by immunostaining, and the intensities of staining were 
quantified by computer-assisted image analysis. This quantification method using 
Image Pro-Plus has been previously used for the visual assessment of staining in 
specimens including skin sections, which is considered to be accurate and reliable 
(Allen & Southern 2002; Wang et al. 2009). Aberrant epidermal morphology and 
dysregulations of skin barrier proteins were detected in AD patients. However, the 
severities of disturbed skin morphology and the impairments in barrier-related proteins 
varied among different AD individuals. For example, the extents of acanthosis and 
superficial dermal perivascular inflammatory infiltrate were more severe in the lesional 
skin from some AD patients than the others. In addition, up-regulation of KLK5 was 
more obvious in the lesional sites from some AD patients. Furthermore, deficiencies of 
barrier structural proteins DSG1 and FLG were more severe in the lesional skin of some 
affected individuals than the others. In addition, impaired epidermal morphology and 
disturbed expression of barrier-related proteins were already found in the healthy-
looking “nonlesional” skin obtained from some AD patients, although far less 
prominent than those detected in the lesional skin. These findings were consistent with 
the previous reports, which reveal that clinically nonlesional sites of AD also display 
skin barrier abnormalities (Seidenari and Giusti 1995; Jensen et al. 2004; Bieber 2008). 
These variations could be attributed to various disease severities in different individuals. 
The disease phenotypes might already exist in the nonlesional skin of patients with 
more severe AD but not in those with milder AD. Despite the various protein levels 
among different AD patients, our results can reflect the trend of barrier-related proteins 
in AD skin. These preliminary findings provide indications for further investigation. 
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Possible influences of up-regulated KLK5 in AD skin  
The results suggested that KLK5 was up-regulated in AD skin especially in the lesional 
sites, which is consistent with previously reported increased expression and enhanced 
activity of KLK5 in AD (Komatsu et al. 2005, 2007b; Voegeli et al. 2009). 
Interestingly, up-regulated KLK5 has also been reported in other inflammatory skin 
disorders including psoriasis and NS (Descargues et al. 2005, 2006; Hachem et al. 
2006b; Komatsu et al. 2007a). Similar as AD, these diseases were also characterized 
with epidermal barrier dysfunction. Since the etiologies of these skin disorders are 
different, up-regulated KLK5 may not be the initial cause of these diseases. However, 
KLK5 up-regulation could be an important “accelerator”, which can exacerbate the 
epidermal barrier defect and trigger the development of these skin disorders. Therefore, 
it was speculated that up-regulation of KLK5 could play a key role in barrier 
dysfunction in skin diseases such as AD.   
However, the causes of KLK5 up-regulation in AD are unclear. As AD is a chronic skin 
disorder, many genetic and environmental factors could lead to persistent epidermal 
barrier defect in AD, consequently resulting in consistently up-regulated KLK5. For 
example, variants in LEKTI gene can result in lack of inhibition against KLK5, 
subsequently leading to up-regulated activity of KLK5 in AD skin (Fortugno et al. 
2012). In addition, variations of FLG gene and overuse of soap could both exacerbate 
epidermal barrier defect and lead to increased pH in the epidermis of AD skin (Cork et 
al. 2009). As a result, a sustained increase in pH leads to hyperactivity of some 
epidermal proteases such as KLK5, which have optimum activity at slightly alkaline 
pH.  
Up-regulated KLK5 could subsequently contribute to the skin barrier dysfunction in AD 
through its downstream molecules. Since KLK5 is involved in the proteolytic 
processing of epidermal barrier structural proteins DSG1 and FLG, up-regulation of 
KLK5 could result in deficiencies of these molecules in AD. Unopposed activity of 
KLK5 induces over-degradation of corneodesmosomes and consequently leads to 
impaired epidermal barrier integrity (Yang et al. 2004; Descargues et al. 2005; Wang et 
al. 2014). Furthermore, the E420K variant in SPINK5 gene, one of the most common 
polymorphisms in AD and NS, results in the decreased formation of LEKTI D6-D9 
fragment, which displays strong inhibition against KLK5 and KLK5-mediated cleavage 
on DSG1, subsequently leading to over-degradation of DSG1 (Fortugno et al. 2012). 
Results in our study showed reduced level of DSG1 in AD skin, indicating up-regulated 
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KLK5 activity in AD could result in the over cleavage of DSG1 and subsequently lead 
to deficient skin barrier integrity. In addition, up-regulated KLK5 is capable of inducing 
the hyperactivity of ELA2, which degrades both pro-FLG and FLG monomers (Bonnart 
et al. 2010). Unopposed activity of KLK5 in AD might also promote the activation of 
ELA2, consequently leading to the misprocessing and deficiency of FLG. However, 
variations within FLG gene could also result in reduced expression of FLG in AD 
(Barker et al. 2007; Morar et al. 2007; Brown et al. 2008; Ekelund et al. 2008; De 
Benedetto et al. 2008). Although our results showed reduction of FLG in AD skin, the 
AD patients recruited in our study have not been genotyped for FLG mutations, thus the 
deficiency of FLG might also be attributed to variants in FLG gene. Therefore, the 
association between up-regulated KLK5 and decreased level of FLG in AD could not be 
concluded.  
 
Keratinocytes overexpressing KLK5 as a viable model to study the roles of 
KLK5 in AD  
As AD is a multifactorial disease, it is difficult to generate a model of AD, which can 
exhibit all the features of this skin disorder. However, experimental models have been 
generated to dissect the roles of some key factors involved in the onset and development 
of AD. Until now, a number of models have been established. The first model of AD 
(Nc/Nga mice) has been reported in 1997. These mice develop AD-like skin changes 
spontaneously after being repeatedly exposed to various environmental aeroallergens 
(Matsuda et al. 1997). Nc/Nga mice show skin barrier manifestations with increased 
TEWL and impaired ceramide metabolism, all of which might predispose these mice to 
the development of AD (Aioi et al. 2001). In addition, models were developed using 
mechanical injury, which mimic the skin barrier deficiency in AD. Repeated tape-
stripping followed by epicutanous sensitization using ovalbumin on the skin could 
induce the release of IL-10 from keratinocytes and promote the Th2 response (Laouini 
et al. 2003a, b). Furthermore, as AD is characterised Th2 immune response, models 
mimicking the immune dysregulation in AD have been generated. These models dissect 
the roles of immune regulators including cytokines in the development of AD. For 
instance, transgenic mice overexpressing Th2 cytokine IL-4 display features of human 
AD, including acanthosis, mild spongiosis and dermal infiltration (Chan et al. 2001). 
Overexpression of pro-Th2 cytokine TSLP also leads to the skin lesions similar to those 
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observed in human AD, such as acanthosis, spongiosis and dermal infiltration. The 
lesions of TSLP transgenic mice also exhibit up-regulated expression of Th2 cytokines 
(Yoo et al. 2005).  
Pathogenesis of AD involves both skin barrier defect and immune dysregulation. 
Although these established models allow in-depth investigation of critical mediators 
especially immune regulators in AD, the mechanism underlying epidermal barrier 
defect, which is the primary cause of AD, remains largely unexplored. KLKs are key 
regulators of skin barrier function and up-regulation of major epidermal KLKs such as 
KLK5 and KLK7 has been reported in AD. Furthermore, overexpression of KLK7 in 
transgenic mice leads to the development of AD-like skin lesions characterized by 
increased epidermal thickness and dermal inflammation (Hansson et al. 2002). 
Recently, transgenic mice model overexpressing KLK5 has been established. These 
mice display characteristic features of AD, such as increased activity of epidermal 
proteases and up-regulation of inflammatory cytokines including TSLP (Furio et al. 
2014). These findings indicated that up-regulated KLKs including KLK5 could 
contribute to the skin barrier dysfunction in AD. Despite the well-established regulatory 
function of KLK5 in epidermal barrier through its downstream molecules, the 
influences of up-regulated KLK5 on barrier defect in AD is not well defined and needs 
to be further investigated. As the pathogenesis of AD is complicated, dysregulations of 
numerous molecules can contribute to the impaired integrity and defective function of 
epidermal barrier in this skin disorder. In order to dissect KLK5 from other causes of 
AD and investigate the contribution of KLK5 up-regulation alone to the skin barrier 
defect, keratinocytes ectopically overexpressing KLK5 were generated. This cell model 
was further used to study the influences of consistent KLK5 up-regulation on the 
function of epidermal barrier.  
Human keratinocytes overexpressing KLK5 were successfully generated using lentiviral 
vector. Transfer of eGFP reporter genes, either alone or in combination with KLK5 
gene, was readily achieved by exposure of cultured human keratinocytes to a single 
round of virus infection. The proportion of transduced cells confirmed by the expression 
of eGFP was similar in both cases. The results indicated that KLK5 was overexpressed, 
secreted and activated in KLK5-cells, which could mimic the up-regulation of KLK5 in 
the AD skin. As our construct expressed KLK5 as a proprotease, these findings 
suggested that ectopically overexpressed pro-KLK5 was activated in vitro. Previous 
studies have reported that after being secreted into the extracellular compartments, pro-
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KLK5 could be processed into the active form through proteolytic cleavage. Besides of 
auto-activation, pro-KLK5 could be activated by KLK14 in vitro (Brattsand et al., 
2005). Recently, it has been revealed that other serine proteases such as matriptase and 
mesotrypsin can also activate pro-KLK5 in vitro (Sales et al., 2010; Miyai et al. 2014). 
It was speculated that overexpressed pro-KLK5 in keratinocytes could be activated by 
other proteases or through self-activation, which may result in the up-regulated KLK5 
activity in KLK5-cells.  
In order to further investigate the influences of up-regulated KLK5 on the epidermal 
barrier, in vitro OTCs were generated using primary human keratinocytes 
overexpressing KLK5. Adaptation of OTC techniques, also known as rafts, provided the 
tool to evaluate the keratinocyte growth and epidermal formation in vitro. However, 
many factors could affect the three-dimensional skin-equivalent culture, such as 
passages of the primary keratinocytes, replenishment of the fresh culture media and 
maintenance of the air-liquid interface. It was difficult to generate fully stratified 
cultures with low reproducibility between different batches if these factors are not 
properly controlled. Therefore, the experiments were repeated many times to improve 
the consistency of different cultures. Furthermore, previously established bioengineered 
skin-humanized mouse model was also used to study the influences of overexpressed 
KLK5 in vivo (Di Nunzio et al. 2008). Successful skin grafts rely on various factors, 
such as the proportions of complex components in the matrix, confluence of the 
keratinocytes before grafting, thickness of the bioengineered skin constructs and age of 
the mice. In order to improve the successful rate for the grafting, these experimental 
conditions were optimized and strictly controlled during the generation of skin grafts. 
Overexpressed KLK5 in human keratinocytes was able to induce AD-like histological 
features and skin barrier impairments in both in vitro and in vivo experiments. 
Furthermore, overexpression of KLK5 showed potential to induce disorganized 
keratinocyte growth and overexpression of TSLP and IL-10, which have also been 
previously observed in AD skin (Ohmen et al. 1995; Howell et al. 2005; Proksch et al. 
2006). These findings suggested that up-regulated KLK5 could contribute to these 
epidermal barrier impairments in AD. Therefore, our KLK5 overexpression cells 
revealed the importance of KLK5 up-regulation in AD pathogenesis. Although this cell 
model may not completely reflect all the hallmarks of AD, it can be further used as a 
viable model to study the influences of up-regulated KLK5 on epidermal barrier defect 
in AD. 
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Consistently overexpressed KLK5 induced impaired PAR2 function 
As KLK5 is an activator of PAR2 in human keratinocytes (Briot et al. 2004), consistent 
up-regulation of KLK5 may also affect the function of PAR2 in AD. Although 
unchanged expression of PAR2 was found in KLK5-cells, the influences of consistently 
up-regulated KLK5 on PAR2 function remained unknown. Upon being activated, PAR2 
binds to G proteins and triggers the intracellular calcium mobilization, further exerting 
various biological functions in the cells (Kawabata 2002). Therefore, the level of PAR2-
dependent intracellular calcium mobilization can reflect the function of PAR2. Our 
results showed that single stimulation by PAR2-AP or rKLK5 caused PAR2-dependent 
intracellular calcium mobilization in normal keratinocytes. The calcium response was 
relatively slower in cells challenged with rKLK5 compared to those stimulated with 
PAR2-AP. This could be due to the different activating mechanisms of PAR2 mediated 
by PAR2-AP and KLK5, as PAR2-AP triggers the activation of PAR2 through direct 
binding, while rKLK5 activates the receptor via proteolytic cleavage. However, there 
was reduced PAR2-dependent intracellular calcium mobilization in keratinocytes 
overexpressing KLK5, suggesting the function of PAR2 was impaired under the 
consistent stimulation by overexpressed KLK5.  
We speculated PAR2 desensitization could be responsible for the impaired PAR2 
function in KLK5-cells. Previous studies revealed that exposure to PAR2 stimuli at a 
supramaximal concentration or repeated stimulation leads to the desensitization of 
PAR2 (Böhm et al. 1996; Dery et al. 1998; Oikonomopoulou et al. 2006). When PAR2 
undergoes desensitization, G protein receptor kinase and b-arrestin mediate the 
phosphorylation of activated PAR2 on its C-terminus, consequently disrupt the 
interaction between PAR2 and G proteins in this domain (Böhm et al. 1996; Dery et al. 
1998). This can trigger the uncoupling of activated PAR2 from G proteins, resulting in 
the termination of PAR2-mediated signal (Böhm et al. 1996; Dery et al. 1998). 
Therefore, desensitization of PAR2 protects the cells from uncontrolled stimulation by 
its stimuli, which renders the cells irresponsive to further stimulation of PAR2 stimuli 
for a considerable period of time, until the plasma membrane is replenished with intact 
PAR2 through a regulatory mechanism called resensitization (Böhm et al. 1996). 
During the resensitization of PAR2, the level of membrane-bound intact PAR2 is 
replenished through synthesis of new receptors and mobilization of intracellular pools 
of the receptor (Böhm et al. 1996). As a result, the responsiveness of PAR2 to its 
stimuli can be recovered. It could be theorized that consistent overexpression of KLK5 
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in keratinocytes resulted in continuous stimulation on PAR2, further triggering the 
desensitization of PAR2, which can consequently induce aberrant termination of PAR2-
mediated signal transduction. Although PAR2 desensitization could be partially 
compensated by resensitization, the level of membrane-bound intact PAR2 may not be 
completely restored. As a result, the function of PAR2 was diminished in KLK5-cells, 
and the level of PAR2-dependent intracellular calcium mobilization was decreased. If 
PAR2 is desensitized in KLK5-cells, the level of PAR2 phosphorylated on C-terminus 
should be increased. However, this was not confirmed in this study, since we currently 
lack antibodies to this form of PAR2.  
As a chronic skin disorder, many factors such as SPINK5 and FLG gene 
polymorphisms and overuse of soap could result in consistently up-regulated KLK5 in 
AD. In addition, overexpression of KLK5 was already observed in the nonlesional sites 
of some AD patients, suggesting the up-regulation of KLK5 in AD skin was consistent. 
As a result, PAR2 could be desensitized under the continuous stimulation of up-
regulated KLK5 in AD. Furthermore, our results showed that PAR2-dependent 
intracellular calcium mobilization was recovered in KLK5-cells treated with SFTI-G, 
indicating the impaired function of PAR2 was restored after SFTI-G treatment. It could 
be theorized that SFTI-G inhibited the uncontrolled activity of KLK5, which protected 
PAR2 from being repeatedly stimulated by consistently overexpressed KLK5. Then the 
desensitization of PAR2 was relieved and the function of PAR2 was restored, further 
causing the recovered PAR2-dependent intracellular calcium mobilization in KLK5-
cells. These results confirmed that PAR2 desensitization could be induced by 
consistently up-regulated KLK5, which was reversed by inhibiting unopposed KLK5 
activity.  
 
Up-regulated KLK5 may contribute to disorganized keratinocyte growth  
Apart from AD-like epidermal barrier disruptions, impaired suprabasal morphology and 
poorly differentiated appearance of keratinocytes were also found in OTCs and skin 
grafts generated from KLK5-cells, suggesting up-regulation of KLK5 possibly 
interfered keratinocyte proliferation and differentiation. Therefore, human phospho–
kinase antibody array that contains numerous kinases relevant to keratinocyte growth 
was performed. The levels of 43 phospho-kinases were examined in KLK5-cells. The 
results showed that overexpression of KLK5 induced up-regulation of phospho-p53S392 
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in keratinocytes. In comparison, the levels of p53 phosphorylated on S15 and S46 were 
unchanged in KLK5-cells (Appendix 3).  
p53 is a transcription factor regulating the expression of numerous growth-related 
genes. Activation and stabilization of p53 is mediated through phosphorylation 
(Jimenez et al. 1999; Maclaine & Hupp 2009). There are eighteen different 
phosphorylation sites in p53, phosphorylation may occur at different sites in response to 
certain stress (Jimenez et al. 1999; Maclaine & Hupp 2009). The phosphorylation of 
p53 is regulated by numerous kinases, including protein kinases belongs to the MAPK 
family such as ataxia telangiectasia mutated (ATM), checkpoint kinases 1 and/or 2 
(CHK1/2), cyclin-dependent kinases (CDKs) and casein kinase 2 (CK2) (Claudio et al. 
2006; Jimenez et al. 1999; Maclaine & Hupp 2009). CDKs and CK2 are involved in the 
phosphorylation of p53 on S392 (Claudio et al. 2006). Overexpressed KLK5 could 
trigger the phosphorylation of p53 on S392 through activation of CDKs/CK2. In 
addition, our results showed the up-regulation of phospho-p53S392 in KLK5-cells was 
inhibited after SFTI-G treatment. These findings confirmed that the increased level of 
phospho-p53S392 was caused by overexpressed KLK5, which could be reversed through 
inhibition of up-regulated KLK5 activity. 
Previous study reported that maximum expression of p53 was found in proliferating 
keratinocytes (Dazard et al. 2000), where phospho-p53S392 could be the major form of 
p53 that functions to ensure the correct control of cell cycle and cell division. In this 
study, down-regulation of p53 and up-regulation of MDM2 were also detected in 
keratinocytes transitioning from proliferation to differentiation (Dazard et al. 2000). 
MDM2 is one of the transcriptional targets of p53, which can inactivate p53 protein by 
forming the complex with it in a negative feedback loop, consequently triggering the 
degradation of p53 by the proteasome through ubiquitin system and in turn down-
regulating p53 (Piette et al. 1997; Freedman et al. 1999). These results suggested that 
the switch from p53 to MDM2 occurs during the transformation of keratinocytes from 
proliferation to differentiation, and the levels of p53 and MDM2 are delicately 
controlled during the growth of keratinocytes. However, up-regulated phospho-p53S392 
may correlate with imbalanced keratinocyte proliferation and differentiation in KLK5-
cells, which could consequently result in disrupted skin barrier formation. In order to 
confirm this, the level of MDM2 and expression of proliferation/differentiation markers 
in KLK5-cells can be evaluated in future experiments.  
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AD is characterized with disrupted keratinocyte proliferation and differentiation. 
Enlarged expression and increased levels of proliferation-associated proteins including 
keratin 5 and Ki-67 are detected in both AD nonlesional and lesional skin (Proksch et 
al. 2006). In addition, diffused staining zone and reduced expression of differentiation-
related molecules, such as FLG, involucrin and keratin 10, are also found in AD skin 
especially in the lesional sites (Proksch et al. 2006). Furthermore, disorganized 
keratinocyte growth is also found in previously established models of AD. For instance, 
the lesions of Nc/Nga mice exhibit skin manifestations including parakeratosis, 
suggesting the disturbed differentiation of keratinocytes in this AD animal model 
(Matsumoto et al. 1997). In addition, overexpression of KLK7 in transgenic mice leads 
to the development of AD-like skin impairments characterized by marked acanthosis, 
indicating an increased cell number resulted from up-regulated keratinocyte 
proliferation (Hansson et al. 2002). These findings indicated that AD-like lesion is 
characterized with disrupted keratinocyte proliferation and differentiation, which can 
lead to impaired epidermal barrier formation and exacerbate the barrier dysfunction in 
AD skin. Overexpressed KLK5 could contribute to disorganized keratinocyte growth in 
AD by up-regulating phospho-p53S392. Therefore, our KLK5-cells could be used as a 
viable model to study the influences of up-regulated KLK5 on keratinocyte growth, 
which may be part of KLK5-triggered vicious cycle of skin barrier defect in AD. 
 
Overexpressed KLK5 could trigger the up-regulation of proinflammatory 
cytokines in keratinocytes  
The results also showed increased level of HSP60 in KLK5-cells. HSP60 exhibits 
multiple regulatory functions in various cellular signalling pathways. Like other HSPs, 
HSP60 is up-regulated when cells are exposed to cellular stresses such as elevated 
temperature, which can prevent or correct the protein misfolding caused by heat. Apart 
from its typical role as a heat shock protein, HSP60 is also a mitochondrial chaperonin, 
which involves in the transportation and maintenance of mitochondrial proteins 
(Vargas-Parada et al 2001; Cappello et al. 2006; Urushibara et al. 2007). In addition, 
HSP60 plays a potential role in a “danger signal cascade” in the immune response 
(Pockley 2001). It can stimulate the secretion of a wide range of inflammatory 
cytokines, consequently promoting the inflammation in numerous types of cells 
(Srivastava 2002; Henderson & Pockley 2010; Kang et al. 2013; Tian et al. 2013).  Our 
results suggested that overexpression of KLK5 resulted in increased levels of 
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inflammatory cytokines IL-8, TSLP and IL-10 in keratinocytes potentially though up-
regulating HSP60. Furthermore, overexpression of HSP60 and inflammatory cytokines 
were inhibited in KLK5-cells treated with SFTI-G, confirming that the up-regulation of 
these molecules was induced by overexpressed KLK5, which could be inhibited by 
controlling the unopposed KLK5 activity. 
AD is characterized with Th2-biased immune response and aberrant cytokine 
production. For example, increased levels of TSLP and IL-10 were detected in the skin 
of AD patients (Ohmen et al. 1995; Soumelis et al. 2002; Howell et al. 2005; Sano et al. 
2013). In addition, immune dysregulation has also been revealed in previously 
established AD models. Topical application of the recombinant house dust mite 
allergens or epicutanous sensitization triggered by ovalbumin can induce AD-like skin 
inflammation characterized with Th2 immune response (Huang et al. 2003; Laouini et 
al. 2003). In addition, transgenic mice overexpressing TSLP exhibit dermal infiltration 
and a Th2 cell profile with the up-regulation of Th2 cytokines, which are also observed 
in AD skin (Yoo et al. 2005). Although these findings revealed the immune dysfunction 
in AD-like lesions, the mechanisms underlying the cytokine imbalance in AD are not 
completely elucidated.   
Up-regulation of KLK5 could contribute to the increased levels of TSLP and IL-10 in 
AD. TSLP can initiate the differentiation of Th2 cells and induce Th2 cytokine 
secretion, and it is involved in the Th2 mediated allergic inflammation including skin 
disorders (Liu et al. 2007; Roan et al. 2012; Bell et al. 2013; Jang et al. 2013). IL-10 is 
also able to promote the Th2 response in a murine model of allergic dermatitis (Laouini 
et al. 2003a). Up-regulation of TSLP and IL-10 could subsequently contribute to the 
skewed Th2 immune response in AD. As a result, up-regulated Th2 cytokines may lead 
to reduced level of lipid production and decreased amount of corneodesmosomes in the 
epidermis, consequently abrogating the intercellular cohesion and exacerbating skin 
barrier defect in AD (Sawada et al. 2012; Hatano et al. 2013). Furthermore, up-
regulated IL-10 could also be responsible for the reduced levels of AMPs such as LL-37 
and b-defensin in AD (Howell et al. 2005). Deficient levels of AMPs leave the skin 
with a lack of protection against the exogenous pathogens. Overexpressed KLK5 could 
contribute to the deficiency of AMPs in AD by up-regulating IL-10, consequently 
favoring the invasion of allergens/pathogens, which can exacerbate the skin barrier 
dysfunction and promote the development of AD (Otto 2004; Clarke et al. 2007; 
Roelandt et al. 2008; Hirasawa et al. 2010). In addition, overexpressed KLK5 caused 
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up-regulation of IL-8 in keratinocytes. Keratinocyte-derived IL-8 functions as a 
chemoattractant to cause the migration of human neutrophils and T cells toward the site 
of inflammation (Barker et al. 1991). Since AD is characterised by dermal perivascular 
inflammatory infiltrate, KLK5 overexpression may trigger the recruitment of 
neutrophils/T cells into the epidermis by increasing the level of IL-8, consequently 
contributing to the inflammatory infiltrate in AD.  
Since the influences of other causes of AD have been eliminated in our KLK5 
overexpression model, the increased levels of IL-8, TSLP and IL-10 are attributed to 
up-regulated KLK5. KLK5 up-regulation could contribute to the immune dysregulation 
in AD by increasing the levels of these proinflammatory cytokines, consequently 
aggravating the barrier dysfunction. However, apart from HSP60, overexpressed KLK5 
may induce the up-regulation of IL-8, TSLP, IL-10 through other regulators, which 
were not evaluated in our study. Therefore, whether this potential role of KLK5-
mediated signalling in inflammatory response relies on HSP60 remained uncertain. In 
order to further confirm that up-regulated KLK5 leads to the overexpression of these 
cytokines in keratinocytes in an HSP60-dependent manner, KLK5-cells could be treated 
with potential HSP60 inhibitors such as mizoribine in future experiments. Mizoribine 
bounds to HSP60 directly and in turn inhibits the function of HSP60 (Itoh et al. 1999). 
The levels of IL-8, TSLP and IL-10 can be examined in KLK5-cells treated with 
mizoribine to check whether the up-regulation of these inflammatory cytokines is 
inhibited by blocking the function of HSP60. 
 
Prospect of potential KLK5-specific inhibitor in AD therapy 
Up-regulated KLK5 not only induced over-degradation of DSG1, but also showed 
potential to cause disrupted cell growth and aberrant cytokine production in 
keratinocytes, possibly through p53 and HSP60. These abnormalities could result in 
impaired skin barrier formation and trigger the immune dysregulation, consequently 
exacerbating the barrier dysfunction and promoting the development of AD. Thus 
KLK5 appeared to be a potential target for the treatment of AD. As barrier defect is the 
primary cause of AD, therapeutic approaches should be first directed at improvement of 
the skin barrier. Inhibition of up-regulated KLK5 may restore the epidermal barrier 
function, making it a promising therapeutic intervention for AD.  
Sunflower trypsin inhibitor (SFTI-1) is a 14 amino acid cyclic peptide (Gly-Arg-Cys-
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Thr-Lys-Ser-Ile-Pro-Pro-Ile-Cys-Phe-Pro-Asp) extracted from the sunflower seeds. It 
exhibits exceptionally potent trypsin-inhibitory activity. SFTI-1 and SFTI-1-derived 
analogues are known to act upon a wide range of serine proteases including cathepsin 
G7, matriptase and KLKs. Mutation of selected SFTI-1 residues can improve its 
inhibitory specificity towards certain substrates (Long et al. 2001; Swedberg et al. 2009; 
De Veer et al. 2013; Tan et al. 2013). In addition, SFTI-1 possesses highly stable fold 
due to its cyclic backbone and a cross-bracing disulphide, thus it is considered as a 
promising peptide-based drug bioscaffold. Insertion of bioactive peptide sequences into 
the circular scaffold of SFTI-1 has been shown to improve its in vivo stability (Chan et 
al. 2011). Due to its size, activity and stability, SFTI-1 and its analogues are attractive 
therapeutic drug candidates.  
In this study, Dr. Macmillan’s group at UCL Chemistry Department demonstrated that 
circular peptides could be prepared via a native chemical ligation-type process. This 
strategy was utilised for the first time to produce the analogues of SFTI-1. Ile10 was 
substituted with glycine, which had been shown to give rise to a folded SFTI-1 
analogue. The synthesised analogue was designated as SFTI-G, which exhibited 
inhibitory activity towards recombinant KLK5 in spectrofluorimetric assay. Further 
experiments were conducted in this project to evaluate the influences of SFTI-G on the 
biological functions of KLK5 in keratinocytes. 
The inhibition of SFTI-G against exogenous recombinant KLK5 was validated. In 
addition, the inhibitory activity of SFTI-G towards endogenously overexpressed KLK5 
in human keratinocytes was also confirmed. SFTI-G inhibited the unopposed activity of 
KLK5, further reversing the abnormalities in KLK5-downstream molecules, which are 
also important proteins involved in skin barrier function. Therefore, inhibition of 
overactive KLK5 could improve the epidermal barrier function and prevent the 
development of AD.  However, the expression/activity of these downstream molecules 
of KLK5 in untransduced cells and eGFP-cells was not significantly affected by SFTI-G 
treatment. It could be theorized that KLK5 was substantially overexpressed in KLK5-
cells, where it appeared to be the main target of SFTI-G. Thus SFTI-G bound to active 
KLK5 predominantly and inhibited the uncontrolled activity of KLK5. Therefore, the 
abnormalities in KLK5-downstream proteins were reversed after SFTI-G treatment. 
Nevertheless, SFTI-G can exhibit inhibition towards numerous types of trypsin-like 
serine proteases, such as other KLKs, cathepsins and matriptases but not only KLK5 
(Long et al. 2001; Swedberg et al. 2009; Tan el al. 2013). Thus, SFTI-G could show 
	 150	
nonspecific inhibition towards many serine proteases, and normal function of 
endogenous serine proteases could be interfered by SFTI-G treatment. Therefore, the 
therapeutic dosage of potential inhibitor needs to be validated and strictly controlled in 
future studies. 
Although SFTI-G may not be a KLK5-specific inhibitor, the results in this study serve 
as a useful starting point for the development of more potent and selective inhibitory 
peptides towards KLK5. In previous reports, an inhibitor that can selectively block the 
proteolytic activity of KLK4 and KLK7 has been generated through modification of 
SFTI-1 template structure (Swedberg et al. 2009, 2011; De Veer et al. 2013). These 
findings raised the possibility that SFTI-1 can be used as a drug scaffold to produce 
potential analogues, which could specifically inhibit the activity of up-regulated KLK5 
and further restore the skin barrier dysfunction in AD patients. 
 
4.2 Conclusion  
KLK5 is a key protease expressed in the epidermis and up-regulated KLK5 has been 
confirmed in the AD skin. Genetic and environmental factors can induce the persistent 
skin barrier defect in AD, subsequently leading to the consistent up-regulation of KLK5 
(Figure 4.1). Our study revealed the importance of overexpressed KLK5 in the 
development of AD. For example, overexpressed KLK5 triggers the over-degradation 
of DSG1, further resulting in impaired skin barrier integrity. Furthermore, up-regulated 
KLK5 could cause the diminished function of PAR2. The consequence of impaired 
PAR2 function in AD is unclear and still needs to be further investigated. In addition, 
up-regulated KLK5 may induce disrupted cell growth and aberrant cytokine production 
in keratinocytes by increasing the levels of p53 and HSP60. Therefore, up-regulation of 
KLK5 results in the abnormalities in numerous barrier-related proteins, consequently 
accelerating epidermal barrier defect and promoting the development of AD. Moreover, 
our results also showed that the impairments caused by up-regulated KLK5 are reversed 
through inhibition of unopposed KLK5 activity. The results showed reduced 
degradation of DSG1, restoration of PAR2 activity, decreased expression of p53/HSP60 
and decreased production of inflammatory cytokines in KLK5-cells treated with SFTI-
G.  	
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Figure 4.1. Potential roles of up-regulated KLK5 in skin barrier defect in AD. 
Genetic factors including polymorphisms in SPINK5 and FLG genes and environmental causes such as 
overuse of soap can both result in consistent up-regulation of KLK5 in AD. As a result, up-regulated 
KLK5 results in over-degradation of DSG1 and may induce immune response via PAR2. Overexpressed 
KLK5 also leads to increased levels of p53 and HSP60, consequently inducing disruption of keratinocyte 
growth and up-regulation of inflammatory cytokines. These impairments were reversed through 
inhibition of unopposed KLK5 activity. 
 
As up-regulated proteolytic activity contributes to disturbed epidermal barrier function 
in AD, restoration of fine-tuned balance between epidermal proteases including KLK5 
and their inhibitors represents an important therapeutic intervention for AD. Therefore, 
application of potential KLK5-specific inhibitor might attenuate unopposed KLK5 
activity and counteract the skin barrier dysfunction in AD patients, which is a promising 
therapeutic approach for AD. SFTI-1 and its analogues possess exceptionally trypsin 
inhibitory activity against numerous serine proteases including KLKs. Although KLK5 
is a one of the major trypsin-like serine proteases expressed in the epidermis, the 
inhibition of SFTI-1 against KLK5 is not specific. SFTI-1-derevied analogues such as 
SFTI-G may still be able to inhibit the activity of other trypsin-like serine proteases, 
thus application of SFTI-G could affect the normal biological functions of other 
proteases in keratinocytes. It has been revealed that SFTI-1 is a natural bioscaffold that 
can be modified to become highly specific upon certain targets (Boy et al. 2010; Lesner 
et al. 2011; Quimbar et al. 2013). In order to improve the selectivity of SFTI-1-derived 
peptides against KLK5, modification of selected residues will be carried out on the 
template of SFTI-1, and crystallography will be performed to screen for the potential 
KLK5-specific inhibitor.	  
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APPENDIX 
 
1: Relevant genes examined in human EGF signaling PCR array were listed in 
Table A1. The fold-change and fold regulation values were calculated (Section 
2.11). 
 
UniGene Symbol Description Fold-change 
Fold up-
/down- 
regulation 
Hs.728857 ACTR2 ARP2 actin-related protein 2 homolog (yeast) 0.96 -1.04 
Hs.525622 AKT1 V-akt murine thymoma viral oncogene homolog 1 0.54 -1.84 
Hs.631535 AKT2 V-akt murine thymoma viral oncogene homolog 2 1.09 1.09 
Hs.498292 AKT3 V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 1.23 1.23 
Hs.446641 ARAF V-raf murine sarcoma 3611 viral oncogene homolog 0.72 -1.40 
Hs.648565 ATF1 Activating transcription factor 1 1.05 1.05 
Hs.592510 ATF2 Activating transcription factor 2 1.16 1.16 
Hs.370254 BAD BCL2-associated agonist of cell death 0.94 -1.06 
Hs.479747 BCAR1 Breast cancer anti-estrogen resistance 1 0.95 -1.05 
Hs.550061 BRAF V-raf murine sarcoma viral oncogene homolog B1 0.93 -1.08 
Hs.141125 CASP3 Caspase 3, apoptosis-related cysteine peptidase 1.08 1.08 
Hs.329502 CASP9 Caspase 9, apoptosis-related cysteine peptidase 0.76 -1.35 
Hs.504096 CBL Cas-Br-M (murine) ecotropic retroviral transforming sequence 1.26 1.26 
Hs.523852 CCND1 Cyclin D1 1.03 1.03 
Hs.198998 CHUK Conserved helix-loop-helix ubiquitous kinase 0.78 -1.29 
Hs.172928 COL1A1 Collagen, type I, alpha 1 0.82 -1.22 
Hs.516646 CREB1 CAMP responsive element binding protein 1 0.86 -1.17 
Hs.644056 CSNK2A1 Casein kinase 2, alpha 1 polypeptide 0.98 -1.02 
Hs.73527 CSNK2B Casein kinase 2, beta polypeptide 1.03 1.03 
Hs.171695 DUSP1 Dual specificity phosphatase 1 1.15 1.15 
Hs.298654 DUSP6 Dual specificity phosphatase 6 0.77 -1.29 
Hs.419815 EGF Epidermal growth factor 0.84 -1.19 
Hs.488293 EGFR Epidermal growth factor receptor 0.69 -1.45 
Hs.326035 EGR1 Early growth response 1 0.96 -1.04 
Hs.249718 EIF4E Eukaryotic translation initiation factor 4E 1.14 1.14 
Hs.181128 ELK1 ELK1, member of ETS oncogene family 0.73 -1.38 
Hs.591160 EPS8 Epidermal growth factor receptor pathway substrate 8 0.75 -1.40 
Hs.2007 FASLG Fas ligand (TNF superfamily, member 6) 0.72 -1.42 
Hs.203717 FN1 Fibronectin 1 0.78 -1.29 
Hs.728789 FOS FBJ murine osteosarcoma viral oncogene homolog 0.78 -1.28 
Hs.220950 FOXO3 Forkhead box O3 0.86 -1.17 
Hs.80720 GAB1 GRB2-associated binding protein 1 0.98 -1.02 
Hs.444356 GRB2 Growth factor receptor-bound protein 2 0.75 -1.34 
Hs.466828 GSK3A Glycogen synthase kinase 3 alpha 0.89 -1.13 
Hs.445733 GSK3B Glycogen synthase kinase 3 beta 0.16 -6.11 
Hs.799 HBEGF Heparin-binding EGF-like growth factor 0.73 -1.35 
Hs.37003 HRAS V-Ha-ras Harvey rat sarcoma viral oncogene homolog 0.79 -1.27 
Hs.597664 IKBKB Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 0.39 -2.59 
Hs.89679 IL2 Interleukin 2 0.51 -1.96 
Hs.207538 JAK1 Janus kinase 1 0.80 -1.16 
Hs.714791 JUN Jun proto-oncogene 0.93 -1.08 
Hs.505033 KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 0.66 -1.51 
Hs.36 LTA Lymphotoxin alpha (TNF superfamily, member 1) 0.65 -1.53 
Hs.145442 MAP2K1 Mitogen-activated protein kinase kinase 1 0.54 -1.87 
Hs.514681 MAP2K4 Mitogen-activated protein kinase kinase 4 0.73 -1.44 
Hs.531754 MAP2K7 Mitogen-activated protein kinase kinase 7 1.13 1.13 
Hs.145605 MAP3K2 Mitogen-activated protein kinase kinase kinase 2 0.89 -1.12 
Hs.431850 MAPK1 Mitogen-activated protein kinase 1 1.38 1.38 
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Hs.125503 MAPK10 Mitogen-activated protein kinase 10 0.38 -2.64 
Hs.861 MAPK3 Mitogen-activated protein kinase 3 1.60 1.60 
Hs.138211 MAPK8 Mitogen-activated protein kinase 8 1.39 1.39 
Hs.484371 MAPK9 Mitogen-activated protein kinase 9 0.88 -1.14 
Hs.371594 MKNK1 MAP kinase interacting serine/threonine kinase 1 0.71 -1.42 
Hs.2256 MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) 1.08 1.08 
Hs.529244 NCK2 NCK adaptor protein 2 0.84 -1.19 
Hs.632209 NFATC3 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 0.81 -1.24 
Hs.654408 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 0.79 -1.27 
Hs.486502 NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog 0.95 -1.05 
Hs.467133 NUP62 Nucleoporin 62kDa 0.92 -1.09 
Hs.535898 PDGFA Platelet-derived growth factor alpha polypeptide 0.71 -1.42 
Hs.1976 PDGFB Platelet-derived growth factor beta polypeptide 0.78 -1.29 
Hs.74615 PDGFRA Platelet-derived growth factor receptor, alpha polypeptide 0.40 -2.50 
Hs.459691 PDPK1 3-phosphoinositide dependent protein kinase-1 2.01 2.01 
Hs.553498 PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide 0.65 -1.55 
Hs.132225 PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 1.19 1.19 
Hs.371344 PIK3R2 Phosphoinositide-3-kinase, regulatory subunit 2 (beta) 0.91 -1.10 
Hs.491582 PLAT Plasminogen activator, tissue 0.82 -1.22 
Hs.268177 PLCG1 Phospholipase C, gamma 1 1.53 1.53 
Hs.483408 PPP2CA Protein phosphatase 2, catalytic subunit, alpha isozyme 0.79 -1.27 
Hs.531704 PRKCA Protein kinase C, alpha 0.75 -1.33 
Hs.500466 PTEN Phosphatase and tensin homolog 0.60 -1.67 
Hs.159130 RAF1 V-raf-1 murine leukemia viral oncogene homolog 1 0.85 -1.17 
Hs.190334 RAP1A RAP1A, member of RAS oncogene family 0.77 -1.30 
Hs.664080 RASA1 RAS p21 protein activator (GTPase activating protein) 1 0.72 -1.39 
Hs.247077 RHOA Ras homolog gene family, member A 0.88 -1.16 
Hs.510225 RPS6KA5 Ribosomal protein S6 kinase, 90kDa, polypeptide 5 0.87 -1.15 
Hs.463642 RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1 1.06 1.06 
Hs.433795 SHC1 SHC (Src homology 2 domain containing) transforming protein 1 0.84 -1.19 
Hs.642990 STAT1 Signal transducer and activator of transcription 1, 91kDa 0.70 -1.43 
Hs.437058 STAT5A Signal transducer and activator of transcription 5A 0.82 -1.22 
 
Table A1. Expression of EGF-related genes in KLK5-cells and eGFP-cells. 
The expression of 82 genes relevant to EGF signaling pathway in KLK5-cells was examined compared to 
eGFP-cells. The results showed that expression of 19 genes were up-regulated, whereas the expression 
of 63 genes were down-regulated. Three-fold change was used as the threshold for selection of differential 
gene expression. The expression of GSK-3β (indicated in red) in KLK5-cells was down-regulated by ~6-
fold compared to eGFP-cells.   
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2: The protein kinases evaluated in human phospho-kinase antibody array were 
listed in the Table A2. The intensities of the blots were quantified by 
densitometry (Section 2.13). Normalized protein levels of phospho-kinases in 
eGFP-cells and KLK5-cells were compared. 
 
Coordinate Target/control Mean pixel density eGFP-cells KLK5-cells 
A1,A2 Reference spot 15674 15283 
A3,A4 p38-alpha 1441 1494 
A5,A6 ERK1/2 1482 1439 
A7,A8 JNK1/2/3 1247 1295 
A9,A10 GSK3a/b 1124 1119 
A13,A14 p53 (S392) 15571 25773 
A17,A18 Reference spot 18648 18581 
B3,B4 EGFR 1378 1391 
B5,B6 MSK1/2 1454 1445 
B7,B8 AMPKa1 1386 1361 
B9,B10 Akt1/2/3 (S473) 1415 1406 
B11,B12 Akt1/2/3 (T308) 1570 1543 
B13,B14 p53 (S46) 2593 2659 
C1,C2 TOR 1113 1104 
C3,C4 CREB 11841 11724 
C5,C6 HSP27 1292 1279 
C7,C8 AMPKa2 1419 1342 
C9,C10 b-cat 28078 28146 
C11,C12 p70 S6 kinase 1205 1280 
C13,C14 p53 (S15) 1223 1216 
C15,C16 c-jun 2497 2555 
D1,D2 Src 1319 1302 
D3,D4 Lyn 1266 1229 
D5,D6 Lck 1345 1375 
D7,D8 STAT2 1637 1663 
D9,D10 STAT5a 1435 1422 
D11,D12 p70 kinase 125 131 
D13,D14 RSK1/2/3 1037 1052 
D15,D16 Enos 135 129 
E1,E2 Fyn 432 411 
E3,E4 Yes 536 525 
E5,E6 Fgr 603 619 
E7,E8 STAT6 1041 1015 
E9,E10 STAT5b 1092 1010 
E11,E12 STAT3 423 435 
E13,E14 p27 1056 1009 
E15,E16 PLC-R1 408 399 
F1,F2 hck 1145 1156 
F3,F4 Chk-2 1063 1039 
F5,F6 FAK 425 411 
F7,F8 PDGF Rb 524 515 
F9,F10 STAT5a/b 506 512 
F11,F12 STAT-3 12267 12426 
F13,F14 WNK1 16084 15529 
F15,F16 PYK2 606 621 
G1,G2 Reference spot 16938 16881 
G3,G4 PRAS40 16768 16250 
G9,G10 Negative control 497 502 
G11,G12 HSP60 17909 28985 
G17,G18 Negative control 320 374 
 
Table A2. Levels of protein kinases in KLK5-cells and eGFP-cells. 
The expression of 43 phospho-kinases and 2 related total proteins in KLK5-cells was examined using 
human phospho-kinase array compared to eGFP-cells. Mean pixel density of each reference/target was 
calculated. Increased blot intensities of phospho-p53S392 and HSP60 (indicated in red) were detected in 
KLK5-cells compared to eGFP-cells.	
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3: The cytokines examined in human cytokine antibody array were listed in the 
Table A3. The intensities of the blots were quantified by densitometry (Section 
2.14). Normalized expression of cytokines in eGFP-cells and KLK5-cells were 
compared.  
 
 
Coordinate Target/control Mean pixel density eGFP-cells KLK5-cells 
A1,A2 Reference spot 17896 17701 
A3,A4 C5/C5a 232 245 
A5,A6 CD40 ligand 216 241 
A7,A8 G-CSF 308 327 
A9,A10 GM-CSF 341 319 
A11,A12 GRO-alpha 18958 19110 
A13,A14 I-309 327 338 
A15,A16 sICAM-1 404 420 
A17,A18 IFN-gamma 336 312 
A19,A20 Reference spot  16350 16222 
B3,B4 IL-1a 188 209 
B5,B6 IL-1b 217 232 
B7,B8 IL-1ra 15933 15899 
B9,B10 IL-2 297 268 
B11,B12 IL-4 322 301 
B13,B14 IL-5 275 291 
B15,B16 IL-6 397 380 
B17,B18 IL-8 15922 22598 
C3,C4 IL-10 224 8236 
C5,C6 IL-12 p70 313 326 
C7,C8 IL-13 406 415 
C9,C10 IL-16 359 360 
C11,C12 IL-17 448 465 
C13,C14 IL-17E 385 397 
C15,C16 IL-23 535 519 
C17,C18 IL-27 449 456 
D3,D4 IL-32a 398 386 
D5,D6 IP-10 421 409 
D7,D8 ITAC 415 406 
D9,D10 MCP-1 399 394 
D11,D12 MIF 12868 13310 
D13,D14 MIP-1a 275 298 
D15,D16 MIP-1b 393 415 
D17,D18 Serpin E1 18256 18166 
E1,E2 Reference spot 17510 17566 
E3,E4 RANTES 435 466 
E5,E6 SDF-1 449 425 
E7,E8 TNF-alpha 398 412 
E9,E10 sTERM-1 421 435 
E19,E20 Negative control 275 261 
 
Table A3. Production of cytokines in KLK5-cells and eGFP-cells. 
The expression of 36 cytokines in KLK5-cells was examined using human cytokine array compared to 
eGFP-cells. Mean pixel density of each reference/target was calculated. Increased blot intensities of IL-8 
and IL-10 (indicated in red) were detected in KLK5-cells compared to eGFP-cells.	
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4: Protein levels of phospho-kinases in eGFP-cells and KLK5-cells with or 
without SFTI-G treatment were compared using human phospho-kinase 
antibody array. The intensities of the blots were quantified by densitometry 
(Table A4). 
 
Coordinate Target/control Mean pixel density eGFP- eGFP+ KLK5- KLK+ 
A1,A2 Reference spot 15674 15538 15283 15502 
A3,A4 p38-alpha 1441 1398 1494 1402 
A5,A6 ERK1/2 1482 1512 1439 1499 
A7,A8 JNK1/2/3 1247 1266 1295 1304 
A9,A10 GSK3a/b 1124 1032 1119 1106 
A13,A14 p53 (S392) 15571 15639 25773 16022 
A17,A18 Reference spot 18648 18301 18581 18992 
B3,B4 EGFR 1378 1302 1391 1411 
B5,B6 MSK1/2 1454 1414 1445 1477 
B7,B8 AMPKa1 1386 1396 1361 1407 
B9,B10 Akt1/2/3 (S473) 1415 1399 1406 1425 
B11,B12 Akt1/2/3 (T308) 1570 1502 1543 1563 
B13,B14 p53 (S46) 2593 2607 2659 2599 
C1,C2 TOR 1113 1093 1104 1222 
C3,C4 CREB 11841 11792 11724 11821 
C5,C6 HSP27 1292 1302 1279 1228 
C7,C8 AMPKa2 1419 1444 1342 1393 
C9,C10 b-cat 28078 28102 28146 28298 
C11,C12 p70 S6 kinase 1205 1199 1280 1203 
C13,C14 p53 (S15) 1223 1242 1216 1273 
C15,C16 c-jun 2497 2501 2555 2622 
D1,D2 Src 1319 1359 1302 1314 
D3,D4 Lyn 1266 1251 1229 1325 
D5,D6 Lck 1345 1422 1375 1408 
D7,D8 STAT2 1637 1625 1663 1709 
D9,D10 STAT5a 1435 1398 1422 1409 
D11,D12 p70 kinase 125 111 131 150 
D13,D14 RSK1/2/3 1037 1112 1052 1098 
D15,D16 Enos 135 123 129 161 
E1,E2 Fyn 432 425 411 509 
E3,E4 Yes 536 512 525 587 
E5,E6 Fgr 603 699 619 704 
E7,E8 STAT6 1041 998 1015 1021 
E9,E10 STAT5b 1092 1142 1010 1265 
E11,E12 STAT3 423 399 435 502 
E13,E14 p27 1056 1110 1009 1099 
E15,E16 PLC-R1 408 415 399 325 
F1,F2 hck 1145 1099 1156 1251 
F3,F4 Chk-2 1063 1113 1039 1212 
F5,F6 FAK 425 506 411 465 
F7,F8 PDGF Rb 524 499 515 532 
F9,F10 STAT5a/b 506 586 512 604 
F11,F12 STAT-3 12267 12315 12426 12601 
F13,F14 WNK1 16084 15456 15529 16123 
F15,F16 PYK2 606 666 621 709 
G1,G2 Reference spot 16938 16910 16881 16823 
G3,G4 PRAS40 16768 16617 16250 16438 
G9,G10 Negative control 497 520 502 616 
G11,G12 HSP60 17909 17615 28985 18821 
G17,G18 Negative control 320 298 374 333 
 
Table A4. Levels of protein kinases in cells with or without SFTI-G treatment.  
The expression of 43 phospho-kinases and 2 related total proteins in KLK5-cells treated with SFTI-G was 
examined using human phospho-kinase array compared to un-treated cells and eGFP-cells. Mean pixel 
density of each reference/target was calculated. Decreased blot intensities of phospho-p53S392 and HSP60 
(indicated in red) were detected in KLK5-cells treated with SFTI-G but not in untreated cells.	
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5: The profiles of cytokines expression in eGFP-cells and KLK5-cells with or 
without SFTI-G treatment were compared using human cytokine antibody array. 
The intensities of the blots were quantified by densitometry (Table A5). 
 
 
Coordinate Target/control Mean pixel density eGFP- eGFP+ KLK5- KLK+ 
A1,A2 Reference spot 17896 17221 17701 17193 
A3,A4 C5/C5a 232 294 245 302 
A5,A6 CD40 ligand 216 259 241 226 
A7,A8 G-CSF 308 299 327 302 
A9,A10 GM-CSF 341 367 319 298 
A11,A12 GRO-alpha 18958 19020 19110 19212 
A13,A14 I-309 327 381 338 306 
A15,A16 sICAM-1 404 394 420 441 
A17,A18 IFN-gamma 336 385 312 397 
A19,A20 Reference spot  16350 16361 16222 16119 
B3,B4 IL-1a 188 226 209 198 
B5,B6 IL-1b 217 275 232 202 
B7,B8 IL-1ra 15933 15659 15899 16021 
B9,B10 IL-2 297 310 268 289 
B11,B12 IL-4 322 338 301 297 
B13,B14 IL-5 275 311 291 298 
B15,B16 IL-6 397 344 380 393 
B17,B18 IL-8 15922 15273 22598 16276 
C3,C4 IL-10 224 243 8236 268 
C5,C6 IL-12 p70 313 289 326 301 
C7,C8 IL-13 406 484 415 461 
C9,C10 IL-16 359 331 360 314 
C11,C12 IL-17 448 429 465 438 
C13,C14 IL-17E 385 375 397 408 
C15,C16 IL-23 535 521 519 569 
C17,C18 IL-27 449 425 456 406 
D3,D4 IL-32a 398 331 386 350 
D5,D6 IP-10 421 452 409 398 
D7,D8 ITAC 415 429 406 466 
D9,D10 MCP-1 399 411 394 429 
D11,D12 MIF 12868 12525 13310 12806 
D13,D14 MIP-1a 275 310 298 322 
D15,D16 MIP-1b 393 404 415 438 
D17,D18 Serpin E1 18256 18010 18166 18125 
E1,E2 Reference spot 17510 17725 17566 17621 
E3,E4 RANTES 435 509 466 428 
E5,E6 SDF-1 449 399 425 462 
E7,E8 TNF-alpha 398 439 412 402 
E9,E10 sTERM-1 421 461 435 489 
E19,E20 Negative control 275 211 261 293 
 
Table A5. Production of cytokines in cells with or without SFTI-G treatment.  
The expression of 36 cytokines in KLK5-cells treated with SFTI-G was examined using human cytokine 
antibody array compared to un-treated cells and eGFP-cells. Mean pixel density of each reference/target 
was calculated. Reduced blot intensities of IL-8 and IL-10 (indicated in red) were detected in KLK5-cells 
treated with SFTI-G but not in untreated cells.	
 
